

CURRICULUM VITAE

July 1, 2022

Name: Arshag D. Mooradian

Citizenship: U.S.A.

Address: Department of Medicine
University of Florida
653-1 West 8th Street
4th Floor - LRC
Jacksonville, FL 32209

Phone: (904)-244-8846

Fax: (904)-244-8844

E-mail: arshag.mooradian@jax.ufl.edu

Undergraduate Education:

American University of Beirut	1973-1976	B.Sc. With High Distinction
American University of Beirut	1976-1980	M.D. with Distinction and Penrose Award

Post-Graduate Training:

American University Hospital	7/1/79 - 6/30/80	Internship (straight) in Internal Medicine
American University Hospital	7/1/80 - 6/30/82	Residency (Internal Medicine)
University of Minnesota	7/1/82 - 6/30/85	Fellowship - Endocrinology

CERTIFICATIONS AND LICENSURES:

I. General:

Bachelor of Sciences (B.Sc. in Biology), 1976

National Board Examination (Part I), 1977

National Board Examination (Part II), 1979

E.C.F.M.G. Certification, 1979

Doctor of Medicine (M.D.), 1980

F.L.E.X. Certification, 1980

A.C.L.S. Certification, 1984

II. Specialty Boards:

Internal Medicine (Certified, 09/16/1987)

Endocrinology, Diabetes and Metabolism (Certified, 11/07/89)

Geriatric Medicine (Certified, 01/01/1990)

III. Professional Licenses:

New York State (1981) License No. 145493

Minnesota (1982) License No. 27670

California (1985) License No. C41800

Arizona (1988) License No. 18049

Missouri (1991) License No. MDR1P91

Illinois (1992) License No. 003-036-084534-01

Florida (2006) License No. ME 95499

Academic and Professional Appointments:

University of Florida	5/1/2006 - Present	Chairman; Department of Medicine
University of Florida	5/1/2006 - Present	Professor of Medicine Tenured: 5/1/2006
University of Florida	5/1/2011 - 6/30/2013	Director; Clinical Research Unit (CTSI)
Shands Hospital-Jacksonville	5/1/2006- Present	Chief; Medical Service
Saint Louis University	7/1/1991 - 5/14/2006	Director, Division of Endocrinology, Diabetes and Metabolism
Saint Louis University	7/1/1991 - 5/14/2006	Professor of Internal Medicine Tenured: 7/1/1992
Sun Yat-Sen University (People's Republic of China)	4/1/2001 - 4/1/2003	Professor of Internal Medicine/Endocrinology (Honorary)
St. Louis VA Medical Center	7/1/1991 - 5/1/2006	Staff Physician (WOC since 1997)
University of Arizona	7/1/1988 - 6/30/1991	Associate Professor of Internal Medicine Tenured: 7/1/1989
Tucson VA Medical Center	7/1/1988 - 6/30/1991	Staff Physician
University of Arizona	7/1/1988 - 6/30/1991	Director of Gerontological Research
University of California Los Angeles	7/1/1985 - 6/30/1988	Assistant Professor of Internal Medicine
Sepulveda VA Medical Center	7/1/1985 - 6/30/1988	Staff Physician

Honors and Awards:

1. Alpha Omega Alpha Honor Medical Society, 1979.
2. Phi Kappa Phi Honor Society, 1984.
3. Penrose Award, 1980.
4. N.I.H. Individual Fellowship Award 1984.
5. Veterans' Administration Merit Award: 1985
6. Veterans' Administration Merit Award: 1987.
7. Veterans' Administration Merit Award: 1990.
8. Veterans' Administration Merit Award: 1993.
9. Who's Who in Science and Engineering, 1992-
10. Who's Who in the Midwest, 1993-
11. Who's Who in Medicine and Healthcare, 1995-
12. International Who's Who in Medicine, 1995-
13. Who's Who in America (51st edition) 1997-
14. Who's Who in American Education 2003-
15. Guide to America's Top Physicians 2003-
16. Elected foreign member of the National Academy of Sciences, Republic of Armenia, Nov 28, 2008.
17. USA TODAY Most Influential Doctors, 2009-present
18. Best Doctors in America—2009-present
19. National Consumers Survey's Book "Florida: Most Recommended Physicians" 2011-
20. Exemplary Teacher Award, University of Florida College of Medicine, 2012.
21. American Men & Women of Science 33rd, 34th and 35th editions; 2015- current
22. University of Florida Research Foundation (UFRF) Professorship Award 2016-2018.
23. University Term Professor award for the period July 1, 2017 – June 30, 2020.
24. Exemplary Teacher Award, University of Florida College of Medicine, 2020.

Professional Societies:

1. American Association for the Advancement of Science
2. The Endocrine Society
3. Gerontological Society of America
4. American Diabetes Association
5. Saint Louis Society of Internal Medicine
6. Association of Professors of Medicine (APM) 2006-

Editorial Boards:

1. American Journal of Therapeutics: Section Editor for Internal Medicine; March 2010-May 2016
2. Austin Pharmacology and Pharmaceutics
3. Pragmatic and Observational Research; 2010-present
4. World Journal of Diabetes (WJD) 2010-present
5. Academic Internal Medicine Insight 2008-June 2015
6. Drugs 2007-Present
7. Drugs and Aging 1990-Present
8. Diabetes Spectrum 1992-1996
9. Journal of the American Geriatrics Society 1989-1992

Ad Hoc Reviewer for Grant Applications:

1. Veterans Affairs Research Service
2. National Institute of Health
3. Medical Research Council (Canada)
4. The Wellcome Trust
5. Texas Institute for Research and Education on Aging (TIREA)
6. Austrian Science Fund
7. Diabetes UK (the operating name of The British Diabetic Association)
8. National Academy of Sciences, Republic of Armenia; Scientific Advisor
9. The Netherlands Organisation for Health Research and Development (ZonMw).
10. Health Research Board (HRB) (Ireland)
11. MRC - UK-Malaysia Newton Fund

Ad Hoc Reviewer for the Following Journals:

1. Acta Neurochirurgica
2. Acta Neuropathologica
3. The American Journal of Clinical Nutrition
4. The American Journal of Medicine
5. The American Journal of Physiology
6. American Journal of Cardiovascular Drugs
7. The American Journal of Kidney Disease
8. The Archives of Internal Medicine
9. Annals of Nutrition and Metabolism
10. Biochimica et Biophysica Acta (BBA)
11. Brain Research
12. British Journal of Nutrition
13. British Journal of Pharmacology
14. Clinica Chimica Acta
15. Clinical Pharmacology and Therapeutics
16. Diabetes
17. Diabetes Care
18. Diabetic Medicine
19. Diabetes and Metabolism Research and Reviews
20. Diabetes Spectrum
21. Drugs
22. Drugs and Aging
23. Endocrinology
24. Endocrine
25. Expert Opinion on Pharmacotherapy.
26. Life Sciences
27. Metabolism: Clinical and Experimental
28. Obesity
29. Journal of the American Geriatrics Society
30. Journal of Applied Physiology
31. Journal of Gerontology
32. Journal of Clinical Investigation
33. Journal of Clinical Endocrinology and Metabolism
34. Journal of Endocrinology
35. Journal of Hospital Medicine
36. Journal of Laboratory and Clinical Medicine
37. Journal of Molecular Endocrinology
38. Journal of Molecular and Cellular Biochemistry
39. Journal of Neurochemistry
40. Journal of Nutrition, Health and Aging
41. Journal of Nutritional Biochemistry
42. Journal of Pharmacology and Experimental Therapeutics
43. Journal of Physiology.
44. Molecular Endocrinology
45. Neurobiology of Aging
46. Neuroscience Letters
47. Nutrition
48. Pharmacological Research
49. Proceedings of the Society of Experimental Biology and Medicine
50. The Lancet
51. PLOS One
52. Drugs & Therapy Perspective

National /Regional Committees:

1. Association of Professors of Medicine (APM), Communications Committee July 2008- June 2012.
2. Academic Medical Center (AMC) Advisory Board meeting; Pfizer Inc. 2008, 2009.
3. Committee for selection of Diabetes Visiting Professorship sponsored by Pfizer Inc. 2007, 2008, 2009.
4. Reviewer for Effective Health Care Programs; the Agency for Healthcare Research and Quality, Rockville, MD. 2008.
5. American Diabetes Association Task Force for writing Nutrition Principles for the Management of Diabetes and Related Complications, 2005-2006.
6. Scientific Advisory Board of the American Society of Klinefelter's Syndrome, 2000-2005.
7. Society of Internal Medicine (St. Louis) President: Dec.2002-Dec. 2003
8. Society of Internal Medicine (St. Louis) President-elect: Dec.2001-Dec.2002.
9. Chairman of Council on Nutrition and Metabolism, the American Diabetes Association, 7/1/2000-7/1-2002.
10. American Diabetes Association Task Force for writing Nutrition Principles for the Management of Diabetes and Related Complications, 2000-2001.
11. American Diabetes Association Task Force on Diabetes in Older Adults, 1998.
12. V.A./JDF Diabetes Centers of Excellence Review Committee, 1998.
13. Chair, the American Diabetes Association Steering Committee for Continuing Education Programs on Diabetes in the Elderly, 1995-1997.
14. NIH/NIA Claude Pepper Centers Review Committee, 1995.
15. Chair of the American Diabetes Association Task Force on Micronutrients in Diabetes, 1990-1994.

Local Committees at the University of Florida:

1. Corporate Structure and Function Evaluation Committee. 2014.
2. Board of Directors, the University of Florida Jacksonville Healthcare, Inc. May 2006-Present.
3. Treasurer University of Florida Jacksonville Healthcare, Inc. June 29, 2011-Present.
4. Executive Committee, the University of Florida, College of Medicine Jacksonville, May 2006-Present.
5. Medical Executive Committee, Shands Hospitals, Jacksonville, FL. May 2006-Present
6. Clinical Operations Committee, University of Florida Jacksonville Healthcare, Inc. May 2006-Present.
7. Best Practices Committee, the University of Florida, College of Medicine Jacksonville, February 2012-2014
8. Executive Committee of the Department of Medicine, University of Florida College of Medicine, Jacksonville, May 2006-Present
9. Search Committee for the Assistant Dean for Research, 2006.
10. Dean's advisory committee for development and promotion of research October 2006-present
11. Scholarly activity taskforce for GME-2006.
12. Academic achievement enhancement committee 2006-2012
13. Chairman of the Search Committee for the Chairman of the Department of Surgery
14. Chairman of the nominating committee for the University of Florida Jacksonville Healthcare, Inc (UFJHI) Board membership at large- August 2007.
15. Finance Committee of University of Florida Jacksonville Healthcare, Inc. August 2007-Present
16. Planning and Development Committee. December 2007-2012
17. International Healthcare Advisory Committee May 2008-2012
18. Chairman of the University of Florida COM-JAX Industry Conflict Task Force. May 2008-Present
19. UF CTSA (Clinical and Translational Science Award) Scientific Advisory Board member 2007-2013
20. UF GRECC (Geriatric Research Education and Clinical Center) Advisory Board member 2008-present.
21. Service Excellence Committee 2009-2013.
22. Self-Pay Policy Task force 2009.
23. Search Committee for the Chairman, Department of Medicine, University of Florida COM Gainesville campus.
24. Investment Committee for the University of Florida Jacksonville Healthcare, Inc. 2010-present.
25. Search Committee for the Chairman, Department of Radiology, University of Florida COM Jacksonville.
26. Search Committee for the Chief Medical Officer, Vice President and Senior Associate Dean for Quality and Patient safety Affairs, Shands Hospital and University of Florida COM Jacksonville.

Local Committees at Saint Louis University:

1. Executive Committee, Department of Internal Medicine, Saint Louis University, 1995-2006.
2. Board of Trustees Saint Louis University, Clinical Affairs Committee: December 2002- 2005.
3. Committee for Conflict of Commitment. 2004.
4. Residency Review Committee of the Division of Plastic Surgery, 2004.
5. Chairman of the Executive Committee of the University Medical Group (UMG), Saint Louis University, 4/2000-4/2002. (*Responsible for overseeing the implementation of policies and procedures as well as financial operations of the UMG*).
6. Governing Board of the University Medical Group (UMG), Saint Louis University, 4/2000-4/2002.
7. Committee for negotiating Master Lease Agreement with Tenet Inc., 6/2002.
8. Physician's Incentive Compensation Committee, Saint Louis University, 1997-2000.
9. Residency Review Committee of the Department of Surgery, 2000.
10. Residency Review Committee of the Department of Psychiatry, 1998.
11. Residency Review Committee for the Department of Orthopedic Surgery, 1996.
12. Diabetes Advisory Committee of Saint Louis University, 1991-1997.
13. Ancillary Testing Committee, St. Louis V.A. Medical Center, 1994-1996.
14. Search Committee OB-Gyn Chairman, 1995-1997.

Organizer of Regional or National Educational Symposia:

1. Annual Symposium on Endocrinology and Diabetes, Saint Louis University, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2003.
2. St. Louis Endocrine Club: Quarterly Meetings, 1991-2006.
3. Directors of Endocrinology Meeting; Caribbean, 1996.
4. National Meeting: Diabetes in Older Adults, Cancun, Mexico, 1998.

Consultant for the following pharmaceutical companies:

1. Alza, Inc.
2. Eli Lilly, Co.
3. Merck, Sharp and Dohme
4. Novartis
5. Andrx Laboratories
6. Pfizer, Inc.
7. Cygnus Therapeutic Systems
8. Bayer Pharmaceutical Company
9. Parke-Davis
10. Alpha Therapeutics
11. Astra Merck
12. Nissan Pharmaceuticals
13. Williamson Major Group
14. Novo Nordisk
15. Toler Rx Inc.
16. Matsutani Co.

Post Doctoral Fellows Mentored/Trained in the Laboratory

1. Gregory A. Mintz, DMD, M.D (Gerodontology) 1987
2. Elaine M. Wynn Pharm D. (Geropharmacy) 1987
3. Shahe' G. Boghosian, M.D. (Geriatrics) 1987
4. Daniel Petrasek, M.D. (Geriatrics) 1988
5. Gary D. Kavonian, M.D. (Geriatrics) 1988
6. Lynn Hernandez, Pharm D (Geropharmacy) 1988
7. Vicky L. Grieff, M.D. (Geriatrics) 1989
8. Joan M. Hartnell, M.D. Ph.D. (Gerontology) 1986-1988
9. Chien C. Lung Ph.D. (Immunology) 1990-1991
10. Mohamad D. Yahya Ph.D.(Immunology) 1990-1991
11. Kent R. Wehmeier, M.D (Endocrinology) 1991-1993.
12. Wael Girgus, M.D. (Endocrinology) 1993-1995
13. Mencio Chez, M.D. (Endocrinology) 1993-1995
14. Jerome E. Thurman, M.D. (Endocrinology) 1995-1997
15. Reza Rofugaran, M.D. (Endocrinology) 1995-1997
16. Joe M. Chehade, M.D. (Endocrinology) 1997-2000
17. Joohee Kim, M.D (Endocrinology) 1997-1999.
18. George Thampy, M.D. Ph. D. (Endocrinology) 2000
19. Christopher C. Case, M.D. (Endocrinology) 2000.
20. Mary J. Deleon, M.D. (Endocrinology) 1999-2001
21. Vikram Chandurkar, M.D. (Endocrinology) 1999-2001.

Post Doctoral Fellows Mentored/Trained in the Laboratory (Cont'd)

22. Khuram Wadud, M.D. (Endocrinology) 2000-2002
23. Bibi Hasanain M.D. (Endocrinology) 2001-2003.
24. Mohamad H. Horani M.D. (Endocrinology) 2001-2003.
25. Rula Sawaf, M.D. (Endocrinology) 2002.
26. Freij Gobal M.D. (Endocrinology) 2003.
27. Amjad Mreyoud, M.D. (Endocrinology) 2001.
28. Mary Hovsepyan, Ph. D. (Endocrinology) 2003.
29. Ralph Oiknine, M.D (Endocrinology) 2002-2004
30. Ann Beers, M.D. M.D. (Endocrinology) 2003-2005.
31. Rachel Fishman, M.D. (Endocrinology) 2003-2005.
32. Shant A. Parseghian, M.D. (Endocrinology) 2004-2006.
33. Baha Laz, M.D (Endocrinology) 2004-2006.
34. Sahar B. Hachem, M.D. (Endocrinology) 2005-2006.
35. Kenneth Ligaray, M.D. (Endocrinology) 2005-2006.
36. Sinan M. Sultan, M.D. (Endocrinology) 2008-2010.
37. Abdul R Alamir, M.D. (Endocrinology) 2008-2010.
38. Imad Naem, M.D. (Endocrinology) 2009-2011.
39. Rosie Alcalde, M.D. (Endocrinology) 2009-2011.
40. Sandra.Mesliniene, M.D. (Endocrinology) 2010-2012.
41. Margaret.Gladysz, M.D. (Endocrinology) 2010-2012.
42. Anna Sweitlik, M.D. (Endocrinology) 2011-2013.

Post Doctoral Fellows Mentored/Trained in the Laboratory (Cont'd)

43. Hagop Kojanian, M.D. (Endocrinology) 2011-2013.
44. Salma Makhoul Ahwath M.D. (Endocrinology) 2012-2014
45. Melanie Thomas, M.D. (Endocrinology) 2012-2014
46. Harshit Shah, M.D. (Endocrinology) 2013-2015
47. William Kurban, M.D. (Endocrinology) 2013-2015
48. Monica Plazarte, M.D. (Endocrinology) 2014-2016
49. Ayham Chamssedin, M.D. (Endocrinology) 2014-2016
50. Mary lou Jurado-Flores, M.D. (Endocrinology) 2015-2017
51. Ramadan Hammoud, M.D. (Endocrinology) 2015-2017
52. Victoria Feng, M.D. (Endocrinology) 2016-2018
53. Krista Gonzales, M.D. (Endocrinology) 2016-2018
54. Priyanka Bikkina, M.D. (Endocrinology) 2017-2019
55. Marie Angelica Landicho, M.D. (Endocrinology) 2017-2019
56. Shrina Parekh, M.D. (Endocrinology) 2018-2020
57. Poonam Kapadia, M.D. (Endocrinology) 2018-2020
58. Angelina Richter, D.O. (Endocrinology) 2019-2021
59. Firas Warda, D.O.. (Endocrinology) 2020-2022
60. Ailyn Rivero , M.D. (Endocrinology) 2020-2022

Research Grants (Investigator initiated):

1. N.I.H. Individual Fellowship Award 1984; “Trans-cellular transport of thyroid hormone”
2. Veterans’ Administration RAG Award: 1985-1987; “Effect of age on the blood-brain barrier”; (Role: PI).
3. Burroughs Wellcome 1988-1991; “Preclinical trials of a novel class of gluconeogenesis inhibitors”; (Role: PI).
4. Veterans’ Administration Merit Award: 1985-1987; “Effect of age on the blood-brain barrier”; (Role: PI).
5. Veterans’ Administration Merit Award: 1987-1990; “Effect of age and diabetes on the blood-brain barrier”; (Role: PI).
6. Veterans’ Administration Merit Award: 1990-1993; “Effect of age and diabetes on the blood-brain barrier”; (Role: PI).
7. Veterans’ Administration Merit Award: 1993-1997; (Role: PI) “Effect of age and diabetes on the blood-brain barrier”; (Role: PI).
8. Pfizer Investigator Initiated Grant 1995-1997; “The effect of Glipizide GITS on islet cell hormonal responses”; (Role: PI).
9. Bayer Investigator Initiated Grant 1997-1998; “Role of acarbose in the elderly diabetic subjects“; (Role: PI).
10. Thyroid Research Advisory Council Award 1998-2000; “Characterization of thyroid hormone responsive proteins in the brain”; (Role: PI).
11. Takeda Investigator Initiated Grant 1999-2001; “Mechanisms of apo AI expression in HepG2 cells; (Role: PI).
12. NHLBI. , National Institute of Health, Grant # U01 HL61744-01; 3/1/2001-11/1/2009 “Bypass Angioplasty Revascularization Investigation in type 2 diabetes”; (Role: Site PI).
13. AstraZeneca Investigator Initiated Grant 2003-2004; “Diabetes-related alterations in endothelial barrier function: The role of Rho inactivation with rosuvastatin”; (Role: PI)
14. Merck Investigator Initiated Grant 2003-2004; “Amelioration of diabetes-related alterations in endothelial barrier function with simvastatin”; (Role: PI)

Research Grants (Investigator initiated) (Cont'd):

15. NIH- National Institute on Aging Small Business Innovation Research Grant 1 R43 AG028218-01; (SBIR) 2007-2009 “Formulated Phytosterols – A New Treatment for Benign Prostatic Hyperplasia,” Protocol No. ZNX 1.003-C (Role: CO-PI)
16. American Heart Association “Role of novel Na⁺/H⁺ antiporters in essential hypertension” 07/01/2010-06/30/2014; (Role: CO-PI); Xiang M (PI).
17. American Association of Diabetes Educators (AADE) “Integration of diabetes self management education into a patient centered medical home: demonstration project” 4/2011-4/2012; (Role CO-Investigator); Dr. Kenyata Lee (PI).
18. NIH RO1DK091710 “Mechanism of diet induced leptin resistance in ARC and VTA” 6/2012-5/2017; (Role Consultant); Dr. Philip Scarpace (PI).
19. NIH R33AG056540 “The University of Florida Jacksonville Aging Studies Center (JAX-ASCENT)” 9/15/2017-5/31/2022; (Role CO-Investigator 5% FTE); Dr. Marco Pahor (PI) \$3,696,891
20. NIH- National Institute on Aging/National Heart Lung and Blood Institute, NCT04262206 “PRagmatic EVAluation of evENTs And Benefits of Lipid-lowering in oldEr adults (PREVENTABLE)” 5/2020 -6/2025; (Role site PI).

Clinical Trials Funded by Pharmaceutical Industry (Role PI):

1. Clinical trials of Simvastatin® (Merck, Sharp and Dohme); 1989-1991.
2. The role of growth hormone in the management of frail elderly (Genentech, Inc.); 1990-1992.
3. The role of growth factors in healing diabetic foot ulcers (Merck, Sharp and Dohme); 1992-1994.
4. The efficacy of enalapril/diltiazem combination in the treatment of essential hypertension (Merck, Sharp and Dohme); 1992-1994.
5. The efficacy of enalapril/Felodipine combination in the treatment of essential hypertension (Merck, Sharp and Dohme); 1992-1994.
6. The role of insulin analogues in the management of non-insulin dependent diabetic patients (Eli Lilly Co.); 1993-1994.
7. The safety and efficacy of Miglitol in non-insulin dependent diabetic patients (Miles, Inc.); 1994-1996.
8. The safety and efficacy of Glipizide GITS in Type II diabetes mellitus (Pratt/Pfizer); 1995-1996.
9. The pharmacokinetic comparison of serum testosterone levels following Testoderm I application compared to intramuscular Testosterone cypionate (Alza, Inc.); 1995-1996.
10. The pharmacokinetics of serum testosterone following Testoderm II applications (Alza, Inc.); 1995-1996.
11. A comparative study of Testoderm II and Androderm (Alza, Inc.); 1995-1996.
12. The safety and efficacy of pimagedine in the treatment of diabetic nephropathy of insulin dependent diabetic subjects (Hoechst Marion Merrell Dow); 1995-1999.
13. The safety and efficacy of pimagedine in the treatment of diabetic nephropathy of non-insulin dependent diabetic subjects (Hoechst Marion Merrell Dow); 1995-1999.
14. The role of Sibutramine in obese hypertensive patients on ACE inhibitors (Knoll Pharmaceutical); 1996-1997.
15. The role of Sibutramine in obese hypertensive patients treated with calcium channel blockers (Knoll Pharmaceutical); 1996-1997.

Clinical Trials Funded by Pharmaceutical Industry (Role PI) (cont'd):

16. The role of Sibutramine in the management of obese patients with Type II diabetes (Knoll Pharmaceutical); 1996-1997.
17. The comparative efficacy and safety of Bay W6228 400 µg compared to 200 µg once daily in primary hypercholesterolemia. (Bayer Corporation); 1996-1998.
18. The role of Amylin in management of Type I diabetes. (Amylin Pharmaceuticals); 1996-1998.
19. Management of diabetes in the elderly: role of voglibose (Takeda, Inc.); 1997-1999.
20. The efficacy of metformin-glyburide combination therapy in Type II diabetes (Bristol Myers Squibb); 1997-1998.
21. The efficacy and safety of nerve growth factor (NGF) in treatment of diabetic peripheral neuropathy. (Genentech, Inc.); 1997-1998.
22. The efficacy and safety of sildenafil in the treatment of erectile failure in diabetes. (Pfizer, Inc.); 1997-1998.
23. Safety and efficacy of fixed combination metformin/glyburide products as first line therapy in patients with type 2 diabetes. (Bristol Myers Squibb); 1998 – 2000.
24. The safety and efficacy of a long acting insulin analogue in the management of type 2 diabetes. (Hoechst Marion Roussel); 1998-2000.
25. Comparison of an incremental weight-based dose regimen with an individualized dosage adjusted according to the IGF-1 response in adults with growth hormone deficiency (Eli Lilly Co.); 1998-2002.
26. Antiproteinuric effects of Omapatrilat and amlodipine in Type 2 diabetics with hypertension and microalbuminuria or overt nephropathy. Bristol Myers Squibb; 1998-1999.
27. Safety and efficacy of sibutramine 20 mg given in titrated doses to patient with obesity (Knoll Pharmaceutical) 1998-2000. (Bristol Myers Squibb) 1998-2000.
28. Pharmacokinetic studies of V2001: a novel hypoglycemic agent. (Purdue Pharmaceuticals); 1998-1999.
29. The efficacy of Avasimibe in patients with peripheral arterial disease. (Parke-Davis); 1999-2000.

Clinical Trials Funded by Pharmaceutical Industry (Role PI) (cont'd):

30. The role of Zenestatin in comparison to simvastatin and pravastatin in the treatment of hypercholesterolemia. (Zeneca Pharmaceuticals); 1999-2000.
31. Effects of chronic somatropin treatment on bone mineral density in patients diagnosed with adult onset growth hormone deficiency. (Eli Lilly); 1999-2001.
32. The efficacy of omapatrilat in hypertensive subjects poorly controlled on calcium channel blocker monotherapy. (Bristol Myers Squibb); 1999-2000.
33. The efficacy of omapatrilat in hypertensive subjects poorly controlled on ACE inhibitor monotherapy. (Bristol Myers Squibb); 1999-2000.
34. The efficacy of Orlistat plus diet as compared to Orlistat plus phentermine plus diet in severely obese patients. (Roche); 2000-2001.
35. The efficacy of cerivastatin in the treatment of osteoporosis in postmenopausal women (CHARMstudy). (SmithKline Beecham); 2000 - 2002.
36. The efficacy of omapatrilat in poorly controlled hypertensive subjects (OCTAVE) trial. (Bristol Myers Squibb); 2000-2001.
37. Safety and efficacy of fixed combination therapy of metformin/glipizide in Type 2 diabetic subjects. (Bristol Myers Squibb), 2000-2001.
38. Efficacy, safety and tolerability of metformin ER and metformin immediate release in Type 2 diabetes mellitus. (Depo Med Inc.), 2001-2002.
39. Randomized, double blind multicenter study comparing glycemic control characteristics of carvedilol and metoprolol in hypertensive patients with Type 2 diabetes mellitus. (Glaxo Smith Kline Beechem), 2001-2002.
40. Multicenter trial of raloxiphen and alendronate comparison in post menopausal women with osteoporosis. (Eli Lilly Co.) 2001-2005.
41. Phase II randomized, double blind, placebo controlled dose ranging study to determine the efficacy, tolerability and pharmacokinetics of RO 205-2349 in patients with type 2 diabetes. (Roche Pharmaceuticals) 2002-2003.
42. Multicenter, randomized, double-blind study to evaluate the tolerability and efficacy of the co-administration of simvastatin and fenofibrate in patients with combined hyperlipidemia. Merck & Co. 2002.

Clinical Trials Funded by Pharmaceutical Industry (Role PI) (cont'd):

43. Multicenter, randomized, double-blind study to evaluate the tolerability and efficacy of metformin/glipizide combination pill in subjects with type 2 diabetes. PPD Inc. 2002-2003.
44. A multicenter, double blind study to evaluate the effect of pre-treatment with a daily dose of viagra (sildenafil citrate) on the PRN efficacy of viagra in men with erectile dysfunction and type 2 diabetes, Pfizer Co. 2003-2004.
45. Clopidogrel for high atherothrombotic risk and ischemic stabilization, management and avoidance (CHARISMA). Sanofi Pharmaceuticals; 2003-2007.
46. A phase 3, randomized, double-blind, placebo controlled, multicenter trial to evaluate the safety and efficacy of BMS-298585 in combination with glyburide therapy in subjects with type 2 diabetes who have inadequate glycemic control on sulfonylurea therapy alone. Bristol-Myers Squibb, 2003- 2004.
47. A phase 3, randomized, double-blind, placebo controlled, multicenter trial to evaluate the safety and efficacy of BMS-298585 in combination with metformin therapy in subjects with type 2 diabetes who have inadequate glycemic control on metformin therapy alone. Bristol-Myers Squibb, 2003-2004.
48. An-open label study to evaluate the efficacy and safety of tadalafil administered “on demand” to men of various populations with erectile dysfunction. Lilly/ICOS. 2003-2004.
49. A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment and 28 week extension with LAF237 (50mg qd or bid) to placebo as add-on therapy to glimepiride in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Novartis. 2004-2005.
50. A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment and 28 week extension with LAF237 (50mg qd or bid) to placebo as add-on therapy to pioglitazone 45 mg qd in patients with type 2 diabetes inadequately controlled with thiazolidinedione monotherapy. Novartis, 2004-2005.
51. A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment and 28 week extension with LAF237 (50mg qd or bid) to placebo as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Novartis, 2004-2005.
52. A double blind placebo controlled study of the effect of formulated soy sterols on circulating levels of testosterone and dihydrotestosterone. Life Technologies, 2004-2005.

Clinical Trials Funded by Pharmaceutical Industry (Role PI) (cont'd):

53. The safety and efficacy of a combination of niacin ER and simvastatin in patients with dyslipidemia: a dose-ranging study. Kos Pharmaceuticals 2005-2006.
54. Apidra (insulin glulisine) administered premeal vs postmeal in adult subjects with type 2 diabetes mellitus receiving Lantus (insulin glargine) as basal insulin: a multicenter, randomized, parallel, open label clinical study. Aventis, 2005-2006.
55. A 24-week randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy, safety and tolerability of tesaglitazar therapy when added to the therapy of patients with type 2 diabetes poorly controlled on insulin.(GALANT 9) , Astra Zeneca 2005-2006.
56. Double blind, placebo controlled, multicenter, pharmacokinetic, pharmacodynamics and tolerability study of ETC-588 in patients with stable atherosclerosis. Pfizer 2005-2006.
57. A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of fenofibric acid and rosuvastatin calcium combination therapy to fenofibric acid and rosuvastatin calcium monotherapy in subjects with mixed dyslipidemia. Abbott 2006-2007.
58. A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of fenofibric acid and simvastatin combination therapy to fenofibric acid and simvastatin monotherapy in subjects with mixed dyslipidemia. Abbott 2006-2007.
59. PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr adults (PREVENTABLE)" NIH- National Institute on Aging/National Heart Lung and Blood Institute, NCT04262206. 5/2020 -6/2025; (Role site PI).

Visiting Professorships:

1. University of California in Los Angeles, Department of Internal Medicine. 1990.
2. Washington University, Department of Neurobiology, 1992
3. University of Wisconsin, Division of Endocrinology, 1994.
4. Cleveland Clinic Foundation, Division of Endocrinology, 1995.
5. University of Missouri, Kansas City, MO, School of Pharmacy, 1995.
6. Southern Illinois University Carbondale, IL, Department of Physiology, 1996.
7. University of Calgary, Calgary, Canada, Division of Endocrinology, 1997.
8. Brown University, Providence RI, Division of Endocrinology, 1997.
9. University of Arkansas, Little Rock, AK, Division of Endocrinology, 1998.
10. University of Arizona, Tucson, AZ. Division of Endocrinology, 1998.
11. University of Missouri, Columbia, MO, Division of Endocrinology, 1998.
12. Bombay University, Endocrinology and Diabetes Group, Bombay, India.
13. Tufts University, New England Medical Center, Boston, MA, 1998.
14. State University of New York at Stony Brook, Nassau County Medical Center, Department of Medicine, New York, NY, 1999.
15. University of Wisconsin, Division of Endocrinology, Madison, WI, 1999.
16. University of Southern Alabama, Division of Endocrinology, Mobile, AL, 2000.
17. University of Kansas School of Medicine, Wichita, KS. 2001.
18. Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences, Beijing, China. 2001.
19. Harbin Medical University, Harbin, China, 2001.
20. Sun Yat-sen University of Medical Sciences, Guangzhou, China, 2001.

Visiting Professorships (Cont'd):

21. Case Western Reserve University, Department of Internal Medicine/ Division of Endocrinology, Cleveland, Ohio, 2001.
22. Texas A & M University, Department of Internal Medicine, College Station/ Temple, Texas, 2001.
23. Texas Tech University, Department of Research and Development, El Paso, Texas 2002.
24. University of Wisconsin, Division of Endocrinology, Madison, Wisconsin, 2002.
25. Rush-Presbyterian-Saint Lukes Medical Center, Department of Internal Medicine, Chicago, IL, 2003.
26. Cleveland Clinic Foundation, Department of Endocrinology, Cleveland, OH. 2006.
27. University of Wisconsin, Division of Endocrinology, Madison, Wisconsin, 2006.
28. Saint Louis University, Department of Medicine, Saint Louis, MO., 2007.
29. Loyola University, Department of Medicine/Cardiology, Chicago, IL. 2011.
30. University of California in Davis, Department of Medicine, Sacramento, CA. 2011.
31. Robert Wood Johnson Medical School, Department of Medicine, New Brunswick, NJ. 2011
32. Kagawa University Medical School, Kagawa, Japan; March 2018

Invited Presentations at National/International Symposia:

1. The role of micronutrients in aging. GRECC Nutrition Conference; Sepulveda, CA 1986.
2. Nutritional management of the elderly diabetic. American College of Physicians Intensive Course in Geriatric Medicine, Santa Monica, CA, 1987.
3. Aging blood brain barrier. Gerontologic Society of America Research Symposium, Washington, DC, 1987.
4. Theories of Aging. American College of Physicians Intensive Course in Geriatric Medicine, Beverly Hills, CA, 1988.
5. Sexual dysfunction in the Elderly. University of Arizona Postgraduate Course in Geriatrics. Tucson, AZ, 1988.
6. Management of Sexual dysfunction. American Geriatric Society Symposium on Sexuality, Chicago, IL, 1989.
7. Micronutrient in Diabetes. Arizona Geriatrics Society Meeting, Phoenix, AZ, 1989.
8. Endocrine changes of aging. University of Arizona Postgraduate Course in Geriatrics, Tucson, AZ, 1990.
9. Biology of Aging. University of Arizona Postgraduate Course in Geriatrics, Tucson, AZ, 1990.
10. Sexual dysfunction. University of Arizona Postgraduate Course in Internal Medicine, Tucson, AZ, 1990.
11. Thyroid disease in the elderly. Arizona Geriatrics Society meeting, Phoenix, AZ, 1991.
12. Diabetes-related changes in blood-brain barrier. Juvenile Diabetes Foundation Symposium, Washington, DC, 1991.
13. Diabetes in the Elderly. Annual Update of Diabetes, St. Louis, MO, 1991.
14. CNS effects of diabetes. NIH Symposium on Neurobiology, Bethesda, MD, 1992.
15. Insulin resistance. V.A. National Training Program, Symposium on Diabetes. St. Louis, MO, 1992.
16. Management of Dyslipidemia. V.A. National Training Program, Symposium on Diabetes. St. Louis, MO, 1993.

Invited Presentations at National/International Symposia (cont'd):

17. Theories of Aging. GRECC annual meeting, St. Louis, MO, 1993.
18. Micronutrient in Diabetes. Nutrition Symposium, Annual Meetings of the American Diabetes Association, Las Vegas, NV, 1993.
19. Diabetes and heart Disease. GRECC Annual Meeting, St. Louis, MO, 1995.
20. Diabetes in the Elderly. American Association of Osteopathic Instructors, Ft. Lauderdale, FL, 1995.
21. Thyroid hormone and aging. GRECC Annual Meeting, St. Louis, MO, 1996.
22. Micronutrients in Diabetes. American Diabetes Association Postgraduate Course. New York, NY, 1996.
23. Age-related changes in blood brain barrier. International Symposium of Neurobiology and Neuroendocrinology, Bregenz, Austria, 1996.
24. Diabetes in the Elderly. University of Rochester, Symposium on Diabetes, Rochester, NY, 1996.
25. Micronutrients in Diabetes. American Diabetes Association Postgraduate Course. Kingston, Jamaica, 1997.
26. Diabetes in the older adult. American Diabetes Association Postgraduate Course. New Orleans, LA, 1997.
27. Diabetes in the Elderly. American Association of Clinical Endocrinologists. Keystone, CO, 1997.
28. Nutritional Therapy of Diabetes. Case Western University Symposium on Clinical Advances in Geriatric Nutrition. Cleveland, OH, 1997.
29. Diabetes in older Adults. American Geriatrics Society Bayer Symposium on Diabetes. Atlanta, GA, 1997.
30. Drug Therapy of Diabetes. Annual meeting of Consultants for Long Term Care. Scottsdale, AZ, 1997.
31. The role of antioxidants in diabetes. Nutrition Symposium in Annual meetings of the American Diabetes Association, Boston, MA, 1997.

Invited Presentations at National/International Symposia (cont'd):

32. Diabetes in Older Adults. The Endocrine Society/NIA Symposium on Endocrinology and Aging. Minneapolis, MN, 1997.
33. Diabetes in Older Adults. Annual Meeting of the National Association of Directors of Nursing Homes, Austin, TX, 1997.
34. Pharmacokinetic Profile of Statins. St. Louis College of Pharmacy Symposium on Cholesterol, St. Louis, MO, 1997.
35. Glucotoxicity. Annual GRECC Meeting, St. Louis, MO, 1997.
36. Diabetes in Older Adults. St. Louis University Annual Symposium on Diabetes, St. Louis, MO, 1997.
37. Diabetes in Older Adults. American Dietetics Association Annual Meeting, Boston, MA, 1997.
38. Diabetes in the Elderly. State University of New York, Buffalo, NY, Symposium on Diabetes, Buffalo, NY, 1997.
39. Diabetes in Older Adult, Providence Endocrine Society Meeting, Providence, RI, 1997.
40. Drug Therapy of Type 2 Diabetes. Annual Meetings of Missouri Chapter of American College of Physician, Osage Beach, MO, 1997.
41. Diabetes in Older Adult, University of Arkansas Annual Symposium on Diabetes Little Rock, AK, 1998.
42. Diabetes in Older Adult. Southern Illinois University Annual Symposium on Diabetes, Springfield, IL, 1998.
43. Drug Therapy of Older Diabetic. NIH/American Diabetes Association Symposium on Type 2 diabetes in the elderly, Phoenix, AZ, 1998.
44. Drug Therapy of Diabetes in Older Adult. National Symposium on Diabetes in Elderly, Cancun, Mexico, 1998.
45. Thiazolidinediones: role in management of diabetes Washington University Symposium on Excellence in Diabetes care. St. Louis, MO, 1998.
46. Diabetes in older adult. Annual Meetings of the Association of Consultant Pharmacists. Orlando, FL, 1998.

Invited Presentations at National/International Symposia (cont'd):

47. Management of type 2 diabetes. Missouri Department of Health seminar. A look at diabetes care and coverage in Missouri. St. Louis, MO, 1999.
48. Sexual dysfunction in diabetes. The Annual meetings of the American Urological Association, Dallas, TX, 1999.
49. Hypothyroidism: a new look at an old problem. Wisconsin Endocrine Society, Madison, WI, 1999.
50. The treatment of postprandial hyperglycemia. University of Oklahoma Symposium: Diabetes in the New Millennium, Afton, OK, 1999.
51. New drug therapies for type 2 diabetes. University of Kansas Symposium; Demystifying drug therapy: New treatments for common problems, Wichita, KS, 1999.
52. New drug therapies for hyperlipidemia. University of Kansas Symposium; Demystifying drug therapy: New treatments for common problems. Wichita, KS, 1999.
53. Diabetes in older adults. American Diabetes Association Symposium, Springfield, IL, 2000.
54. Micronutrients in diabetes mellitus. The American Diabetes Association Annual meetings. Nutrition symposium, San Antonio, TX, 2000.
55. Obesity: A rational target for managing Type 2 diabetes. 30th International Symposium on Growth Hormone, Monte Carlo, Monaco, 2000.
56. The role of Thiazolidinediones in the treatment of diabetes. Annual meetings of Mississippi Academy of Family Medicine, Natchez, MI. 20001
57. Increased oxidative load in diabetes. American Diabetes Association Annual Meetings. Symposium on Diabetes and Antioxidants, Philadelphia, PA 2001.
58. Drug therapy of type 2 diabetes. Annual Meetings of Southern Illinois Medical Association, Bellville IL 2002.
59. Erectile dysfunction in aging men. Rocky mountain androgen conference, Banff, Alberta, Canada 2002.
60. Cardiovascular Disease in Diabetes. Annual Meeting of American Association of Osteopathic Family Physicians, Kansas City, MO. 2003.

Invited Presentations at National/International Symposia (cont'd):

61. New insulin therapies. Western Hormone Alliance Meetings. Kananaskis, Alberta, Canada, 2003.
62. The rationale for combination therapy in diabetes. Post Graduate Course of Mexican Diabetes Society, Mexico City, Mexico. 2003.
63. Diabetes in long term care. Annual Symposium of the California Association of Long Term Care Physicians, Los Angeles, CA 2004.
64. Towards a single tablet therapy of type 2 diabetes. Annual Meetings of Mexican Society of Internal Medicine, Veracruz, Mexico, 2004.
65. Nutritional therapy of diabetes. Annual Meetings of Mexican Society of Internal Medicine, Veracruz, Mexico, 2004.
66. Nutritional therapy of diabetes. Middle East Medical Assembly, Beirut, Lebanon, 2005.
67. Novel therapies for type 2 diabetes. Middle East Medical Assembly, Beirut, Lebanon, 2005.
68. New insulin therapies. Armenian Medical World Congress; San Francisco, CA. 2005
69. Antioxidants and diabetes. Nestle Nutrition Workshop, Hangzhou, China 2005.
70. The role of dietary and supplemental antioxidants in diabetes, The American Diabetes Association Annual Meetings, Washington, DC, 2006.
71. Diabetes in Klinefelter's syndrome; Causes and management. Seventh National conference of the American Association for Klinefelter syndrome; Saint Louis, MO 2006.
72. Obesity in the Elderly. First International Obesity Congress, Cleveland, OH, 2006.
73. ADA 2006 nutrition guidelines for people with diabetes. 17th Annual advances and controversies in clinical nutrition, Mayo College of Medicine; Savannah, GA, 2007.
74. Evidence based recommendation guidelines for the prevention and treatment of diabetes. International Armenian Medical Society meetings, Yerevan, Armenia June 2007.
75. Drug therapy of diabetes. International Armenian Medical Society meetings, Yerevan, Armenia, June 2007.
76. Obesity in the elderly. 8th Annual Conference in obesity, University of Southern Florida, Clearwater FL, 2007.

Invited Presentations at National/International Symposia (cont'd):

77. Dietary guidelines for diabetes. 8th Annual Conference in obesity, University of Southern Florida, Clearwater FL, 2007.
78. ADA nutrition guidelines for people with diabetes. 10th symposium of Diabetes and Endocrinology, Saint Louis University, Saint Louis, MO. 2008
79. Obesity in the elderly. 9th Annual Conference in obesity, University of Southern Florida, Orlando, FL, 2008.
80. Dietary guidelines for diabetes. 9th Annual Conference in obesity, University of Southern Florida, Orlando, FL, 2008.
81. Obesity in the elderly. 10th Annual Conference in obesity, University of Southern Florida, Orlando, FL, 2009.
82. Dietary guidelines for diabetes. 10th Annual Conference in obesity, University of Southern Florida, Orlando, FL, 2009.
83. Clinical Pharmacology of diuretics. American Thoracic Society meeting, New Orleans, LA. May, 2010.
84. Diabetes in the Elderly. Endocrine Society meetings, San Diego CA, June 2010.
85. A tale of two diets: Low carb vs. Low fat. 11th Annual Conference in Obesity, University of Southern Florida, Orlando, FL, 2010.
86. Therapeutic targeting of HDL through enhanced production of apolipoprotein AI production. National Academy of Sciences, Republic of Armenia, Yerevan, Armenia, April 2011.
87. Insulin therapy in type 2 diabetes: When and How? International University of Ecuador, Quito, Ecuador, April, 2015
88. Insulin therapy in hospitalized patient. International University of Ecuador, Quito, Ecuador, April 2015.
89. Dyslipidemia in Diabetes: 27th Multidisciplinary Course of Diabetes in Mexico City; Oct. 2017.
90. Dyslipidemias. Special presentaion for the National Academy of Sciences, Mexico City; Oct. 2017.
91. Effect of naturally occurring rare sugars on cellular stress: Japan Physiologic Society; March 2018.

Presentations at Scientific Meetings (Abstracts):

1. Cortas N, Mooradian A, Abras E, Walser M. The response to aldosterone of toad and turtle bladder is associated with changes in adenine nucleotide levels. *Kidney Int.* 21:270, 1982.
2. Frayha RA, Mooradian A, Abdelnoor A, Shamma'a M, Tamar H. Familial clustering of hepatitis B and multiple vasculopathies. *Arthritis Rheum.* 25 (suppl.) E2, 1982.
3. Suidan JS, Arngoat M, Zaydan R, Mooradian A, Cortas N. Relative estrogen excess in pregnancy-induced hypertension. *Clinical and Experimental Hypertension B1:* 250, 1982.
4. Mooradian AD, Beyer HS, Ma KW, Kaiser F, Levine AS, Korchick W, Brown DM, Morley JE. The effect of aging, chronic renal failure and diabetes mellitus on human red and white cell calmodulin levels. *Endocrinology* 112:839A, 1983.
5. Shafer RB, Mooradian AD, Morley JE, Ma KW, Korchik W. Thyroid function in hemodialysis patients. *J. Nucl. Med.* 24:65, 1983.
6. Mooradian AD, Billington CJ, Nuttall FQ. Effect of co-ingestion of protein and glucose on the plasma glucose and insulin response to a glucose load. *J. Am. College of Nutr.* 2:102A, 1983.
7. Morley GK, Mooradian AD, Levine AS, Morley JE. Glucose infusion produces hyperalgesia in humans. *Clin. Res.* 31(2):392A, 1983.
8. Billington CJ, Mooradian AD, Duffy L, Lange P, Morley JE. Testosterone therapy in impotent patients with normal testosterone. *Clin Res.* 31(4):713A, 1983.
9. Mooradian AD, Schwartz HL, Oppenheimer JH. Free intranuclear and cytosolic T₃: Evidence for reduction in active transport of T₃ in the isolated hepatocyte as compared to in situ cells. Program of 60th Annual Meeting of American Thyroid Association, 1984.
10. Freake HC, Mooradian AD, Schwartz HL, Oppenheimer JH. Stereospecific transport of T₃ to cytoplasm and nucleus in GH cells. Program of the Annual Meeting of the Endocrine Society, 1985.
11. Mooradian AD, Mariash CN. Effect of insulin on gene expression in isolated hepatocyte cultures. Program of the Annual Meeting of the Endocrine Society, 1986.
12. Mooradian AD. Blood-brain barrier (BBB) choline transport in aged rats. 16th Annual Neuroscience Meeting, 409.10, 1986.
13. Hartnell JM, Mooradian AD, Morley JE. DNA strand breaks in white blood cells of young, aged, and aged diabetic subjects. *Clin. Res.* 35(1):97A, 1987.

Presentations at Scientific Meetings (Abstracts) (cont'd):

14. Osterweil D, Mooradian AD, Petrusek D, Morley JE. Diabetes mellitus in ambulatory elderly and nursing home patients: A survey of clinical characteristics and management. Clin. Res. 35(1):98A, 1987.
15. Korenman SG, Stanik-Davis S, Mooradian AD, Viosca S, Garza D. Evidence for a high prevalence of hypogonadotropic hypogonadism in sexually dysfunctional older men. Clin. Res. 35(1):182A, 1987.
16. Mooradian AD, Song MK. Using chamber studies of intestinal zinc transport rate in the aged rat. Clin. Res. 34(1):98A, 1987.
17. Mintz GA, Mooradian AD. Age-related morphologic changes in rat sublingual salivary glands. Fed. Proc. 46(3):1091, 1987.
18. Song MK, Mooradian AD. Effects of streptozotocin-induced diabetes, insulin and arachidonic acid on the intestinal zinc flux rate of rats. Fed. Proc. 46(3):599, 1987.
19. Flood JM, Morley JE, Mooradian AD. Learning and memory impairment in diabetic mice. Fed. Proc 46(3):1279, 1987.
20. Hartnell JM, Husain K, Mooradian AD, Morley JE. DNA strand breaks in white blood cells of young, aged and aged diabetic subjects. Clin. Res. 35:505A, 1987.
21. Mooradian, AD. Blood-brain barrier choline transport is reduced in diabetic rats. Clin. Res. 35:512A, 1987.
22. Mooradian, AD. The effect of ascorbate and dehydroascorbate on tissue uptake of glucose. Clin. Res. 35:512A, 1987.
23. Kaiser FE, Viosca SP, Morley JE, Mooradian AD, Davis SS, Korenman SG. Clinical and hormonal correlates of impotence in men over the age of 40. Clin. Res. 36(1):123A, 1988.
24. Korenman SG, Mooradian AD, Kaiser FE, Morley JE, Davis SS, Viosca SO. Treatment of vasculogenic sexual dysfunction with pentoxifylline. Clin. Res. 36(1):123A, 1988.
25. Mooradian AD, Norman DC, Morley JE. The effect of zinc status on the immune function of diabetic rats. Clin. Res. (36):157A, 1988.
26. Kaiser FE, Viosca SP, Mooradian AD, Morley JE, Korenman SG. Impotence and aging: alterations in hormonal secretory patterns with age. Clin. Res. 21.

Presentations at Scientific Meetings (Abstracts) (cont'd):

27. Mooradian, A.D. Blood-brain barrier choline transport is reduced in diabetic rats. Clin. Res. 35:512A, 36(1):96A, 1988.
28. Deebaj L, Song MK, Mooradian AD. The effect of dietary zinc content on micronutrient status of control and diabetic rats. Clin. Res. 36(1):166A, 1988.
29. Mooradian AD, Lieberman J. The serum angiotensin-converting enzyme (ACE) activity is decreased in the aged rat. The role of thyroidal status and food intake. Clin. Res. 36(1):96A, 1988.
30. Hartnell JH, Mooradian AD. Alkali-induced DNA unwinding is reduced in the liver and brain of aged rats. Clin. Res. 36(1):96A, 1988.
31. Mooradian AD, Song MK. Age-related alterations in intestinal calcium transport rate in rats. Clin. Res. 36(1):97A, 1988.
32. Deebaj L, Song MK, Mooradian AD. Levels and distribution of zinc, copper, magnesium, and calcium in control and diabetic rats fed different levels of dietary zinc. J. FASEB 2:A635, 1988.
33. Kaiser FE, Viosca SP, Mooradian AD, Morley JE, Korenman SG. Impotency and aging: Alterations in hormonal secretory patterns with age. Program of the Annual Meeting of the Endocrine Society, p. 215, 1988.
34. Mooradian AD. Effect of aging on stereospecific transport of 3-5-3' triiodothyronine (T₃) to cytoplasm and nucleus in rat liver. Program of the Annual Meeting of the Endocrine Society, p 217, 1988.
35. Hartnell JM, Storrie MC, Mooradian AD. Alkali-induced DNA unwinding is reduced in liver and brain of aged rats. Program of the Annual Meeting of the Gerontological Society of America, 1988.
36. Hartnell JM, Storrie MD, Mooradian AD. Alkali-induced DNA unwinding is reduced in diabetic rats and mice. Clin. Res. 37(1), 1989.
37. Deebaj L, Song MK, Mooradian AD. The effect of dietary zinc content on the levels and distribution of copper and zinc in control and diabetic rats. American Chemical Society Symposium Copper Bioavailability and Metabolism. Dallas, Texas, 1989.
38. Clements N, Bluestein M, Reed R, Mooradian AD. Bacterial pneumonia in hospitalized young, old, and old-old patients: Comparison of presentation on admission. The Annual Meeting of the American Geriatrics Society, Boston, MA, 1989.

Presentations at Scientific Meetings (Abstracts) (cont'd):

39. Mooradian AD, Deebaj L, Wegerhoff J, Wong NCW. Age-related alterations in the response of hepatic lipogenic enzymes to altered thyroid states. The Program of the Annual Meeting of the Endocrine Society, Seattle, WA, 1989.
40. Kershner Riggs G, Greiff V, Mooradian A, Meredith K, Reed R, Yochum K, Martinez C. Medical and psychosocial determinants of sexuality in elderly women. Program of the Annual Meeting of the Gerontological Society of America, 1989, p 48A.
41. Hartnell J, Mooradian AD. Alkali-induced DNA unwinding rate: A potential biomarker of aging. Program of the Annual Meeting of the Gerontological Society of America, 1989. Session #86.
42. Reed RL, Mooradian AD, Osterweil D, Clements N, Scuderi P. Lack of an association between the presence of tumor necrosis factor or interleukin-1 alpha in the blood and weight loss among elderly patients. Clin. Res. 38:82A, 1990.
43. Mooradian AD. The blood-brain barrier transport of glucose and butyrate is reduced in aged rats. Clin. Res. 38:81A, 1990.
44. Osterweil D, Mooradian AD, Mazorra L, Marshall CE. The effect of body weight loss on blood glucose levels in institutionalized diabetic patients. Program of the Annual Meeting of the American Geriatrics Society, 1990.
45. Habib M, Dickerson F, Mooradian AD. Increased in vivo ethane production in diabetes. Program of the Annual Meeting of the American Thoracic Society, 1990, Am. Rev. Resp. Dis. 141:A544, 1990.
46. Mooradian AD, Dickerson F, Habib M. The effect of age and food restriction on thyroid hormone-induced lipid peroxidation. Program of the Annual Meeting of the Endocrine Society. Atlanta, GA, 1990.
47. Romney JS, Solyol MA, Deschamps BJ, Wanke IE, Carr FE, Mooradian AD, Wong NCW. L-triiodothyronine (T₃) regulates S11/Apolipoprotein A₁ (APO A₁) gene expression in rat liver and small intestine. Program of the Annual Meeting of the Endocrine Society, Atlanta, GA, 817 A, 1990.
48. Evans SE, Lee I, Yee D, Nixon B, Mooradian AD. The prevalence and nature of podiatric problems in elderly diabetic patients. Program of the Annual Meeting of the Gerontological Society of America, Boston, 1990.
49. Scuderi P, Reed R, Mooradian AD. In vitro interleukin-1 beta production is reduced in healthy elderly subjects. Program of the Annual Meeting of the Gerontological Society of America, Boston, 1990.

Presentations at Scientific Meetings (Abstracts) (cont'd):

50. Reed RL, Perlmutter L, Yochum K, Meredith KE, Mooradian AD. The relationship between muscle mass and muscle strength in the elderly. Program of the Annual Meeting of the Gerontological Society of America, Boston, 1990.
51. Mooradian AD, Scarpace PJ. Adrenergic beta receptor activity of cerebral microvasculature is reduced in aged rats. Program of the Annual Meeting of the Gerontological Society of America, Boston, 1990.
52. Mooradian AD. Biomarkers of Aging. Program of the 26th Annual Meeting of the Society of Prospective Medicine, Mesa, 1990.
53. Reed RL, Osterweil D, Scuderi P, Mooradian AD. Elevated serum levels of tumor necrosis factor alpha predicts early mortality in elderly institutionalized patients. Clin. Res. 39:87A, 1991.
54. Mooradian AD. Age-related changes in protein profile of rat cerebral microvessels. Computer analysis of two-dimensional (2D) electrophoresis. Clin. Res. 39:87A, 1991.
55. Ruttinger AC, Reed R, DenHartog R, Perlmutter L, Yochum K, Mooradian AD. A comparison of hand held isometric strength measurement with isokinetic muscle strength measurement in the elderly. Program of the 48th Annual Meeting of the American Geriatrics Society. Chicago, 1991 p. 43.
56. Reed R, Yochum K, Perlmutter L, Mooradian AD. The level of physical exercise in healthy elderly population is not a predictor of body adiposity. Program of the 48th Annual Meeting of the American Geriatrics Society. Chicago, 1991, p. 76.
57. Friedman D, Mooradian AD. The prevalence of overmedication with levothyroxine in ambulatory elderly patients. Program of the 48th Annual Meeting of the American Geriatrics Society. Chicago, 1991, p. 44.
58. Scuderi P, Reed R, Duerr M, Mooradian AD. The effect of age and diabetes mellitus on serum levels of lymphotoxin tumor necrosis factor beta (TNF β). Program of the Annual Meeting of the Gerontological Society of America. San Francisco, 1991; p 79.
59. Escobar G, Mooradian AD. Age-related differences in dietary regulation of lipogenic enzymes in rat liver and adipose tissue. Program of the Annual Meeting of the Gerontological Society of America. San Francisco, 1991, p 76.
60. Reed R, Kligman E, Yochum K, Perlmutter L, Meredith K, Mooradian AD. Predictors of the serum lipid profile in a healthy elderly population. Program of the Annual Meeting of the Gerontological Society of America. San Francisco, 1991, p 360.

Presentations at Scientific Meetings (Abstracts) (cont'd):

61. Mooradian AD, Smith TL. The effect of age on lipid composition and order of rat cerebral microvessels. Program of the Annual Meeting of the Gerontological Society of America. San Francisco, 1991, P 279.
62. Mooradian AD, McCuskey RS. In vivo microscopic studies of age-related changes in the structure and the reactivity of cerebral microvessels. Clin Res. 40: 17A, 1992.
63. Mooradian AD, Scarpace PJ. Beta-adrenergic receptor activity of cerebral microvessels. Clin Res. 40:108A, 1992.
64. Mooradian AD, Scarpace PJ. Beta-adrenergic receptor activity of cerebral microvessels in experimental diabetes mellitus. 74th Annual Meeting of the Endocrine Society, 1992, p 92.
65. Mooradian AD, Grabau G, Uko-eninn A. In Situ quantitation of the age-related and diabetes-related changes in cerebral endothelial barrier antigen. Clin Res 41:9A, 1993.
66. Mooradian AD, Pinna JL, Lung CC, Yahya MD, Meredith K. Diabetes-related changes in the protein composition of rat cerebral microvessels. Clin Res 41:69A, 1993.
67. Meijer ME, Mooradian AD, Wong NCW. Aging alters the activity of specific transcription factors that regulate the thyroid hormone responsive S₁₄ gene. Clin Res 41:83A, 1993.
68. Reed R, Kligman E, Abyad A, Yochum K, Mooradian A. Predictors of the lipid profile in a healthy elderly population. Clin Res 41:103A, 1993.
69. Giddings SS, Carnaghi LR, Mooradian AD. Effects of aging on gene expression in islet cells. 75th Annual Meeting of the Endocrine Society 1993, p. 368.
70. Wehmeier KR, Mooradian AD. Antioxidative potential of glucose and other simple carbohydrates. 75th Annual Meeting of the Endocrine Society 1993, P 424.
71. Friedman D, Reed R, Verdari R, Mooradian AD. Growth hormone therapy in the elderly. Annual Meeting of Am Geriatric Society 1993.
72. Fox-Robichaud A, Mooradian AD, Wong NCW. Senescence alters the activity of specific transcription factors that regulate the thyroid hormone responsive S₁₄ gene. Canadian Society of Clinical Investigation 1993.
73. Mooradian AD, Bastani B. The blood brain barrier proton translocating ATPases in diabetic and aged rats. Clin Res 42:13A, 1994.

Presentations at Scientific Meetings (Abstracts) (cont'd):

74. Shah G, Byers P, Mahmoud S, Wong NC, Mooradian AD. Age-related changes in thyroid hormone induced hepatic Apo A₁ mRNA expression. 76th Annual Meeting of the Endocrine Society, 1994, P538.
75. Shah G, Mooradian AD. Age-related shortening of poly (A) tail of albumin mRNA. J. Invest. Med. 43:156A. 1995.
76. Shah G, Byers P, Mooradian AD. Identification of thyroid hormone responsive genes in adult rat cerebral tissue. 77th Annual Meeting of the Endocrine Society 1995. P2-447.
77. Shah GN, Mooradian AD. Differential display of thyroid hormone responsive mRNA in adult rat cerebral tissue. J. Invest. Med. 44:104A, 1996.
78. Shah, GN, Giddings SJ, Mooradian AD. Shortening of poly (A) tail of GLUT-1 mRNA in experimental diabetes mellitus. 10th International Congress of Endocrinology, 1996 P2-68.
79. Shah GN, Mooradian AD. Cloning of the cDNA and characterization of a thyroid hormone responsive protein in adult rat cerebrum. J. Invest Med. 1997.
80. Mooradian AD, Shah GN. Age-related changes in GLUT-1 mRNA structure and function. J. Invest. Med. 1997.
81. Mooradian AD, Neumann C. PRECOSE resolution of optimal titration to enhance current therapies (PROTECT) study: Experience in the elderly. Annual Meeting of the American Geriatrics Society, Atlanta, GA, 1997.
82. Shah GN, Li J-P, Schneiderjohn P, Mooradian AD. Characterization of a thyroid hormone responsive protein in adult rat cerebrum. Annual Meeting of the Endocrine Society, Minneapolis, MN, 1997.
83. Shah GN, Mooradian AD. Cerebral tissue responsiveness to thyroid hormones in aging rats. J. Invest Med. 1998.
84. Shah GN, Mooradian AD. Cerebral tissue responsiveness to thyroid hormones in aging rats. Annual Meeting of the Endocrine Society, New Orleans, LA, 1998.
85. Freedman BI, Weurth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS. Design end baseline characteristics for the aminoguanidine clinical trial in overt type II diabetic nephropathy. (ACTION II). Annual Meeting of the American Diabetes Association, Chicago, IL, 1998.

Presentations at Scientific Meetings (Abstracts) (cont'd):

86. Fujioka K, Weinstein SP, Rowe E, Mooradian AD. Sibutramine enhances weight loss and maintenance in obese hypertensive patients taking calcium channel blocker. European Congress on Obesity, Milan, Italy, 1999.
87. Chehade J, Kim J, Pinnas J, Mooradian AD. Malondialdehyde modification of rat cerebral proteins is reduced in experimental hypothyroidism. Annual Meetings of the Western Society of Clinical Investigation, Carmel, CA, 1999.
88. Thampy KJ, Haas MJ, Mooradian AD. Troglitazone activates acetyl-coenzyme A carboxylase at a post-translational level. The Annual Meeting of the Endocrine Society, San Diego, CA, 1999. p.464.
89. Thampy KJ, Haas MJ, Li J-P, Mooradian AD. Age-related changes in mRNA expression and activity of acetyl-coenzyme A carboxylase. The Annual Meeting of the Endocrine Society, San Diego, CA, 1999. p. 228.
90. Kim J, Chehade J, Pinnas JL, Mooradian AD. Malondialdehyde modification of rat cerebral proteins is reduced in experimental hypothyroidism. The Annual Meeting of the Endocrine Society, San Diego, CA, 1999. p. 207.
91. Haas MJ, Pun K, Reinacher D, Wong NCW, Mooradian AD. Fasting induces apolipoprotein A1 expression: The role of ketones. The Annual Meeting of the Endocrine Society. San Diego, CA, 1999. p.352.
92. Fujioka K, McMahan FG, Mendel CM, Rowe E, Mooradian AD. Efficacy and safety of sibutramine in promoting and maintaining weight loss in obese African Americans and Caucasians with hypertension controlled by calcium channel blockers. Annual Meeting of the North American Association for the Study of Obesity (NAASO), Charleston, SC, 1999.
93. Mooradian AD, Weber MA, Shreve PE. Well-controlled hypertension in obese patients remains well-controlled during weight reduction on sibutramine treatment. The American Society of Hypertension Meetings, New York, NY, May, 2000. Published in Am. J. Hypertension,13 (4, part 2), 2000, S128
94. Haas MJ, Li J-P, Mooradian AD. Thyroid hormone responsive protein (THRP) is not the rat homologue of c-Abl interactor protein (Abi-2). The Annual Meetings of the Endocrine Society, Toronto, Canada, 2000, p. 377.
95. Chehade JM, Hurd R, Punn K, Haas MJ, Mooradian AD. Age-related changes in plasma leptin binding activity in rats. A comparison of a simple acid-ethanol precipitation technique with column chromatography. The Annual Meetings of the Endocrine Society. Toronto, Canada, 2000, p.73.

Presentations at Scientific Meetings (Abstracts) (cont'd):

96. Chehade JM, Mooradian AD. Serum leptin response to endogenous hyperinsulinemia in aging rats. The Annual Meetings of the Endocrine Society, Toronto, Canada, 2000, p.73.
97. Chehade JM, Silverberg AB, Kim J, Case C, Mooradian AD. The role of repeat fine-needle aspiration of thyroid nodules with benign cytologic findings. The Annual Meetings of the Endocrine Society, Toronto, Canada, 2000, p.592.
98. Haas MJ, Reinacher D, Wong NCW, Mooradian AD. Regulation of apolipoprotein A1 gene expression in acidosis: Requirement for transcriptional repressor. The Annual Meetings of the Endocrine Society, Toronto, Canada, 2000, p.113.
99. Haas MJ, Punn K, Reinacher D, Wong NCW, Mooradian AD. Effects of ketoacidosis on rat apolipoprotein A1 gene expression: A link with acidosis but not with ketones. The Annual Meetings of the Endocrine Society. Toronto, Canada, 2000, p.88.
100. Deleon MJ, Horani M, Haas MJ, Mooradian AD. Androgenic steroids downregulate apolipoprotein A1 promoter activity. The Annual Meetings of the Endocrine Society. Toronto, Canada, 2000, p.114.
101. Garber A, Mooradian A, Schneider S, Piper BA, Henry D. Metformin/glyburide tablets as first-line therapy in type 2 diabetes achieve glycemic control at lower final doses versus metformin or glyburide. The Annual Meetings of the American Association of Clinical Endocrinologists, Atlanta, GA, 2000.
102. Donovan DS, Mooradian A, Schneider S, Piper BA, Henry D. Treatment of type 2 diabetes with metformin/glyburide tablets: An open label study, interim report. The Annual Meetings of the American Association of Clinical Endocrinologists, Atlanta, GA, 2000.
103. Poretsky L, Mooradian A, Buse J, Kyner J, Henry D. Effect of metformin/glyburide tablets on lactic acid in patients with type 2 diabetes. The Annual Meetings of the American Diabetes Association. San Antonio, TX, 2000.
104. Davidson J, Garber A, Mooradian A, Schneider S, Henry D. Metformin/glyburide tablets as first line treatment in type 2 diabetes: Distribution of HbA1c response. The Annual Meetings of the American Diabetes Association, San Antonio, TX, 2000.
105. Garber A, Mooradian A, Davidson J, Piper BA. Effect of metformin/glyburide tablets on HbA1c in first-line treatment of type 2 diabetes. The Annual Meetings of the American Diabetes Association, San Antonio, TX, 2000.

Presentations at Scientific Meetings (Abstracts) (cont'd):

106. Donovan D, Mooradian A, Rosenstock J, Henry D. Effect of metformin/glyburide tablets on fasting glucose in type 2 diabetes. The Annual Meetings of the American Diabetes Association. San Antonio, TX, 2000.
107. Haas MJ, Kahn A, Li J, Wong NCW, Mooradian AD. Changes in intracellular PH and ion balance repress the apolipoprotein A1 gene promoter. The Annual Meetings of the Endocrine Society, Denver, CO. 2001.p.154.
108. Chehade JM, Haas MJ, Mooradian AD. Diabetes-related changes in rat cerebral occludin and zona occludens 1 (zo-1) expression. The Annual Meetings of the Endocrine Society, Denver, CO. 2001. p.223.
109. De Leon MS, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 (GLP-1) response to acarbose in elderly type 2 diabetic subjects. The Annual Meetings of the Endocrine Society, Denver, CO. 2001.p.415.
110. Haas MJ, Reinacher D, Wong NC, Mooradian AD. Basal apolipoprotein A1 gene expression in HepG2 cells: Requirement for MEK and protein kinase C. The Annual Meetings of the Endocrine Society, Denver, CO. 2001.p.539.
111. Haas MJ, Parseghian SA, Sajid RM, Mooradian AD. Effect of exogenous thyroid hormone responsive protein (THRP) expression on PC12 cell survival. The Annual Meetings of the Endocrine Society, San Francisco CA., 2002, page 201.
112. Haas MJ, Horani M, Plummer B, Li J-P, Wong NCW, Mooradian AD. Induction of the apolipoprotein AI promoter by insulin is repressed by saturated fatty acids. The Annual Meetings of the Endocrine Society, San Francisco CA., 2002, page584.
113. Haas MJ, Wadud K, Wong NCW, Mooradian AD. Antioxidants suppress the apolipoprotein AI (apoAI) promoter in the cultured hepatoma cell line, HepG2. The Annual Meetings of the Endocrine Society, San Francisco CA., 2002, page 262
114. Stewart G Albert SG, Mooradian AD, Cestia AT, Hackney LS Low-dose growth hormone (GH) as an adjuvant to life style modifications in the therapy of obesity. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
115. Haas MJ, Horani M, Wong NCW, Mooradian AD. Suppression of apolipoprotein AI gene expression by TNF α and IL-1 β . The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.

Presentations at Scientific Meetings (Abstracts) (cont'd):

116. Horani M, Gobal F, Haas MJ, Wong NCW, Mooradian AD. Cyclooxygenase (COX) inhibition is associated with downregulation of apolipoprotein AI (Apo-AI) promoter activity in cultured hepatoma cell line-HepG2. The Annual Meetings of the Endocrine Society, Philadelphia, PA. 2003.
117. Haas MJ, Wong NCW, Mooradian AD. Induction of apolipoprotein AI gene expression by glucosamine. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
118. Haas MJ, Horani M, Wong NCW, Mooradian AD. Saturated fatty acids repress insulin-induction of the apolipoprotein AI gene promoter through inhibition of Sp1 activity. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
119. Myers SE, Albert SA, Haas MJ, Mooradian AD. Pubertal changes in serum leptin levels in type 1 diabetic adolescents: A controlled longitudinal study. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
120. Haas MJ, Parseghian SA, Sajid RM, Mooradian AD. Cell specificity of thyroid hormone responsive protein (THRP) –related cytotoxicity. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
121. Haas MJ, Fishman M, Mreyoud A, Mooradian AD. Thyroid hormone responsive protein (THRP) mediates thyroid hormone-induced cytotoxicity in primary neuronal cultures. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
122. Horani M, Haas MJ, Mooradian AD. Rapid adaptive changes in oxidative burst induced by high glucose in human umbilical vein endothelial cells (HUVEC). The Annual Meetings of the American Diabetes Association, New Orleans, LA, 2003.
123. Haas MJ, Mreyoud A, Fishman M, Mooradian AD. Microarray analysis of thyroid hormone induced changes in mRNA expression in the adult rat brain. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
124. Haas MJ, Fishman M, Mreyoud A, Mooradian AD. Induction of thyroid hormone responsive protein and cell death by thyroid hormones in primary rat cerebral neurons. The Annual Meetings of the Endocrine Society, New Orleans, LA., 2004, p207.
125. Snyder PJ, Biller MK, Zagar A, Jackson I, Arafah BM, Nippoldt TB, Cook DM, Mooradian AD, Althouse SK, Chipman JJ, Hartman ML. Growth hormone (GH) replacement increases lumbar spine bone mineral density (BMD) in patients with adult onset GH deficiency. The Annual Meetings of the Endocrine Society, New Orleans, LA., 2004, p258.

Presentations at Scientific Meetings (Abstracts) (cont'd):

126. Haas MJ, Horani M, Mooradian AD. Carvedilol suppresses hyperglycemia-induced superoxide formation and endothelial cell toxicity. The Annual Meetings of the Endocrine Society, New Orleans, LA., 2004, p318.
127. Haas MJ, Wadud K, Wong NCW, Mooradian AD. Differential effects of antioxidants on apolipoprotein AI gene expression in Hep G2 cells. The Annual Meetings of the Endocrine Society, New Orleans, LA., 2004, p350.
128. Wehmeier KW, Haas MJ, Mooradian AD. Apolipoprotein A-I promoter is down-regulated by vitamin D. Annual Meetings of the American Society of Bone and Mineral Metabolism, 2004.
129. Wehmeier KW, Beers AE, Haas MJ, Wong NCW, Mooradian AD. Vitamin D receptor antagonist ZK-191784 reverses inhibition of apo AI gene expression by 1α , 25-dihydroxycholecalciferol. The Annual Meetings of the Endocrine Society, San Diego, CA, 2005, p225.
130. Haas MJ, Wadud K, Mooradian AD. High-dose antioxidants down regulate apolipoprotein AI gene expression through a negative antioxidant response element within site A of the promoter. The Annual Meetings of the Endocrine Society, San Diego, CA, 2005, p230.
131. Haas MJ, Feman SS, Mooradian AD. Prevention of endothelial barrier dysfunction of diabetes with rosuvastatin treatment. The Annual Meetings of the Endocrine Society, San Diego, CA, 2005, p263.
132. Haas MJ, Horani MH, Mooradian AD. Free-fatty acids selectively augment oxidative burst induced by high dextrose in human umbilical vein endothelial cells. The Annual Meetings of the Endocrine Society, San Diego, CA, 2005, p263.
133. Beers AE, Haas MJ, Wong NCW, Mooradian AD. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor α : Roles for MEK/ERK and JNK signaling. The Annual Meetings of the Endocrine Society, San Diego, CA, 2005, p373.
134. Albert SG, Hasnain BI, Ritter DG, Joist H, Mooradian AD. Aspirin sensitivity of platelet aggregation in diabetes mellitus. The Annual Meetings of the American Diabetes Association, New San Diego, CA, 2005. 689 p in Diabetes 54 (suppl 1):A170.
135. Albert SG, Haas MJ, Mooradian AD. The effect of recombinant human growth hormone (rhGH) supplementation on vascular inflammatory markers in obese subjects. The Annual Meetings of the American Diabetes Association, New San Diego, CA, 2005. 1823 p in Diabetes 54 (suppl1):A438.

Presentations at Scientific Meetings (Abstracts) (cont'd):

136. Wehmeier KW, Haas MJ, Beers AE, , Mooradian AD. Vitamin D receptor antagonist ZK 191784 augments apoA1 gene expression The Annual Meetings of the American Society for Bone and Mineral Research, Nashville, TN, 2005.
137. Haas, Michael J., Parseghian, S., Laz, B., Wong, N.C.W., and Mooradian, A.D. Inhibition of apolipoprotein AI gene expression by TNF α : requirement for JNK/c-jun activation. The Annual Meetings of the Endocrine Society, Boston, MA, 2006, Abstract # P1-455, p. 275.
138. Haas, M.J., and Mooradian, A.D. Statins ameliorate glomerular permeability changes in streptozotocin diabetic rats. The Annual Meetings of the Endocrine Society, Boston, MA, 2006, Abstract # P3-107, p. 663.
139. Parseghian S., Horain M.H., Haas, M.J., and Mooradian, A.D. Prevention of dextrose-induced endothelial cell dysfunction by statins through possible inhibition of superoxide formation. The Annual Meetings of the Endocrine Society, Boston, MA, 2006, Abstract # P3-412, p. 741.
140. Wehmeier, K.R., Haas, M.J., Beers, A., Wong, N.C.W., and Mooradian, A.D. Differential effects of vitamin D receptor ligands on apolipoprotein AI gene expression. The Annual Meetings of the Endocrine Society, Boston, MA, 2006, Abstract # P3-53, p. 649.
141. Mooradian AD, Albert SG, Lombardero M, Brooks MM, for the BARI 2D Trial Investigators. Anti-diabetes drug utilization in diabetic patients with coronary heart disease (CHD) enrolled in BARI 2D trial. The 67th Annual Meetings of the American Diabetes Association, Chicago, IL. Diabetes 56 (suppl 1); A549, 2007
142. Albu JB, Lu J, Mooradian AD, Nesto RW, Porter M, Rana JS, Rogers WJ, Gottlieb S. Comparison of the association of body mass index vs. waist circumference with atherogenic risk factors in subjects with type 2 diabetes and documented coronary disease in the BARI2D trial. The 67th Annual Meetings of the American Diabetes Association, Chicago, IL. Diabetes 56 (suppl 1); A268, 2007
143. Ligaray K, Hachem S, Mazza A, Senkottaiyan N, Wong NCW, Mooradian AD, Haas MJ. Repression of apolipoprotein A-I gene expression by anandamide. The 67th Annual Meetings of the American Diabetes Association, Chicago, IL. Diabetes 56 (suppl 1); A56, 2007
144. Wehmeier KR, Hachem S, Ligary K, Mazza A, Senkottaiyan N, Wong NCW, Mooradian AD, Haas MJ. Differential tissue-specific effects of vitamin D receptor ligands on apolipoprotein A-I gene expression. The Annual Meetings of the Endocrine Society, Toronto, Canada, 2007
145. Chehade JM, Lim W, Silverberg AB, Mooradian AD. The incidence of Hashimoto's disease in nodular goiter: The concordance in serologic and cytologic findings. The Annual Meetings of the Endocrine Society, San Francisco, CA, 2008.

Presentations at Scientific Meetings (Abstracts) (cont'd):

146. Haas MJ, Wong NCW, Mooradian AD. Regulation of apolipoprotein A-I gene expression by tumor necrosis factor α and activator protein-1. The Annual Meetings of the Endocrine Society, San Francisco, CA, 2008.
147. Sheikh-Ali, M., Sultan, S., Alamir, A.-R., Haas, M.J., and Mooradian, A.D. Hyperglycemia-induced endoplasmic reticulum stress in endothelial cells: evidence for mitochondrial origin of the stress signal. Endocrine Society 91st Annual Meeting, Washington DC, 2009.
148. Alamir, A.-R., Wehmeier, K.R., Sultan, S., Haas, M.J., Wong, N.C.W., and Mooradian, A.D. Regulation of apolipoprotein A-I gene expression by the vitamin D metabolite 24, 25 dihydroxycholecalciferol. Endocrine Society 91st Annual Meeting, Washington DC, 2009.
149. Sultan, S., Sheikh-Ali, M, Alamir, A.-R., Haas, M.J., and Mooradian, A.D. Uncoupling of hyperglycemia-induced oxidative stress and endoplasmic reticulum stress in endothelial cells. Endocrine Society 91st Annual Meeting, Washington DC, 2009.
150. Chegade JM, Alcalde R, Naem E, Sultan S, Alamir A-R, Haas MJ, Wong NCW, Mooradian AD. Induction of apolipoprotein A-I gene expression by Glucagon-Like Peptide-1 and Exendin-4. The Endocrine Society Annual Meeting, San Diego, CA 2010.
151. Sheikh-Ali M, Raheja P, Hass MJ, Mooradian AD. Sex steroid-dependent inhibition of hyperglycemia-induced endoplasmic reticulum stress in endothelial cells. American Association of Clinical Endocrinologists Annual Meeting, Boston, MA.2010
152. Alcalde R, Naem E, Sultan S, Alamir A-R, Haas MJ, Mooradian AD. Inhibition of endoplasmic reticulum stress in hepatocytes by high density lipoproteins (HDL). The Endocrine Society Annual Meeting, San Diego, CA 2010
153. Naem E, Haas MJ, Mooradian AD. Inhibition of hepatic apolipoprotein A-I secretion by endoplasmic reticulum stress. Annual Meeting of the American Association of Clinical Endocrinologist, Boston, MA, April 2010.
154. Naem E, Alcalde R, Gladysz M, Mesliniene S, Sheikh-Ali M,, Haas MJ, Wong NCW, Mooradian AD. Smoking-related dyslipidemia and inhibition of apolipoprotein A-I gene expression by the aryl hydrocarbon receptor. Endocrine Society 93rd Annual Meeting, Boston, MA, 2011.
155. Mesliniene S, Gladysz M, Naem E, Alcalde R, Wehmeier KR, Mooradian AD, Haas MJ. Upregulation of apolipoprotein A-I gene expression in vitamin D receptor knockout mice. Endocrine Society 93rd Annual Meeting, Boston, MA, 2011.

Presentations at Scientific Meetings (Abstracts) (cont'd):

156. Alcalde R, Naem E, Raheja P, Sheikh-Ali M, Mooradian AD, Haas MJ. Estrogen-dependent inhibition of hyperglycemia-induced endoplasmic reticulum stress and superoxide generation in endothelial cells. American Association of Clinical Endocrinologists 20th Annual Meeting, San Diego, CA, 2011.
157. Gladysz M, Alcalde R, Naem E, Mesliniene S, Jaimungal S, Mooradian AD, Wong NCW, Haas MJ. Inhibition of apolipoprotein A-I gene expression in hepatocytes by TNF alpha requires the pro-inflammatory transcription factor c-jun. American Association of Clinical Endocrinologists 20th Annual Meeting, San Diego, CA, 2011.
158. Maharaj J, Jaimungal S, Wehmeier K, Mooradian AD, Haas MJ. Non genomic signaling by 24, 25-dihydroxyvitamin D3 in HepG2 cells. Southern AFMR Meetings. J. Invest. Med 60:348, 2012.
159. Jafri SH, Wang J, Wang S, Mooradian A, Haas, M. Inhibition of endoplasmic reticulum stress by vitamin D in endothelial cells. Southern AFMR Meetings. J. Invest. Med 60:435, 2012.
160. Gladysz M, Meslinienne S, Wong NCW, Mooradian AD, Haas MJ. Inhibition of hepatic apolipoprotein A-I gene expression by tumor necrosis factor alpha: Requirement for *c-jun*. Endocrine Society 94th Annual Meeting, Houston, TX, 2012.
161. Szafran-Swiertlik A, Jafri SH, Wang J, Wang S, Mooradian AD, Haas, MJ. Inhibition of endoplasmic reticulum stress by vitamin D in endothelial cells. Endocrine Society 94th Annual Meeting, Houston, TX, 2012.
162. Meslinienne S, Gladysz M, Naem E, Wehmeier K, Mooradian AD, Haas MJ. Elevated apolipoprotein A-I gene expression in vitamin D receptor knockout mice. American Association of Clinical Endocrinologists, 21st Annual Meeting, Philadelphia, PA. 2012.
163. Haas MJ, Onstead-Haas L, Naem E, Gladysz M, Mesliniene S, Sheikh-Ali M, Wong NCW, Mooradian AD. Inhibition of hepatic apolipoprotein A-I gene expression by aryl hydrocarbon receptor agonists. American Association of Clinical Endocrinologists, 21st Annual Meeting, Philadelphia, PA. 2012.
164. Wehmeier, KR, Jaimungal S, Maharaj J, Mooradian AD, Haas MJ. 24, 25-Dihydroxyvitamin D3 signals through non-vitamin d receptor pathways in HepG2 cells. ASBMR annual meeting, Minneapolis, MN 2012
165. Makhoul-Ahwach, S., Onstead-Haas, L.M., Mooradian, A.D., and Haas, M.J. The effect of black seed (*Nigella sativa*) extract on FOXO3 expression in HepG2 cells. Endocrine Society 95th Annual Meeting, San Francisco, CA, 2013.

Presentations at Scientific Meetings (Abstracts) (cont'd):

166. Kojanian, H., Onstead-Haas, L.M., Naem, E., Wong, N.C.W., Mooradian, A.D., and Haas, M.J. Induction of apolipoprotein A-I gene expression by black seed (*Nigella sativa*) extracts. Endocrine Society 95th Annual Meeting, San Francisco, CA, 2013.
167. Makhoul-Ahwach S, Onstead-Haas L, Mooradian AD, Haas MJ. The effect of black seed (*Nigella sativa*) extract on FOXO3 expression in HepG2 cells. Annual Meetings of the American College of Endocrinology, 2014.
168. Thomas M, Haas MJ, Onstead-Haas L, Szafran-Swietlik A, Kojanian H, Davis T, Armstrong P, Wong NCW, Mooradian AD. Induction of hepatic apolipoprotein A-I gene expression by the isoflavones quercetin and isoquercitrin. Annual Meetings of the Endocrine Society, 2014
169. Kurban W, Kojanian H, Szafran-Swietlik A, Onstead-Haas LM, Haas MJ, Mooradian AD. Statins prevent dextrose-induced endoplasmic reticulum stress and oxidative stress in endothelial and HepG2 cells. Annual Meetings of the Endocrine Society, 2014
170. Shah H, Jafri M, Wehmeier KR, Onstead-Haas LM, Haas MJ, Mooradian AD. Inhibition of endoplasmic reticulum stress and oxidative stress by vitamin D in endothelial cells. Annual Meetings of the American College of Endocrinology, 2014
171. Wehmeier KR, Makhoul-Ahwach S, Thomas M, Kurban W, Shah H, Chamseddin A, Sheikh-Ali M, Onstead-Haas LM, Haas MJ, Mooradian AD. Inhibition of ABCA1 protein expression and cholesterol efflux by TNF α in MLO-Y4 osteocytes. The American Society for Bone and Mineral Research annual meeting; Houston, TX, September 2014.
172. Shah H, Kurban W, Onstead-Haas L, Haas MJ, Mooradian AD. Beta blockers suppress dextrose-induced endoplasmic reticulum stress, oxidative stress and apoptosis in human coronary artery endothelial cells. American Association of Clinical Endocrinologists Annual Meeting; Nashville, TN, May 2015.
173. Kurban W, Makhoul-Ahwach S, Thomas M, Onstead-Haas L, Mooradian AD, Haas MJ. The glutathione mimic ebselen inhibits oxidative stress but not endoplasmic reticulum stress in endothelial cells. American Association of Clinical Endocrinologists Annual Meeting; Nashville, TN, May 2015.
174. Plazarte M, Wehmeier KR, Makhoul Ahwach S, Thomas M, Kurban W, Shah H, Chamseddin A, Sheikh-Ali M, Onstead-Haas LM, Haas MJ, Mooradian AD. Inhibition of ABCA1 protein expression and cholesterol efflux by TNF α in MLO-Y4 osteocytes. American Association of Clinical Endocrinologists Annual Meeting; Nashville, TN, May 2015.

Presentations at Scientific Meetings (Abstracts) (cont'd):

175. Naem E, Onstead-Haas L, Mooradian AD, Haas MJ. The effect of black seed (*Nigella sativa*) extract on lipid metabolism in HepG2 cells. American Association of Clinical Endocrinologists Annual Meeting; Nashville, TN, May 2015.
176. Jurado-Flores, M., Onstead-Haas, L, Mooradian, A.D., Haas, M.J. Differential effects of AT1 receptor inhibition on superoxide generation and endoplasmic reticulum stress in human coronary artery endothelial cells. Annual Meetings of the Endocrine Society, Boston, MA, 2016.
177. Plazarte, M., Chamseddin, A., Onstead-Haas, L., Mooradian, A.D., Haas, M.J. High-throughput analysis to identify drugs that alter apolipoprotein a-i production. Annual Meetings of the Endocrine Society, Boston, MA, 2016.
178. Gonzales K, Jurado-Flores M, Haas MJ, Hammoud R, Feng V, Onstead-Haas L, Mooradian AD. The effect of AT1 inhibitors on pro-inflammatory cytokine secretion by human coronary endothelial cells. Poster presentation at: Endocrine Society, Orlando, FL, 2017.
179. Jurado-Flores M, Haas MJ, Hammoud R, Feng V, Gonzales K, Onstead-Haas L, Mooradian AD. The effects of antioxidants on pro-inflammatory cytokine secretion by human coronary endothelial cells. Poster presentation at: Endocrine Society, Orlando, FL, 2017.
180. Hammoud R, Gonzales K, Jurado-Flores M, Feng V, Onstead-Haas L, Wong NCW, Mooradian AD, Haas MJ. Regulation of apolipoprotein A-I gene expression by antihistamines. Poster presentation at: Endocrine Society, Orlando, FL, 2017.
181. Feng V, Jurado-Flores M, Haas MJ, Hammoud R, Gonzales K, Onstead-Haas L, Mooradian AD. The effects of statins and β -blockers on pro-inflammatory cytokine secretion by human coronary endothelial cells. Poster presentation at: AACE 26th Annual Meeting & Clinical Congress, Austin, TX, 2017.
182. Gonzales K, Mooradian AD. An overlooked etiology of hyperthyroidism: the Jod-Basedow phenomenon with chronic iodinated mouth wash use in a patient with Graves' disease. Poster presentation at: AACE 27th Annual Meeting & Clinical Congress, Boston, MA. 2018.
183. Gonzales K, Haas M, Feng V, Bikkina P, Landicho AM, Onstead-Haas L, Mooradian A. The effect of nicotine and high-dextrose on endoplasmic reticulum stress in human coronary artery endothelial cells. Poster presentation at: AACE Annual Meeting 2018, Boston, MA, 2018.
184. Landicho MA, Haas M, Jurado-Flores M, Hammoud R, Gonzales K, Bikkina P, Feng V, Plazarte G, Onstead-Haas L, Wong NCW, and Mooradian A. Regulation of apolipoprotein A-I gene expression by the histamine H1 receptor: Requirement for NF- κ B. Endocrine Society, Chicago, IL, 2018

Presentations at Scientific Meetings (Abstracts) (cont'd):

185. Bikkina P, Landicho MA, Haas MJ, Mooradian AD. Differential effects of cox2 inhibitors on the unfolded protein response in primary human coronary artery endothelial cells. 28TH AACE Annual Meeting, Los Angeles, CA, 2019.
186. Landicho MA, Bikkina P, Feng V, Gonzales K, Onstead-Haas L, Haas MJ, Mooradian AD. TFEB-mediated inhibition of endoplasmic reticulum stress in human coronary artery endothelial cells. 28TH AACE Annual Meeting, Los Angeles, CA, 2019.
187. Kalidas P, Bikkina P, Landicho AM, Parekh S, Onstead-Haas L, Haas M, and Mooradian A. The effects of select GLP1R agonists and SGLT2 inhibitors on the unfolded protein response in primary human coronary artery endothelial cells. Poster presentation at: Endocrine Society, New Orleans, LA, March 2019.
188. Kalidas, P., Parekh, S., Bikkina, P., Landicho, A.M., Onstead-Haas, L., Haas, M.J., and Mooradian, A.D. Differential effects of COX2 inhibitors on the unfolded protein response in primary human coronary artery endothelial cells. Endocrine Society, San Francisco, CA, 2020.
189. Kalidas, P., Parekh, S., Richter, A., Landicho, A.M., Feng, V., Bikkina, P., Gonzales, K., Onstead-Haas, L., Haas, M.J., and Mooradian, A.D. TFEB-mediated inhibition of endoplasmic reticulum stress in human coronary artery endothelial cells. Endocrine Society, San Francisco, CA, 2020.
190. Parekh, S., Kalidas, P., Richter, A., Haas, M.J., Wong, N.C.W., and Mooradian, A.D. Induction of apolipoprotein A-I gene expression by the rare sugar allulose. Endocrine Society, San Francisco, CA, 2020.
191. Richter, A., Parekh, S., Kalidas, P., Haas, M.J., and Mooradian, A.D. Endocannabinoids induce endoplasmic reticulum stress in hepatocytes and human coronary artery endothelial cells. Poster presentation. Endocrine Society, San Francisco, CA, 2020.

Scientific Publications:

1. Frayha R.A., Mooradian A., Tabbara K.F. Transudative knee effusions in Milroy's disease. *J. Rheumatol.* 8:670-672, 1981.
2. Salti I.S., Mooradian A., Amiri Z., Khalil A. Hypopituitarism in a patient with idiopathic hypoparathyroidism. *Can. Med. Assoc. J.* 126:942-943, 1982.
3. Mooradian AD, Shammaa M. Liver cirrhosis in middle eastern population. A comparative study of clinical and histological features. *Arab J. Med.* 1(2):7-11, 1982.
4. Mooradian A., Ghusn H., Cortas N., Salti I. Serum hyperphosphatasia in pubertal gynecomastia: Case report and review of the literature. *Arab. J. Med.* 1(5):9-10, 1982.
5. Mooradian AD, Khouri JY, Arnaout MS, Cortas N. The effect of hemodialysis on serum alkaline phosphatase. *Arab J. Med.* 1(6):9-11, 1982.
6. Mooradian A., Budeir A., Faraidy Y. Cimetidine for treatment of alkalemia. *Can. Med. Assoc. J.* 127:462, 1982 (letter).
7. Mooradian A., Morley J.E., Simon G., Shafer R.B. Propranolol induced hyperthyroxinemia. *Arch. Int. Med.* 43:2193-2195, 1983.
8. Mooradian A.D., Allam C.K., Khalil M.F., Salti I., Salem Ph.A. Anaplastic transformation of thyroid cancer. *J. Surg. Oncology* 23:95-98, 1983.
9. Nuttall P.Q., Mooradian A.D., DeMarais R., Parker S. The glycemic effect of different meals approximately isocaloric and similar in protein, carbohydrate and fat content as calculated using the A.D.A. exchange lists. *Diabetes Care* 6:432-435, 1983.
10. Mooradian A.D., Morley J.E., Ma K.W., Korchik W., Shafer R.B. Thyroid function in hemodialysis patients. *Eur. J. Nucl. Med.* 8:495-498, 1983.
11. Mooradian A.D., Morley G.K., McGeachie R., Lundgren S., Morley J.E. Spontaneous periodic hypothermia. *Neurology* 34:79-82, 1984.
12. Morley J.E., Levine A.S., Beyer H.S., Mooradian A.D., Kaiser F.E., Brown D.M. The effect of aging and diabetes mellitus on human red and white cell calmodulin levels. *Diabetes* 33:77-80, 1984.
13. Cortas N., Abras E., Arnaout M., Mooradian A., Maukasah S. Energetics of sodium transport in the urinary bladder of the toad: Effect of aldosterone and cyanide. *J. Clin. Invest.* 73:46-52, 1984.

Scientific Publications (cont'd):

14. Morley G.K., Mooradian A.D., Levine A.S., Morley J.E. Why is diabetic peripheral neuropathy painful? The effect of glucose on pain perception in humans. *Am. J. Med.* 77:79-82, 1984.
15. Mooradian A.D., Morley J.E., Levine A.S., Ma K.W., Korchik W., Beyer H.S., Kaiser F.E., Brown D.M. The effect of chronic renal failure on human red and white cell calmodulin levels. *J. Clin. Endocrinol. Metab.* 58:1010-1013, 1984.
16. Nuttall F.Q., Mooradian A.D., Gannon M.C., Billington C., Krezowski P. Effect of protein ingestion on the glucose and insulin response to a standardized oral glucose load. *Diabetes Care* 7:465-470, 1984.
17. Mooradian A.D., Morley J.E. Endocrine dysfunction in chronic renal failure. *Arch. Int. Med.* 144:351-353, 1984.
18. Mooradian A.D., Morley J.E., Levine A.S. The effect of aging on calcium-binding protein. *Geriatric Medicine Today*, 3:30-40, 1984.
19. Mooradian A.D., Shamma'a M., Salti I., Cortas N. Hypophyseal-gonadal dysfunction in men with non-alcoholic liver cirrhosis. *Andrologia* 17:72-79, 1985.
20. Mooradian A.D., Frayha R. Multiple vasculopathies and hepatitis B in a family. *Br. J. Rheumatol.* 24:19-23, 1985.
21. Mooradian A.D., Nuttall F.G. Insulin sensitivity in joggers: evaluation by mini-dose insulin infusion test. *Int. J. Sports Med.* 6:212-214, 1985.
22. Mooradian A.D., Morley J.E., Korchik W.P., Ma K.W., Hartfel M.A., Parsons J.A. Comparison between the bioactivity and immunoreactivity of serum prolactin in uremia. *Clin. Endocrinol.* 22:241-247, 1985.
23. Mooradian A.D., Schwartz H.L., Mariash C.N., Oppenheimer J.H. Transcellular and transnuclear transport of T₃ in isolated hepatocytes. *Endocrinology* 117:2449-2456, 1985.
24. Freake H.C., Mooradian A.D., Schwartz H.L., Oppenheimer J.H. Stereospecific transport of T₃ to cytoplasm and nucleus in GH1 cells. *Mol. Cell. Endocrinol.* 44:25-35, 1986.
25. Mooradian A.D., Morley J.E., Levine A.S., Prigge W.F., Gebhard R.L. Abnormal intestinal permeability to sugars in diabetes mellitus. *Diabetologia* 29:221-224, 1986.
26. Morley J.E., Silver A., Fiatarone M., Mooradian A.D. UCLA Grand Rounds: Nutrition and the Elderly. *J. Am. Geriatric Soc.* 34:823-832, 1986.

Scientific Publications (cont'd):

27. Mooradian A.D. Treatment of diabetes mellitus in the elderly. *Geriatric Medicine Today* 5:87-93, 1986.
28. Lum M.D., Mooradian A.D. Vitamin B12 deficiency in the elderly. *Geriatric Medicine Today* 5:87-93, 1986.
29. Regan J.J., Greenberg C.S., Mooradian A.D., Staley N., Nuttall F.Q. Reversible renal resistance to aldosterone associated with interstitial nephritis. *West. J. Med.* 146:742-745, 1987.
30. Mooradian A.D., Wynn E.M. The usefulness of pharmacokinetic prediction of the serum digoxin concentration in the elderly. *Arch. Int. Med.* 147:650-653, 1987.
31. Boghosian S.G., Mooradian A.D. Usefulness of routine preoperative chest roentgenograms in elderly patients. *J. Am. Geriatr. Soc.* 35:142-146, 1987.
32. Mooradian A.D. The effect of sulfonylurea on the in vivo tissue uptake of glucose in normal rats. *Diabetologia* 30:120-121, 1987.
33. Mooradian A.D., Mariash C.N. Effects of insulin and glucose on cultured rat hepatocyte gene expression. *Diabetes* 36:938-943, 1987.
34. Mooradian A.D. The effect of ascorbate and dehydroascorbate on tissue uptake of glucose. *Diabetes* 36:1001-1004, 1987.
35. Mooradian A.D. The blood-brain barrier choline transport is reduced in diabetic rats. *Diabetes* 36:1094-1097, 1987.
36. Tamai I.C., Sayers J., Mooradian A.D. Aminoglycoside therapy in elderly nursing home residents: outcome of therapy and toxicity. *Drug Intelligence and Clinical Pharmacy* 21:922-923, 1987.
37. Mooradian A.D., Song M.K. The intestinal zinc transport in aged rats. *Mech. Age. Develop.* 41:189-197, 1987.
38. Mooradian A.D., Morley J.E. Micronutrient status in diabetes mellitus. *Am. J. Clin. Nutr.* 45:877-895, 1987.
39. Mooradian A.D., Morley J.E., Korenman S.K. The biological actions of androgens. *Endocrine Review* 8:1-28, 1987.
40. Rosenthal M.J., Hartnell J.M., Morley J.E., Mooradian A.D., Fiatarone M., Kaiser F.K., Osterweil D. UCLA Grand Rounds: Diabetes in the elderly. *J. Am. Geriatr. Soc.* 35:435-447, 1987.

Scientific Publications (cont'd):

41. Morley J.E., Mooradian A.D., Rosenthal M.H., Kaiser F.E. Diabetes mellitus in the elderly: Is it different? *Am. J. Med.* 83:533-544, 1987.
42. Morley J.E., Korenman S.G., Mooradian A.D., Kaiser F.E. UCLA Grand Rounds: Male sexual dysfunction in the elderly. *J. Am. Geriatr. Soc.* 35:1014-1022, 1987.
43. Kavonian G.D., Wong N.C.W., Mooradian A.D. The unusual manifestations of hypothyroidism in an elderly patient. *Geriatric Medicine Today* 6(8):28-37, 1987.
44. Mooradian A.D. Nutritional status and dietary interventions in the elderly diabetic. Manual of Intensive Course in Geriatric Medicine, UCLA, pp 51-55, 1987.
45. Morley J.E., Mooradian A.D. Diabetes mellitus in nursing home patients. *Second Season* 2:1-3, 1987.
46. Mooradian A.D. Discrepancies between the calculated digoxin clearance and the serum digoxin level in elderly patients. (Letter) *Arch. Intern. Med.* 147:1853, 1987.
47. Mooradian A.D. The blood-brain barrier choline transport is reduced in aged rats. *Brain Res.* 440:328-332, 1988.
48. Kaiser F.E., Viosca S.P., Morley J.E., Mooradian A.D., Davis S.S., Korenman S.G. Impotence and aging: clinical and hormonal factors. *J. Am. Geriatr. Soc.* 36:511-519, 1988.
49. Mooradian A.D., Osterweil D., Petrasek D., Morley J.E. Diabetes mellitus in elderly nursing home patients: A survey of clinical characteristics and management. *J. Am. Geriatr. Soc.* 36:391-396, 1988.
50. Morley J.E., Korenman S.G., Kaiser F.E., Mooradian A.D., Viosca S.P. Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older males. *Am. J. Med.* 84:445-448, 1988.
51. Mooradian A.D., Pamplona D.G., Viosca S.P., Korenman S.G. The effect of free fatty acids on the bioavailability of plasma testosterone and dihydrotestosterone. *J. Steroid Biochem.* 29:369-370, 1988.
52. Song M.D., Mooradian A.D. Intestinal zinc transport: influence of streptozotocin-induced diabetes, insulin and arachidonic acid. *Life Sci.* 42:687-694, 1988.
53. Scarpace P.J., Mooradian A.D., Morley J.E. Age-associated decrease in beta-adrenergic receptors and adenylate cyclase activity in rat brown adipose tissue. *J. Gerontol.* 43:B65-B70, 1988.

Scientific Publications (cont'd):

54. Mintz G.A., Mooradian A.D. Age-related morphologic changes in rat sublingual salivary glands. *Gerodontology*, 6:137-144, 1988.
55. Mooradian A.D., Morley J.E., Scarpace P.J. The role of zinc status in altered cardiac adenylate cyclase activity in diabetic rats. *Acta Endocrinologica*, 119:174-180, 1988.
56. Mooradian A.D., Norman D.C., Morley J.E. The effect of zinc status on the immune function of diabetic rats. *Diabetologia*, 31:703-707, 1988.
57. Mooradian A.D., Perryman K., Fitten J., Kavonian G., Morley J.E. Cortical function in elderly non-insulin dependent diabetic patients: Behavioral and electrophysiological studies. *Arch. Int. Med.*, 148:2369-2372, 1988.
58. Mooradian D.G., Viosca S.P., Kaiser F.E., Morley J.E., Korenman S.G. Penile Raynaud's phenomenon: A possible cause of erectile failure. *Am. J. Med.* 85:748-750, 1988.
59. Mooradian A.D. The effect of aging on the blood-brain barrier. *Neurobiol. Aging* 9:31-39, 1988.
60. Mooradian A.D., Morley J.E., Korenman S.G. Endocrinology in Aging. *Disease-a-Month*, 34(7):398-461, 1988.
61. Morley J.E., Gorbien M.J., Mooradian A.D., Silver A.J., Brickman A.S., Kaiser F.E. UCLA Geriatric Grand Rounds: Osteoporosis. *J. Am. Geriatr. Soc.*, 36:845-859, 1988.
62. Mooradian A.D. Digitalis: An update of its clinical pharmacokinetics, therapeutic monitoring techniques, and treatment recommendations. *Clin. Pharmacokinetics*, 15:165-179, 1988.
63. Mooradian A.D. Tissue specificity of premature aging in diabetes mellitus: the role of cellular replicative capacity. *J. Am. Geriatr. Soc.*, 36:831-839, 1988.
64. Mooradian A.D. Diabetic complications of the central nervous system. *Endocrine Reviews*, 9:346-356, 1988.
65. Mooradian A.D., Nutritional modulation of life span and gene expression, pp 891-892. In Morley, J.E., Moderator, *Nutrition in the elderly*. *Ann. Int. Med.*, 109:890-904, 1988.
66. Mooradian A.D., Morley J.E. The Hypothalamus and the Pituitary Glands. In: Diagnosis and Pathology of Endocrine Diseases, Mendelsohn G. (ed.), J.B. Lippincott Co., Philadelphia, PA, 1988, pp 351-377.
67. Mooradian A.D., Song M.K. Age-related alterations in duodenal calcium transport rate in rats. *Mech. Ageing Dev.*, 47:221-227, 1989.

Scientific Publications (cont'd):

68. Mooradian A.D., Hernandez L., Tamai I., Marshall C. Variability of serum phenytoin levels in nursing home patients. *Arch. Int. Med.*, 149:890-892, 1989.
69. Mooradian A.D., Morley J.E., Kaiser F.E., Davis S.S., Viosca S.P., Korenman S.G. The role of biweekly intracavernous injection of papaverine in the treatment of erectile dysfunction. *West. J. Med.*, 151:515-517, 1989.
70. Tamai I., Strome L.S., Marshall C., Mooradian A.D. Drug-drug interactions in an academic nursing home. *Am. J. Hosp. Pharm.* 46:1567-1569, 1989.
71. Hartnell J.M., Morley J.E., Mooradian A.D. Alkali-induced white blood cell DNA unwinding rate is reduced in healthy elderly. A potential biomarker of aging. *J. Gerontol. Biol. Sci.* 44:B125-B130, 1989.
72. Hartnell J.M., Storrie M.D., Mooradian A.D. The tissue specificity of the age-related changes in alkali-induced DNA unwinding. *Mutation Research* 219:187-192, 1989.
73. Mooradian A.D., Scarpace P.J. The response of isoproterenol-stimulated adenylate cyclase activity after administration of L-triiodothyronine is reduced in aged rats. *Hormone and Metabolic Res* 21:638-639, 1989.
74. Mooradian A.D., Greiff V., Bressler R., Reed R., Marcus F. Digitalis in the elderly. *J. Am. Geriatr. Soc.* 37:873-882, 1989.
75. Morley J.E., Kaiser F.E., Mooradian A.D. Impotence. *Saudi Medical Journal*, 10:173-176, 1989.
76. Clements N., Mooradian A.D. The role of sodium fluoride in the treatment of osteoporosis. *Drug Therapy*, May: 69-78, 1989.
77. Mooradian A.D. Psychosocial aspects of diabetes in the elderly. *Diabetes Spectrum* 2:170, 1989.
78. Mooradian A.D. The role of gamma glutamyl transpeptidase in dementias. *Neurobiol. Aging* 10:109, 1989.
79. Mooradian A.D. Age-related differences in body weight loss in response to altered thyroidal status. *Experimental Gerontology* 25:29-35, 1990.
80. Mooradian A.D. Blood-brain transport of triiodothyronine is reduced in aged rats. *Mech. Ageing and Develop.* 52:141-147, 1990.
81. Mooradian A.D. Metabolic fuel and amino acid transport into brain in experimental hypothyroidism. *Acta Endocrinologica*, 122:156-162, 1990.

Scientific Publications (cont'd):

82. Korenman S.G., Viosca S.P., Kaiser F.E., Mooradian A.D., Morley J.E. Use of a vacuum tumescence device in the management of impotence. *J. Am. Geriatr. Soc.*, 38:217-221, 1990.
83. Hartnell J.M., Storrie M.D., Mooradian A.D. Tissue specificity of alkali-induced DNA unwinding rate in diabetes. *Diabetes* 39:345-353, 1990.
84. Mooradian A.D., Reed R.L., Osterweil D., Clements N., Scuderi P. Lack of an association between the presence of tumor necrosis factor or interleukin-1 alpha in the blood and weight loss among elderly patients. *J. Am. Geriatr. Soc.*, 38:397-401, 1990.
85. Habib M., Dickerson F., Mooradian A.D. Ethane production rate in vivo is reduced with dietary restriction. *J. Appl. Physiol.* 68:2588-2590, 1990.
86. Mooradian A.D. The hepatic transcellular transport of 3,5,3'-triiodothyronine is reduced in aged rats. *Biochim. Biophys. Acta* 1054:1-7, 1990.
87. Mooradian A.D., Reed R.L., Osterweil D., Shiffman R., Scuderi P. Decreased serum triiodothyronine (T₃) is associated with increased concentrations of tumor necrosis factor. *J. Clin. Endocrinol. Metab.* 71:1239-1242, 1990.
88. Mooradian A.D., Dickerson F., Smith T.L. Lipid order and composition of synaptic membranes in experimental diabetes mellitus. *Neurochem. Res.* 15:981-985, 1990.
89. Korenman S.G., Morley J.E., Mooradian A.D., Stanik Davis S., Kaiser F.E., Silver A.J., Viosca S.P., Garza D. Secondary hypogonadism in older men: its relation to impotence. *J. Clin. Endocrinol. Metab.* 71:963-969, 1990.
90. Mooradian A.D., Lieberman J. Age-related decrease in serum angiotensin converting enzyme activity: The role of thyroidal status and food intake. *J. Gerontol. Biol. Sci.* 45:B24-B27, 1990.
91. Flood J.F., Mooradian A.D., Morley J.E. Characteristics of learning and memory in streptozotocin-induced diabetic mice. *Diabetes* 39:1391-1398, 1990.
92. Mooradian A.D., Greiff V. Sexuality in older women. *Arch. Int. Med.* 150:1033-1038, 1990.
93. Reed R.L., Mooradian A.D. Drug therapy of elderly diabetic patient. *Drugs of Today* 26:109-123, 1990.
94. Mooradian A.D. Biomarkers of aging: Do we know what to look for. *J. Gerontol. Biol. Sci.* 45:B183-B186, 1990.
95. Mooradian A.D. Digoxin use in the elderly. *Drugs of Today* 26:381-388, 1990.

Scientific Publications (cont'd):

96. Mooradian A.D. Biomarkers of Aging (reprinted). Proceedings of the 26th Annual Meeting of the Society of Prospective Medicine. pp 2-5, 1990.
97. Mooradian A.D. Variability of serum phenytoin concentrations in nursing home patients. (letter) Arch. Intern. Med. 150:918-919, 1990.
98. Mooradian A.D. Phenytoin monitoring in nursing home patients (letter). Arch. Intern. Med. 150:1971-1974, 1990.
99. Mooradian A.D. Endocrine dysfunction due to renal disease. In: Principles and Practice of Endocrinology and Metabolism, K.L. Becker (ed.), Philadelphia, PA, J.B. Lippincott Co. 1990, pp 1533-1536.
100. Mooradian A.D., Kalis J, Neugent C. The nutritional status of ambulatory elderly Type II diabetic patients. AGE 13:87-89, 1990.
101. Mooradian A.D. Molecular Theories of Aging. In: Geriatric Nutrition. A Comprehensive Review. Morley, J.E., Glick Z., Rubenstein, L.Z. (eds.), New York, Raven Press 1990, pp 11-18.
102. Reed R.L., Mooradian A.D. Nutritional status and dietary management of elderly diabetic patient. Clinics in Geriatric Medicine, 6:883-901, 1990.
103. Mooradian A.D., Deebaj L., and N.C.W. Wong. Age-related alterations in the response of hepatic lipogenic enzymes to altered thyroid states in the rat. J. Endocrinol 128:79-84, 1991.
104. Mooradian A.D., Reed R.L., Meredith K., Scuderi P. Serum levels of tumor necrosis factor, IL-1 α and IL-1 β in diabetic patients. Diabetes Care 14:63-65, 1991.
105. Mooradian A.D., Morin A.M. Brain uptake of glucose in diabetes mellitus. The role of glucose transporters. Am. J. Med. Sci. 301:173-177, 1991.
106. Evans S.E., Lee I., Yee D., Nixon B., Mooradian A.D. The prevalence and nature of podiatric problems in elderly diabetic patients. J. Am. Geriatr. Soc. 39:241-245, 1991.
107. Mooradian A.D., Morin A., Clip L., Haspel H. Glucose transport is reduced in the blood-brain barrier of aged rats. Brain Res. 551: 145-149, 1991.
108. Mooradian A.D., Scarpace P.J. β -Adrenergic receptor activity of cerebral microvessels is reduced in aged rats. Neurochem. Res. 16:447-451, 1991.
109. Reed R.L., Perlmutter L., Yochum K., Meredith K.E., Mooradian A.D. The relationship between muscle mass and muscle strength in the elderly. J Am Geriatr Soc 39: 551-561, 1991.

Scientific Publications (cont'd):

110. Mooradian A.D. Increased serum conjugated dienes in elderly diabetic patients. *J Am Geriatr Soc* 39: 571-574, 1991.
111. Mooradian A.D., Reed R.L., Osterweil D., Scuderi P. Detectable serum levels of tumor necrosis factor alpha (TNF) may predict early mortality in elderly institutionalized patients. *J Am Geriatr Soc* 39:891-894, 1991.
112. Mooradian A.D., Reed R.L., Scuderi P. Serum levels of tumor necrosis factor alpha, interleukin-1 alpha and beta in healthy elderly subjects. *AGE* 14:61-64, 1991.
113. Mooradian A.D., Wong N.C.W. *Molecular Biology of Aging, Part I: An introduction to laboratory techniques.* *J. Am. Geriatr. Soc.* 39: 611-619, 1991.
114. Mooradian A.D., Wong N.C.W. *Molecular Biology of Aging, Part II: A synopsis of current research.* *J. Am. Geriatr. Soc.* 39: 717-723, 1991.
115. Reed R., Yochum K., Perlmutter L., Mooradian A.D. The interrelationship between physical exercise, muscle strength and body adiposity in healthy elderly population. *J Am Geriatr Soc*, 39:1189-1193, 1991.
116. Evans S.E., Mooradian A.D. Podiatric problems in elderly diabetic patients (letter). *J Am Geriatr Soc* 39: 946, 1991.
117. Reed R., Mooradian A.D. Treatment of diabetes mellitus in the elderly. *Am Family Physicians.* 44:915-924, 1991.
118. Mooradian A.D. Chronic illness and geriatric sexuality. *Clinics in Geriatric Medicine*, 7:113-130, 1991.
119. Friedman D., Reed R., Mooradian A.D. The prevalence of overmedication with levothyroxine in ambulatory elderly patients. *AGE*, 15:9-13, 1992.
120. Mooradian A.D.: Altered chromatin structure of cerebral nuclei in experimental diabetes mellitus. *Proc Soc of Exp Biol Med*, 199:282-286, 1992.
121. Mooradian A.D., Meredith K.E. The effect of age on protein composition of rat cerebral microvessels. *Neurochem Res* 17:665-670, 1992.
122. Mooradian A.D., Smith T.L. The effect of age on lipid composition and order of rat cerebral microvessels. *Neurochem Res.* 17:233-237, 1992.

Scientific Publications (cont'd):

123. Reed R.L., Kerwin J., Yoshimo M.T., Mooradian A.D. Undetectable serum levels of thyrotropin (TSH) in an older woman with secondary hypothyroidism. *J Am Geriatr Soc*, 40:68-70, 1992.
124. Mooradian A.D. The biological and functional definition of older patient. The role of biomarkers of aging. *Oncology* 6: (Suppl 2); 39-44, 1992.
125. Reed R.L., Perlmutter L., Yochum R., Meredith K.E., Mooradian A.D. Form of presentation of data on muscle strength. *J Am. Geriatr Soc.* 40:103, 1992.
126. Tchekmedyian N.S., Cella D.E., Mooradian A.D. Forward: Care of the older cancer patient. *Oncology* 6 (Suppl 2):7-8, 1992.
127. Mooradian A.D. Management of diabetes in the elderly. In: Endocrinology and Metabolism in the Elderly, Morley, J.E. Korenman, S.G. (eds.), Blackwell Scientific Publications, Boston, 1992, pp 388-405.
128. Mooradian A.D. Water balance in the elderly. In: Endocrinology and Metabolism in the Elderly, Morley J.E., Korenman, S.G., (eds.), Blackwell Scientific Publications, Boston, 1992, pp 124-136.
129. Mooradian A.D. Geriatric Neuroendocrinology. In: Neuroendocrinology, C. B. Nemeroff (ed) CRC Press, Boca Raton, FL, 1992, pp. 541-562.
130. Reed R.L., Mooradian A.D. Diabetes mellitus in the elderly. In: *Primary Care Geriatrics*. R. Ham, P. Sloan (Eds). Mosby-Yearbook Inc. St. Louis, MO.1992, pp 549-560.
131. Mooradian A.D., Scarpace P.J. Beta-adrenergic receptor activity of cerebral microvessels in experimental diabetes mellitus. *Brain Res.* 583:155-160, 1992.
132. Mooradian A.D., McCuskey R.S. In vivo microscopic studies of age-related changes in the structure and the reactivity of cerebral microvessels. *Mech. Ageing Devel.* 64:247-254, 1992.
133. Mooradian A.D., Reed R.L., Duerr M.L., Valdez C., Scuderi P. The effect of age and diabetes mellitus on serum levels of lymphotoxin. *AGE* 15: 95-99, 1992.
134. Romney J.S., Chan J., Carr F.E., Mooradian A.D., Wong N.C.W. Identification of the thyroid hormone responsive mRNA-S₁₁ as apolipoprotein A₁ mRNA and effects of the hormone on the promoter. *Mol Endocrinol* 6: 943-950, 1992.
135. Mooradian A.D. Commentary. Use of glyburide vs glipizide in elderly non-insulin dependent diabetic patients. *Clinical Diabetes* Sept-Oct: 73, 1992.

Scientific Publications (cont'd):

136. Mooradian A.D. Caring for the elderly nursing home patient with diabetes. A complex challenge to clinicians. *Diabetes Spectrum*, 5:318-322, 1992.
137. Campbell S., Mooradian A.D. Diabetes Mellitus. In *Geriatric Pharmacology* R. Bressler and M.K. Katz (eds.). McGraw-Hill, Inc. New York, NY, 1993, pp 409-425.
138. Nolan P., Mooradian A.D. Digoxin. In: *Geriatric Pharmacology*, R. Bressler and M.K. Katz (eds.), McGraw-Hill, Inc. New York, NY, 1993, pp. 151-163.
139. Mooradian AD. Evaluation of the endocrine status of neurosurgical patients. In: Decision Making in Neurological Surgery. R. Bucholz (ed), B. C. Decker, New York, NY, 1993.
140. Mooradian A.D., Smith T.L. The effect of experimentally induced diabetes mellitus on the lipid order and composition of rat cerebral microvessels. *Neurosci Lett* 145:145-148, 1992.
141. Mooradian A.D. Mechanisms of age-related endocrine alterations in mammals. Part I Drugs and Aging. 3: 81-97, 1993.
142. Mooradian A.D. Mechanisms of age-related endocrine alterations in mammals. Part II Drugs and Aging. 3:131-146, 1993.
143. Reed RL, Hartog RD, Yochum K, Pearlmutter L, Ruttinger AC, Mooradian AD. A comparison of hand-held isometric strength measurement with isokinetic muscle strength measurement in the elderly. *J Am Geriatr Soc.* 41: 53-56, 1993.
144. Mooradian AD, Grabau G, Uko-eninn A. In-situ quantitative estimates of the age-related and diabetes-related changes in cerebral endothelial barrier antigen. *Brain Res* 309:41-44, 1993.
145. Mooradian AD, Smith TL. Membrane disordering effect of ethanol on cerebral microvessels of aged rats. *Neurobiol Aging.* 14:229-232, 1993.
146. Lung CC, Pinnas JL, Yahya D, Meinke GC, Mooradian AD. Malondialdehyde modified proteins and their antibodies in the plasma of control and streptozotocin induced diabetic rats. *Life Sci* 52:329-337, 1993.
147. McGinnis J, Bernbaum M, Brusca S, Plummer S, Albert SG, Mooradian AD. *Managing your diabetes a guide for individuals with diabetes mellitus.* St. Louis University Press, St. Louis, MO 1992.
148. Mooradian AD. Biomarkers of Aging. *Facts and Research in Gerontology* 8:80-86, 1994.

Scientific Publications (cont'd):

149. Mooradian AD, Siverly FD. Qualitative differences in the visual retention test performance of older non-insulin dependent diabetic patients. *AGE* 16:67-69, 1993.
150. Mooradian AD. Antioxidant properties of steroids. *J. of Steroid Biochem Mol Biol* 45:509-511, 1993.
151. Bernbaum M, Albert SG, McGinnis J, Brusca S, Miller D, Hoffman J, Kaiser FE, Mooradian AD. Laboratory assessment of glucose markers does not predict reliability of clinical performance. *Laboratory Medicine* 25:32-34, 1994.
152. Bernbaum M, Albert SG, Brusca S, McGinnis J, Miller D, Hoffman JW, Mooradian AD. Effectiveness of glucose monitoring systems modified for the visually impaired. *Diabetes Care* 16:1363-1366, 1993.
153. Bernbaum M, Albert SG, McGinnis J, Brusca S, Mooradian AD. The reliability of self blood glucose monitoring in elderly diabetic patients. *J. Am Geriatr Soc* 42:779-781, 1994.
154. Mooradian AD. Micronutrients in diabetes mellitus. In drugs, diet and disease. *Mechanistic Approaches to Diabetes*. Vol 2, 183-200, 1995.
155. Mooradian AD, Bastani B. Identification of proton-translocating adenosine triphosphatases in rat cerebral microvessels. *Brain Res.* 629:128-132, 1993.
156. Mooradian AD, Pinnas JL, Lung CC, Yahya MD, Meredith K. Diabetes-related changes in the protein composition of rat cerebral microvessels. *Neurochem Res.* 19:123-128, 1994.
157. Mooradian AD. Biology of Aging. In *Rehabilitation of the Aging and Elderly Patient*. G. Felsenthal, S.J. Garrison, F.U. Steinberg (eds). Baltimore, MD., Williams and Wilkins 1994 pp 3-10.
158. Mooradian AD, Scarpace PJ. 3,5,3'-L-triiodothyronine regulation of B-adrenergic receptor density and adenylyl cyclase activity in synaptosomal membranes of aged rats. *Neuroscience. Lett.* 161:101-104, 1993.
159. Mooradian AD, Habib MP, Dickerson F. Age-related changes in the effect of simple carbohydrates, casein hydrolysate and a lipid test meal on ethane exhalation rate. *J. Appl. Physiol* 76:1119-1122, 1994.
160. Wehmeir KR, Mooradian AD. Autooxidative and antioxidative potential of simple carbohydrate. *Free Radical in Biol Med.* 17:83-86, 1994.

Scientific Publications (cont'd):

161. Mooradian AD, Failla M, Hoogwerf B, Isaac R, Maryniuk M, Wylie-Rosett J. Selected vitamins and minerals in diabetes. *Diabetes Care* 17:4645-479, 1994.
162. Mooradian A.D. Behavioral effects of noninsulin-dependent diabetes mellitus in the elderly. *Neurobiol Aging*. 15:565-567, 1994.
163. Habib MP, Dickerson F, Mooradian AD. Effect of diabetes, insulin and glucose load on lipid peroxidation in the rat. *Metabolism* 43:1442-1445, 1994.
164. Mooradian AD, Habib MP, Dickerson F, Yetskievych T. The effect of age on L-3, 5, 3', triiodothyronine induced ethane exhalation. *J. Appl Physiol*. 77:160-164, 1994.
165. Mooradian AD. Potential mechanisms of the age-related changes in the blood-brain barrier. *Neurobiol Aging* 15:751-755, 1994.
166. Mooradian AD. The aging blood-brain barrier commentary. *Neurobiol Aging* 15:765, 1994.
167. Mooradian AD. Diabetes in the elderly editorial. *Diabetes Spectrum* 7:358-383, 1994.
168. Mooradian AD, Wong NCW. Age-related changes in thyroid hormone action. *Eu. J. Endocrinol* 131:451-461, 1994.
169. Mooradian AD, Grabau G, Bastani B. Adenosine triphosphatases of rat cerebral microvessels. Effect of age and diabetes mellitus. *Life Sci*. 55:1261-1265, 1994.
170. Mooradian AD, Shah G, Lung CC, Mahmoud S, Pinnas J. Age-related changes in tissue distribution of malondialdehyde modified proteins. *Life Sci*. 55:1561-1566, 1994.
171. Shah G, Pinnas JL, Lung CC, Mahmoud S, Mooradian AD. Tissue-specific distribution of malondialdehyde modified proteins in diabetes mellitus. *Life Sci*. 55:1343-1349, 1994.
172. Mooradian AD. Normal age-related changes in thyroid hormone economy. *Clinics in Geriatric Medicine* 11:159-169, 1995.
173. Mooradian AD, Fox-Robichaud A, Meijer ME, Wong NCW. Relationship between transcription factors and S₁₄ gene expression in response to thyroid hormone and age. *Proc. Soc. Exp. Biol. Med*. 207:97-101, 1994.
174. Mooradian AD, Uko-eninn A. Age-related changes in the antioxidative potential of cerebral microvessels. *Brain Res*. 671:159-163, 1995.

Scientific Publications (cont'd):

175. Mooradian AD. The antioxidative potential of cerebral microvessels in experimental diabetes mellitus. *Brain Res.* 671:164-169, 1995.
176. Mooradian AD. Endocrine dysfunction due to renal disease. In: *Principles and Practice of Endocrinology and Metabolism.* K.L. Becker (ed.) Philadelphia, PA. J.B. Lippincott Co. pp 1759-1762, 1995.
177. Giddings SJ, Carnaghi LR, Mooradian AD. Age-related changes in pancreatic islet cell gene expression. *Metabolism* 44:320-324, 1995.
178. Mooradian AD, Lung CC, Pinna JL. Cholesterol enriched diet enhances malondialdehyde modification of proteins in cerebral microvessels of rabbits. *Neurosci Lett.* 185:211-213, 1995.
179. Mooradian AD (ed) *Internist's Handbook of Endocrinology, Diabetes and Metabolism.* St. Louis University Press, St. Louis, Mo 1995.
180. Shah NG, Wong NCW, Mooradian AD. Age-related changes in apolipoprotein A₁ expression. *Biochem Biophys Acta* 1259:277-282, 1995.
181. Shah GN, Mooradian AD. Age-related shortening of Poly (A) tail of albumin mRNA. *Arch of Biochemistry Biophysics* 324:105-110, 1995.
182. Bernbaum M, Albert SG, Miller D, Hoffmann JW, Mooradian AD. Reliability of Diascan partner glucose monitor for visually impaired people. *Diabetes Spectrum* 8:322-324, 1995.
183. Mooradian AD. Diabetes in the elderly: Studies dispel common misconceptions. *Clev. Clin J. of Med* 62:1-3, 1995.
184. Mooradian AD. Theories of Aging. In *Geriatric Nutrition. A Comprehensive Review.* Morley J.E., Glick Z., Rubenstein L.Z. (eds) New York Raven Press. 1995; pp 5-13.
185. Bernbaum M, Albert SG, Miller D, Stich T, Hoffmann JW, Mooradian AD. Alternative blood glucose monitoring strips for the One Touch System. *Laboratory Medicine* 27:404-407, 1996.
186. Mooradian AD, Albert SG, Bernbaum M, Plummer S. The effect of glipizide GITS on islet cell hormonal responses to a test meal in NIDDM. *Diabetes Care* 19:883-884, 1996.
187. Mooradian AD. Glycosylation enhances malondialdehyde binding to proteins. *Free Radical Biol. Med.* 21:699-701, 1996.
188. Mooradian AD. Drug therapy of non-insulin dependent diabetes mellitus in the elderly. *Drugs* 51:931-941, 1996.

Scientific Publications (cont'd):

189. Song MK, Rosenthal MJ, Kang KW, Adham NF, Mooradian AD, Arment ME. Animal prostate extract ameliorates diabetic symptoms by stimulating intestinal zinc absorption in rats. *Diabetes Research* 31:157-170, 1996.
190. Mooradian AD, Wong NCW, Shah GN. Age-related changes in the responsiveness of apolipoprotein A₁ to thyroid hormone. *Am J Physiol.* 271:R1602-R1607, 1996.
191. Thurman J, Mooradian AD. How to handle elderly patients. *Medical Interface* Jan: 1997, pp 11-12.
192. Mooradian AD. NIDDM in the elderly. *Drug Therapy for blood glucose control. Medical Progress* Oct: 39-44, 1996.
193. Nowak FV, Mooradian AD. Endocrine Function and Dysfunction with age. *Encyclopedia of Gerontology.* Academic Press, Inc., San Diego, CA. Vol. 1, 1996, pp 447-491.
194. Reed RL, Mooradian AD. Diabetes mellitus. In *Primary Care Geriatrics. A case based approach.* 3rd edition R.J. Ham, P.D. Sloan, (Eds) Mosby-Yearbook Inc., St. Louis, MO 1997 pp 440-447.
195. Nowak FV, Mooradian AD. Thyroid hormone action and aging. In *Geriatric Medicine in the 21st Century: Basic Science Contributions to Clinical Care.* J.E. Morley, H.J. Armbrecht, R.M. Coe. (eds) Springer Verlag, New York, 1997.
196. Mooradian AD, Girgis WE, Shah GN. Thyroid hormone-induced GLUT-1 expression in rat cerebral tissue: effect of age. *Brain Res.* 747:144-146, 1997.
197. Shah GN, Giddings SJ, Mooradian AD. Shortening of poly (A) tail of glucose transporter-one mRNA in experimental diabetes mellitus. *Brain Res.* 754:213-220, 1997.
198. Anderson JH Jr and the Multicenter Insulin Lispro Study Group. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. *Arch Intern Med.* 157: 1249-1255, 1997.
199. Mooradian AD. Are micronutrients important in diabetes management? *West Indian Med. J.* 46(suppl. 1):21, Feb.-Mar, 1997.
200. Mooradian AD. Central nervous system complications of diabetes mellitus. A perspective from the blood-brain barrier. *Brain Res. Rev.* 23:210-218, 1997.
201. Mooradian AD. Pathophysiology of central nervous system disorders in diabetes. *Clin. Neurosci* 4:322-326, 1997.

Scientific Publications (cont'd):

202. Mooradian AD, Nowak FV. Diabetes mellitus and heart disease. In *Cardiovascular Disease in Older Persons*. F.E. Kaiser, J. E. Morley, R. M. Coe (ed) Springer Verlag, New York, 1997, 53-72.
203. Shah GN, Mooradian AD. Age-related changes in the blood brain barrier. *Exp. Gerontol.* 32:501-519, 1997.
204. Thurman J, Mooradian AD. Vitamin supplementation therapy in the elderly. *Drugs and Aging.* 11:433-449,1997.
205. Mooradian AD, Wong NCW, Shah GN. Apolipoprotein A1 expression in young and aged rats is modulated by dietary carbohydrates. *Metabolism* 46:1132-1136, 1997.
206. Enalapril-Felodipine ER Factorial Study Group. Combined enalapril and felodipine extended release (ER) for systemic hypertension. *Am J Cardiol* 79:431-435, 1997.
207. Mooradian AD, Chung HC, Shah GN. GLUT-1 expression in the cerebra of patients with Alzheimer's disease. *Neurobiol Aging*, 18: 469-474, 1997.
208. Mooradian AD, Shah GN. Age-related changes in glucose transporter-one (GLUT-1) mRNA structure and function. *Proc. Soc. Exp. Biol. Med.* 216:380-385, 1997.
209. Mooradian AD, Bastani B. The effect of metabolic acidosis and alkalosis on the H⁺-ATPase of rat cerebral microvessels. *Life Sci* 61:2247-2253, 1997.
210. Shah GN, Li JP, Schneiderjohn P, Mooradian AD. Cloning and characterization of a complementary DNA for a thyroid hormone responsive protein in mature rat cerebral tissue. *Biochemical J.* 327:617-623, 1997.
211. Testa MA, Simonson DC on behalf of Glipizide GITS Study Investigators. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus. A randomized, controlled, double-blind trial. *JAMA* 280: 1490-1496, 1998.
212. Silverberg AB, Mooradian AD. The Thyroid and Aging. *Interdisciplinary Topics In Aging, Functional Endocrinology of Ageing* 29: 27-43, 1998.
213. Reed RL, Mooradian AD. Management of diabetes mellitus in the nursing home. *The Annals of Long Term Care* 6:100-107, 1998.
214. Yu Z, Gupta SK, Hwang SS, Kipnes MB, Mooradian AD, Snyder PJ, Atkinson LE. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men. *J. Clin. Pharmacol.* 37:1139-1145, 1997.

Scientific Publications (cont'd):

215. Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. *Diabetes Care* 21:416-422, 1998.
216. Mooradian AD (ed), *Internist's Handbook of Endocrinology, Diabetes and Metabolism*. St. Louis University Press, 1998.
217. Murao K, Wada Y, Nakamura T, Taylor AH, Mooradian AD, Wong NCW. Effects of glucose and insulin on rat apolipoprotein A1 gene expression. *J. Biol. Chem.* 273:18959-18965, 1998.
218. Shah GN, Li J, Mooradian AD. Novel translational repressor (NAT-1) expression is modified by thyroid state and age in brain and liver. *Eu. J. Endocrinology* 139: 649-653, 1998.
219. Gradman, A, Cutler NR, Pamela J. Davis, PJ et al (Mooradian AD) on behalf of the Enalapril-Felodipine ER Factorial Study Group. Long-term efficacy, tolerability, and safety of the combination of enalapril and felodipine ER in the treatment of hypertension. *Clinical Therapeutics.* 20: 527-538, 1998
220. Mooradian AD, McLaughlin S, Boyer C, Winter J. Diabetes care for the older adult. *Diabetes Spectrum* 12:70-77, 1999.
221. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycemia *Drugs* 57:19-29, 1999.
222. Mooradian AD, Li J, Shah GN. Age-related changes in thyroid hormone responsiveness protein (THRP) expression in cerebral tissue of rats. *Brain Res.* 793:302-304, 1998.
223. Thurman JE, Mooradian AD. Starving for sugar. *Patient Care* 32:142-143, 1998.
224. Mooradian AD. Repaglanide; A viewpoint. *Drugs and Aging.*13:181-182, 1998.
225. Mooradian AD, Albert SG. The age-related changes in lipogenic enzymes: the role of dietary factors and thyroid hormone responsiveness. *Mechanism of Ageing and Development* 108: 139-149, 1999.
226. Chehade J, Kim J, Pinnas J, Mooradian AD. Malondialdehyde binding of rat cerebral proteins is reduced in experimental hypothyroidism. *Brain Research* 829:202-203, 1999.
227. Mooradian AD. Rosiglitazone. A viewpoint. *Drugs* 57:931, 1999.
228. Mooradian AD, Chehade J, Kim J. Age-related changes in thyroid hormone effects on glucose transporter isoforms of rat heart. *Life Sciences* 65:981-989, 1999.

Scientific Publications (cont'd):

229. Freedman BI, Wuerth J-P, Cartwright K, Bain R, Dippe S, Hershon K, Mooradian AD, Spinowitz B. Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy(ACTION II). *Controlled Clinical Trials*. 20:493-510, 1999.
230. Chehade J, Kim J, Pinnas JL, Mooradian AD. Age-related changes in the thyroid hormone effects on malondialdehyde modified proteins in the rat heart.*Proc.Soc.Exp.Biol.Med.*222:59-64, 1999.
231. Mooradian AD, Chehade J. Implications of the UK Prospective Diabetes Study: Questions answered and issues remaining. *Drugs and Ageing* 16:159-164, 2000.
232. Chehade J, Mooradian AD. Drug therapy of diabetes in old age. In *Diabetes in Old Age-2nd edition*, AJ Sinclair, P Finucane, (eds) 2000.
233. Mooradian AD, Albert SG, Wittry S, Chehade J, Kim J, Bellrichard B. Dose-response profile of acarbose in older subjects with Type 2 diabetes. *Am. J. Med. Sci.* 319:334-337, 2000.
234. Chehade J, Mooradian AD. A rational approach to drug therapy of Type 2 diabetes mellitus. *Drugs* 60: 95-113, 2000.
235. Mooradian AD, Chehade J, Hurd R, Haas MJ. Monosaccharide enriched diets cause hyperleptinemia without hypophagia. *Nutrition* 16: 439-441, 2000.
236. Kamel HK, Mooradian AD, Mir T. Biological theories of aging. In: *Contemporary Endocrinology: Endocrinology of Aging*. J.E. Morley and L. van den Berg (eds), Humana Press Inc., Totowa, NJ. pp: 1-9, 2000.
237. Mooradian AD, Li JP. The effect of amitriptyline on the messenger RNA of thyroid hormone responsive genes in rat cerebral tissue. *Experimental Brain Research* 132:276-278, 2000.
238. McMahon FG, Fujioka K, Singh K, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD. Efficacy and safety of sibutramine in obese White and African American patients with hypertension: A one-year, double blind, placebo-controlled, multicenter trial. *Archives of Internal Medicine* 160: 2185-2191, 2000.
239. Mooradian AD, Chehade JM. Serum leptin response to endogenous hyperinsulinemia in aging rats. *Mechanisms of Ageing and Development*. 115:101-106, 2000.
240. Haas MJ, Pun K, Reinacher D, Wong NCW, Mooradian AD. Effects of ketoacidosis on rat apolipoprotein A1 gene expression: A link with acidosis but not with ketones. *J. Molecular Endocrinology* 25: 129-139, 2000.

Scientific Publications (cont'd):

241. Mooradian AD, Thurman J. Glucotoxicity: Potential mechanisms. *Clinics in Geriatric Medicine* 15:255-263, 1999.
242. Thurman JE, Mooradian AD. Age-related carbohydrate intolerance. In *The Science of Geriatrics. Facts, Research and Intervention in Geriatrics Series*. J.E. Morley, H.S. Armbrecht, R.M. Coe, B. Vellas, eds., Serdi Publisher .Paris, 2000.Vol. 2, pp409-417.
243. Todd CC, Mooradian AD. Thyroid changes with aging. In *The Science of Geriatrics. Facts, Research and Intervention in Geriatrics*. J.E. Morley, H.J. Armbrecht, R.M. Coe, B. Vellas, eds., Serdi Publisher, Paris,2000, vol. 1,pp273-281.
244. Korenman SG, Mooradian AD, Hendrick V. Changes in men as they age: The manopause. In: *Menopause. Biology and Pathobiology*. RA Lobo, J Kelsey, and R Marcus (eds), Academic Press, San Diego, CA, 2000, pp. 111-133.
245. Mooradian AD, Hurd R, Chehade J, Pun K, Haas M. Age-related changes in plasma leptin binding activity in rats. A comparison of a simple acid-ethanol precipitation technique with column chromatography. *Proc. Soc. Exp. Biol. Med.* 224: 273-277, 2000.
246. Apfel SC et al for the rhNGF Clinical Investigator Group. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. A randomized controlled trial. *JAMA* 284: 2215-2221, 2000.
247. Haas MJ, Reinacher D, Pun K, Wong NCW, Mooradian AD. Induction of the apolipoprotein A1 gene by fasting: A relationship with ketosis but not with ketone bodies. *Metabolism* 49:1572-1578, 2000.
248. Mooradian AD, Chehade J. Implications of the UK Prospective Diabetes Study. Questions answered and issues remaining. In *Drug Treatment of Type 2 Diabetes*. Andrew J. Krentz (ed.) Adis Int. Ltd. 2000, pp 23-29.
249. Kim J, Chehade J, Pinnas JL, Mooradian AD. Effect of select antioxidants on malondialdehyde-modification of proteins. *Nutrition* 16: 1079-1081, 2000.
250. Thampy KG, Haas MJ, Mooradian AD. Age-related changes in rat hepatic acetyl-coenzyme A carboxylase. *Proc. Soc. Exp. Biol. Med.* 225: 123-127, 2000.
251. Fujioka K and the Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. *Dibetes, Obesity and Metabolism* 2: 175-187, 2000.

Scientific Publications (cont'd):

252. Kim J, Mooradian AD. Hyperinsulinemic hypoglycemia associated with possible hypopituitarism in a patient with acquired immune deficiency syndrome. *Endocrine Practice* 6: 453-455, 2000.
253. Thampy GK, Haas MJ, Mooradian AD. Troglitazone stimulates acetyl-Co A carboxylase activity through a post-translational mechanism. *Life Sci.* 68: 699-708, 2000.
254. Mooradian AD, Reinacher D, Li JP, Pinnas JL. Malondialdehyde-modification of proteins in vitro is enhanced in the presence of acetaldehyde. *Nutrition* 17: 619-622, 2001.
255. Rosenstock J et al for the HOE901 Study Group. Basal insulin therapy in type 2 diabetes. *Diabetes Care* 24: 631-636, 2001.
256. Haas MJ, Reinacher D, Li JP, Wong NCW, Mooradian AD. Regulation of ApoA1 gene expression with acidosis: Requirement for a transcriptional repressor. *J. Mol. Endocrinol.* 27:43-57, 2001.
257. Chehade JM, Silverberg AS, Kim JH, Case CC, Mooradian AD. The role of repeat fine needle aspiration of thyroid nodules with benign cytology. *Endocrine Practice.* 7:237-243, 2001.
258. Mooradian AD. Endocrine dysfunction due to renal disease. In: *Principles and Practice of Endocrinology and Metabolism*. 3rd edition, KL Becker, Editor; Lippincot, Williams and Wilkins, Philadelphia, 2001, pp1908-1911.
259. Mooradian AD, Chehade JM, Thurman JE. The role of thiazolidenediones in the treatment of type2 diabetes. *Treatments in Endocrinology* 1:13-20, 2002.
260. Brown WV et al for the Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52 week trial. *Am. Heart J.* 144:1036-1043, 2002.
261. Deleon MJ, Horani, MH, Haas MJ, Wong NCW, Mooradian AD. Effects of dehydroepiandrosterone (DHEA) on rat apolipoprotein A1 gene expression in the human hepatoma cell line, HepG2. *Metabolism* 56:101-106, 2002.
262. Reed RL, Mooradian AD. Diabetes Mellitus in Primary Care Geriatrics. A Case Based Approach. RJ Ham, P.D.Sloan, G.A.Warshaw (eds), Fourth edition, Mosby Inc., St. Louis, 2002, pp 507-515.
263. Mooradian AD. Obesity: A rational target for managing diabetes mellitus. *Growth Hormone & IGF research (suppl. A):* S1-S5, 2001.
264. Deleon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 (GLP-1) response to acarbose in elderly type 2 diabetic subjects. *Diabetes Research and Clinical Practice* 56:101-106, 2002.

Scientific Publications (cont'd):

265. Franz, MJ, Bantle JP, Beebe CA, Brunzell JD, Jean-Louis Chiasson J-L, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M. Technical Review: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related Complications. *Diabetes Care* 25:148- 198, 2002.
266. Haas MJ, Li J-P, Pun K, Mooradian AD. Partial characterization of a cerebral thyroid hormone responsive protein (THRP). *Archives of Biochemistry and Biophysics* 399:6-11, 2002.
267. Hasanain B, Mooradian AD. Antioxidants and their influence in diabetes. *Current Diabetes Reports* 2:448-456, 2002.
268. Mooradian AD, Kumar H. Thyroid disease in the elderly. In. *Primer on Geriatric Care*. D.E. Rosenblatt and V.S. Natarajan (eds). Printers Castle, Cochin 2002; pp 185-189.
269. Thurman JE, Mooradian AD. Alternative Therapy: Vitamin Use in the Elderly. In *Alternative Medicine for the Elderly*. P. Cherniak, N. Cherniack(eds), Springer Verlag, Berlin Heidelberg, 2003, pp91-109.
270. Chehade JM, Haas MJ, Mooradian AD. Diabetes-related changes in rat cerebral occludin and zonula occludens-1 (ZO-1) expression. *Neurochem. Res.* 27:249-252, 2002.
271. Horani MH, Mooradian AD. Management of obesity in the elderly. Special considerations. *Treatments in Endocrinology* 1:387-398, 2002.
272. McMahon FG and the Sibutramine in Hypertensives Clinical Study Group. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. *J. Hum Hypertens.* 16: 5-11, 2002.
273. Mooradian AD, Haas MJ, Wong NCW, Chehade JH. Apolipoprotein A-I expression in rats is not altered by troglitazone. *Exp. Biol. Medicine* 227:1001-1005, 2002.
274. Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. *Diabetes Obes Metab.* 4:368-375, 2002.
275. Mooradian AD, Haas MJ, Chehade JM. Age-related changes in rat cerebral occludin and zonula occludens-1 (ZO-1). *Mech. Ageing Devel.* 124: 143–146, 2003
276. Mooradian AD. Cardiovascular disease in Type 2 diabetes mellitus: Current management guidelines. *Arch. Intern. Med.* 163:33-40, 2003.

Scientific Publications (cont'd):

277. Haas MJ, Sawaf R, Horani MH, Gobal F, Wong NCW, Mooradian AD. Effect of chromium on apolipoprotein A-I expression in HepG2 cells. *Nutrition* 19:353-357, 2003.
278. Lam JK, Matsubara S, Mihara K, Zheng X, Mooradian AD, Wong NCW. Insulin induction of apolipoprotein A: role of SP1. *Biochemistry* 42:2680-2690, 2003.
279. Marston WA, Hanft J, Norwood P, Pollak R for the Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers. *Diabetes Care* 26: 1701-1705, 2003.
280. Haas MJ, Parseghian SA, Sajid RM, Mooradian, AD. Effect of thyroid hormone responsive protein (THRP) expression on PC12 cell survival. *Exp. Brain Res.* 150: 75-84, 2003.
281. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *Diabetes Care* 26 Suppl 1:S51-61, 2003.
282. Horani M, Mooradian AD. Diabetes and the blood-brain barrier. *Current Pharmaceutical Design* 9:833-840, 2003.
283. Oiknine R, Mooradian AD. Drug therapy of diabetes in the elderly. *Biomed Pharmacother.* 57:231-239, 2003.
284. Haas MJ, Horani M, Mreyoud A, Plummer B, Wong NCW, Mooradian AD. Suppression of apolipoprotein AI gene expression in Hep G2 cells by TNF α and IL-1 β . *Biochem. Biophys. Acta.* 1623: 120-128, 2003.
285. Hasnain BI, Mooradian AD. Clinical implications of recent trials of antioxidant therapy: What should we be telling our patients. *Cleveland Clin J Med.* 71: 327-334. 2004.
286. Ratner RE et al for the Amylin Study Group. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. *Diabetic Medicine* 21: 1204-1212, 2004.
287. Horani M, Gobal F, Haas MJ, Wong NCW, Mooradian AD. Cyclooxygenase (COX) inhibition is associated with down regulation of apolipoprotein AI (apo-AI) promoter activity in cultured hepatoma cell line-HepG2. *Metabolism* 53:174-181, 2004.
288. Mooradian AD, Haas MJ, Wong NCW. Transcriptional control of apolipoprotein A-I gene expression in diabetes mellitus. *Diabetes* 53:513-520, 2004.

Scientific Publications (cont'd):

289. Haas MJ, Wong NCW, Mooradian AD. Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells. *Metabolism* 53: 766-771, 2004.
290. Albert SG, Mooradian AD. Low-dose recombinant human growth hormone (rhGH) as adjuvant therapy to life style modifications in the management of obesity. *J. Clin. Endocrinol Metab.* 89: 695- 701, 2004.
291. Hiatt WR, Klepack E, Mark Nehler M et al (Mooradian AD): The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. *Vasc Med* 2004; 9; 27-277, 2004.
292. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M; American Diabetes Association. Nutrition principles and recommendations in diabetes. *Diabetes Care.* 27 Suppl 1:S36-46, 2004.
293. Horani, MH, Haas MJ, Mooradian AD. Rapid adaptive down regulation of oxidative burst induced by high dextrose in human umbilical vein endothelial cells. *Diabetes Research and Clinical Practice* 66:7-12, 2004.
294. Haas MJ, Mreyoud A, Fishman M, Mooradian AD. Microarray analysis of thyroid hormone induced changes in mRNA expression in the adult rat brain. *Neuroscience Lett.* 365:14-18, 2004.
295. Bolton WK et al for the ACTION I investigator group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. *Am. J. Nephrol.* 24: 32- 40, 2004.
296. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, Raskin P, Wright JT Jr, Oakes R, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators (Mooradian AD). Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA.* 292:2227-2236, 2004.
297. Myers SE, Albert SG, Hass MJ, Clifton D, Mooradian AD. Pubertal changes in serum leptin levels in adolescents with type 1 diabetes: A controlled longitudinal study. *J. Pediatr. Endocrinol. Metab.*17:1653-1662, 2004.
298. Haas MJ, Horani MH, Wong NCW, Mooradian AD. Induction of apolipoprotein AI promoter by Sp1 is repressed by saturated fatty acids. *Metabolism: Clinical and Experimental.* 53:1342- 1348, 2004.
299. Hovsepian MR, Haas MJ, Boyajyan AS, Guevorkyan AA, Mamikonyan AA, Myers SE, Mooradian AD. Astrocytic and neuronal biochemical markers in the sera of subjects with diabetes mellitus. *Neurosci. Lett.* 369:224-227., 2004.

Scientific Publications (cont'd):

300. Hoffman AR et al. on behalf of the T002 Study Group. Efficacy and tolerability of and individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. *J Clin Endocrinol & Metab* 89: 3224- 3233, 2004.
301. Mooradian AD. Towards single-tablet therapy for type 2 diabetes mellitus: rationale and recent developments. *Treat Endocrinol.* 3:279-287, 2004.
302. Mooradian AD. "Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events?" Commentary. *J. Gerontology.* 60(5):598; 2005.
303. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes. *Drugs* 65(3):325-40., 2005.
304. Haas MJ, Fishman M, Mreyoud A, Mooradian AD. Thyroid hormone responsive protein (THRP) mediates thyroid hormone-induced cytotoxicity in primary neuronal cultures. *Exp. Brain Res.* 160: 424-432, 2005.
305. Bhatt D et al on behalf of the CHARISMA Investigators. A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. *Am. Heart J* 150: 401-407, 2005.
306. Albert SG, Hasnain, B, Ritter DG, Mooradian AD. Aspirin sensitivity of platelet aggregation in diabetes mellitus. *Diabetes Research and Clinical Practice* 70(2):195-9. 2005.
307. Chaudhry O, Mayo M, Mooradian AD. Undetectable serum creatinine in a paralyzed patient infected with human immunodeficiency virus (HIV). *Laboratory Medicine* 36:479-481, 2005.
308. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli F, Phillips RA, Raskin P, Wright JT Jr, Waterhouse B, Lukas MA, Anderson KM, Bell DS; GEMINI Investigators (Mooradian AD). Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes. *Hypertension.* 46:1309-1315, 2005.
309. Bakris GL, Bell DS, Fonseca V, Katholi R, McGill J, Phillips R, Raskin P, Wright JT Jr, Iyengar M, Holeslaw T, Anderson KM; GEMINI Investigators (Mooradian AD). The rationale and design of the Glycemic Effects in Diabetes Mellitus Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial. *J Diabetes Complications.* 19:74-79, 2005.
310. Wehmeier K, Beers A, Haas MJ, Wong NCW, Steinmeyer, A, Zugel U, Mooradian AD. Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. *Biochim. Biophys. Acta - Molecular and Cell Biology of Lipids.* 1737(1):16-26.2005.

Scientific Publications (cont'd):

311. Mooradian AD, Haas MJ, Batejko O, Hovsepyan M, Feman SS. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin induced diabetic rats. *Diabetes* 54:2977-82, 2005.
312. Marston WA for the Dermagraft Diabetic Foot Ulcer Study Group. Risk factors associated with healing chronic diabetic foot ulcers: The importance of hyperglycemia. *Ostomy Wound Manage.* 52: 26-39, 2006.
313. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ; CHARISMA Investigators (Mooradian AD). A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. *Am Heart J.*150:401, 2005.
314. Mooradian AD, Haas MJ, Wadud K. Ascorbic acid and α -tocopherol down regulate apolipoprotein AI gene expression in HepG2 and Caco-2 cell lines. *Metabolism: Clinical and Experimental* 55:159-167, 2006.
315. Horani MH, Haas MJ, Mooradian AD. Saturated, unsaturated, and *trans* fatty acids modulate oxidative burst induced by high dextrose in human umbilical vein endothelial cells. *Nutrition* 22:123-127, 2006.
316. Mooradian AD, Haas MJ, Wong NCW. The effect of select nutrients on serum high density lipoprotein cholesterol and apolipoprotein A-I levels. *Endocrine Reviews* 27:2-16, 2006.
317. Mooradian AD, Korenman SG. Management of the cardinal features of andropause. *Am. J. Therapeutics* 13: 145-160, 2006.
318. Oiknine RF, Mooradian AD. Thyroid disorders. In. *Principles and Practice of Geriatric Medicine*, 4th edition, MS John Pathy, AJ Sinclair, JE Morley, John Wiley and Sons, Ltd. 4th edition; Vol 2;,2006; pp: 1405-1414.
319. Mooradian AD. Diabetes and the consequences for the blood-brain barrier. In *Blood-Brain Barriers: From ontogeny to artificial interfaces*. R Dermietzel, D. C. Spray, M. Nedergaard (eds). Wiley-VCH, Weinheim, 2006, pp 649-670.
320. Mooradian AD. Diabetes as a model of premature aging. In: *Handbook of Models for Human Aging*. Michael Cohn Editor, 2006; pp687-695.
321. Steiner G et al. for the BARI 2D Trial Investigators. Statement of the problem. *Am. J. Cardiol* 97[suppl]:3G-8G, 2006. Mooradian AD site PI and member of the Steering committee.

Scientific Publications (cont'd):

322. Brooks MM et al. for the BARI2D Trial Investigators (Mooradian AD). Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 diabetes (BARI 2D) Trial. *Am. J. Cardiol* 97[suppl]:9G-19G, 2006.
323. Magee MF, Isley WL for the BARI2D Trial Investigators (Mooradian AD). Rationale, design and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 diabetes (BARI 2D) Trial. *Am. J. Cardiol* 97 [suppl]:20G-30G, 2006.
324. Barsness GW, Gersh BJ, Brooks MM, Frye RL for the BARI2D Trial Investigators (Mooradian AD). Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 diabetes (BARI 2D) Trial. *Am. J. Cardiol* 97 [suppl]:31G-40G, 2006.
325. Albu J, Gottlieb SH, August P, Nesto R, Orchard TJ for the BARI2D Trial Investigators (Mooradian AD). Modifications of coronary risk factors. *Am. J. Cardiol* 97 [suppl]:41G-52G, 2006.
326. Sobel BE for the BARI2D Trial Investigators (Mooradian AD). Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 diabetes (BARI 2D) Trial: Synergies and opportunities. *Am. J. Cardiol* 97 [suppl]:53G-58G, 2006.
327. Hlatky MA, Meslop KA, Boothroyd DB for the BARI2D Trial Investigators (Mooradian AD). Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease. *Am. J. Cardiol* 97 [suppl]:59G-65G, 2006.
328. Horani MH, Haas MJ, Mooradian AD. Suppression of hyperglycemia-induced superoxide formation and endothelin-1 gene expression by carvedilol. *Am. J. Therapeutics*. 213:2-7, 2006.
329. Case CC, Mooradian AD. Elevated plasma chromogranin A levels secondary to assay interference: A source of diagnostic confusion. *Endocrine Practice* 12:476-477, 2006.
330. Haas MJ, Horani MH, Parseghian SA, Mooradian AD. Statins prevent dextrose-induced endothelial barrier dysfunction possibly through inhibition of superoxide formation. *Diabetes* 55:474-479, 2006.
331. Morgentaler A for the National Tadalafil Study Group. Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: use of a novel non-inferiority study design. *J. Sexual Med.* 3: 492-503, 2006.
332. Beers A, Haas MJ, Wong NCW, Mooradian AD. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor α : Roles for MEK/ERK and JNK Signaling. *Biochemistry* 45:2408-2413, 2006.

Scientific Publications (cont'd):

333. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML. American Diabetes Association Nutrition Recommendations and Interventions for Diabetes–2006 A position statement of the American Diabetes Association. *Diabetes Care* 29:2140-2157, 2006.
334. Mooradian AD. Antioxidants and Diabetes. *Nestle Nutr Workshop Ser Clin Perform Programme*. 11:107-125, 2006.
335. Mooradian AD, Bernbaum M, Albert SG. Narrative review: A rational approach to starting insulin therapy. *Ann. Intern. Med.* 145:125-34, 2006.
336. Mooradian AD. The dietary regulation of high density lipoprotein cholesterol. Commentary May 2006, International Atherosclerosis Society, <http://www.athero.org>; accessed July 15, 2006.
337. Hachem SB, Mooradian AD. Familial dyslipidaemias: An overview of genetics, pathophysiology and management. *Drugs* 66: 1949-1969, 2006.
338. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaud L, Booth J, Topol EJ; CHARISMA Investigators (Mooradian AD). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *N Engl J Med.* 354:1706-1717, 2006.
339. Messerli FH, Bell DS, Fonseca V, Katholi RE, McGill JB, Phillips RA, Raskin P, Wright JT Jr, Bangalore S, Holdbrook FK, Lukas MA, Anderson KM, Bakris GL; GEMINI Investigators (Mooradian AD). Body weight changes with beta-blocker use: results from GEMINI. *Am J Med.* 120:610-615, 2007.
340. Fonseca V, Bakris GL, Bell DS, McGill JB, Raskin P, Messerli FH, Phillips RA, Katholi RE, Wright JT Jr, Waterhouse B, Lukas MA, Anderson KM; GEMINI Investigators (Mooradian AD). Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. *Diabet Med.* 24:759-763, 2007.
341. Mooradian AD, Hass MJ, Albert SG. Low serum HDL cholesterol in obese subjects with normal serum triglycerides: The role of insulin resistance and inflammatory cytokines. *Diabetes, Obesity and Metabolism* 9:441-443, 2007.
342. Nowak FV, Mooradian AD. Endocrine Function and Dysfunction. *Encyclopedia of Gerontology: Age, Aging, and the Aged.* (Second Edition) J. E. Birren (ed); Elsevier Inc. San Diego, CA. Vol. 1; 2007; pp 480-493.

Scientific Publications (cont'd):

343. Mooradian AD. Korenman, SG Endocrinology, in Atlas of Internal Medicine, Eugene Braunwald (ed). Third Edition, Springer, Philadelphia, 2007, pp. 121-179.
344. Mooradian AD. The effect of nutrients on apolipoprotein AI gene expression. In High Density Lipoproteins. From Basic Biology to Clinical Aspects, Christopher. J. Fielding (ed), Wiley-VCH, Weinheim 2007; 399-423.
345. Chandurkar V, Mooradian AD. Intermittent hyponatremia as a clinical presentation of adrenal insufficiency caused by pituitary adenoma. Hospital Physician 43: 51-55, 2007.
346. Bosi E et al Mooradian AD site PI. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30: 890- 895, 2007.
347. Garber AJ et al and Mooradian AD site PI. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes, Obesity and Metabolism 9:166-174, 2007.
348. Goldstein I et al for MOMENTUS Study Investigators. Efficacy and Safety of Tadalafil in Men with Erectile Dysfunction with a High Prevalence of Comorbid Conditions: Results from MOMENTUS: Multiple Observations in Men with Erectile Dysfunction in National Tadalafil Study in the US J. Sexual Med. 4: 166-175, 2007.
349. Mooradian AD, Haas MJ. Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats. Am. J. Therap. 14:41-45, 2007.
350. Albert SG, Obediah J, Parseghian SA, Hurley W, Mooradian AD. Severe insulin resistance associated with subcutaneous amyloid deposition. Diabetes Research and Clinical Practice 75:374-376, 2007
351. Albert SG, Haas MJ, Mooradian AD. Effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C - reactive protein in obese subjects.. Growth Hormone & IGF Research 17:19-25, 2007
352. Snyder PJ, Biller BM, Zagar A, Jackson I, Arafah BM, Nippoldt TB, Cook DM, Mooradian AD, Kwan A, Scism-Bacon J, Chipman JJ, Hartman ML. Effect of growth hormone replacement on bone mineral density in adult-onset growth hormone deficiency. J Bone Miner Res. 22:762-770, 2007.

Scientific Publications (cont'd):

353. Wylie-Rosett J, Albright AA, Apovian C, Clark NG, Delahanty L, Franz MJ, Hoogwerf B, Kulkarni K, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler M. 2006-2007 American Diabetes Association nutrition recommendations: issues for practice translation. *J Am Diet Assoc.* 107:1296-304, 2007
354. Albert SG, Oiknine R, Parseghian S, Mooradian AD, Haas MJ, McPherson T. The effect of glucosamine on serum high density lipoprotein cholesterol and apolipoprotein AI levels in people with diabetes mellitus. *Diabetes Care* 30:2800-2803, 2007.
355. Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ; CHARISMA Investigators (Mooradian AD). An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. *Eur Heart J.* 28:2200-2207, 2007.
356. Saw J, Brennan DM, Steinhubl SR, Bhatt DL, Mak KH, Fox K, Topol EJ; CHARISMA Investigators (Mooradian AD). Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. *J Am Coll Cardiol.* 50:291-595, 2007.
357. Bhatt DL, Flather MD, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Fabry-Ribaudo L, Hu T, Topol EJ, Fox KA; CHARISMA Investigators (Mooradian AD). Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. *J Am Coll Cardiol.* 49:1982-1988, 2007.
358. Mooradian AD, Haas MJ, Wehmeier K, Wong NCW. Obesity-related changes in high density lipoprotein metabolism. *Obesity* 16:1152-1160, 2008.
359. Lowman E, Mooradian AD. Macromelia masquerading as an acromegaloid syndrome in an adult with Klippel-Trenaunay syndrome. *Endocrine Practice.* 14:109-111, 2008.
360. Mooradian AD. Asymptomatic hyperthyroidism in older adults? Is it a distinct clinical and laboratory entity? *Drugs & Aging* 25:371-80, 2008.
361. Wehmeier, KR, Mazza, A, Hachem, S, Ken Ligaray K, Mooradian AD, Wong, NC, Haas MJ. Differential regulation of apolipoprotein A-I gene expression by vitamin D receptor modulators *Biochim. Biophys. Acta* 1780:264-273, 2008.
362. American Diabetes Association, Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. *Diabetes Care.* Jan; 31 Suppl 1:S61-78, 2008.

Scientific Publications (cont'd):

363. The Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group and Mooradian A. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Am. Heart J.* 156:528-536, 2008.
364. Phillips RA, Fonseca V, Katholi RE, McGill JB, Messerli FH, Bell DS, Raskin P, Wright JT Jr, Iyengar M, Anderson KM, Lukas MA, Bakris GL; GEMINI Investigators (Mooradian AD). Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. *J Cardiometab Syndr.* 3:211-217, 2008.
365. Hart RG, Bhatt DL, Hacke W, Fox KA, Hankey GJ, Berger PB, Hu T, Topol EJ; CHARISMA Investigators (Mooradian AD). Clopidogrel and aspirin versus aspirin alone for the prevention of stroke in patients with a history of atrial fibrillation: subgroup analysis of the CHARISMA randomized trial. *Cerebrovasc Dis.* 25:344-347, 2008.
366. Palacio C, Masri G, Mooradian AD. Black cohosh for the management of menopausal symptoms: a systematic review of clinical trials. *Drugs Aging.* 26:23-36, 2009.
367. Palacio CC, Alexandraki I, House J, Mooradian AD. A comparative study of unscheduled hospital readmissions in a resident staffed teaching service and a hospitalist based service. *Southern Medical Journal* 102:145-149, 2009
368. Chegade J, Mooradian AD. Drug Therapy: Current and emerging agents for hyperglycemia. In: Diabetes in Old Age. 3rd edition, Alan .J, Sinclair (ed.), John Wiley & Sons Ltd, 2009; pp: 245-264.
369. Reddy P, Mooradian AD. Diuretics: An update on the pharmacology and clinical uses. *American Journal of Therapeutics.* 16:74-85, 2009.
370. Kim LJ, King SB 3rd, Kent K, Brooks MM, Kip KE, Abbott JD, Jacobs AK, Rihal C, Hueb WA, Alderman E, Sing IR, Attubato MJ, Feit F; BARI 2D (Bypass Angioplasty Revascularization Investigation Type 2 Diabetes) Study Group (Mooradian A). Factors related to the selection of surgical versus percutaneous revascularization in diabetic patients with multivessel coronary artery disease in the BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) trial. *JACC Cardiovasc Interv.* 2:384-392, 2009.
371. Alexandraki A, Palacio CC, House J, Catalano C, Mooradian AD. Resource-based relative value scale analysis between teaching and non-teaching hospitalist services. *The Health Care Manager* 28:81-85, 2009.

Scientific Publications (cont'd):

372. Mooradian AD. Dyslipidemia of type 2 diabetes mellitus. *Nature Clinical Practice Endocrinology & Metabolism*. 5:150-159, 2009
373. Reddy P, Mooradian AD. Clinical utility of anion gap in deciphering acid-base disorders. *International Journal of Clinical Practice* 63: 1516-1525, 2009.
374. Pambianco G, Lombardero M, Bittner V, Forker A, Kennedy F, Krishnaswami A, Mooradian AD, Pop-Busui R, Rana JS, Rodriguez A, Steffes M, Orchard TJ and the BARI 2D Investigators. Control of lipids at baseline in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. *Preventive Cardiology* 12: 9-18, 2009.
375. Pop-Busui R, Lu J, Lopes N, Jones TL, BARI 2D Investigators (Mooradian A). Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. *J Peripher Nerv Syst*. 14:1-13, 2009.
376. Schwartz L, Kip KE, Alderman E, Lu J, Bates ER, Srinivas V, Bach RG, Mighton LD, Feit F, King S 3rd, Frye RL; BARI 2D Study Group (Mooradian A). Baseline coronary angiographic findings in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). *Am J Cardiol*. 103:632-638, 2009.
377. Reddy P, Mooradian AD. Diagnosis and management of hyponatremia in hospitalized patients. *International Journal of Clinical Practice* 63: 1494–1508, 2009.
378. Chehade JM, Sheikh-Ali. M, Mooradian AD. The role of micronutrients in managing diabetes mellitus. *Diabetes Spectrum* 22:214-218, 2009.
379. Berger JS, Bhatt DL, Steinhubl SR, Shao M, Steg PG, Montalescot G, Hacke W, Fox KA, Lincoff AM, Topol EJ, Berger PB; CHARISMA Investigators (Mooradian AD). Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. *Circulation*. 120:2337-2344, 2009.
380. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, Fox KA, Montalescot G, Weber MA, Haffner SM, Dimas AP, Steg PG, Topol EJ; CHARISMA Investigators (Mooradian AD). Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial). *Am J Cardiol*. 103:1359-1363, 2009.
381. Steinhubl SR, Bhatt DL, Brennan DM, Montalescot G, Hankey GJ, Eikelboom JW, Berger PB, Topol EJ; CHARISMA Investigators (Mooradian AD). Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. *Ann Intern Med*. 150:379-386, 2009.

Scientific Publications (cont'd):

382. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; CHARISMA Investigators (Mooradian AD). Patients with peripheral arterial disease in the CHARISMA trial. *Eur Heart J.* 30:192-201, 2009.
383. BARI 2D Study Group (Mooradian A). Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *N. Engl J Med.* 360:2503-2515, 2009.
384. Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RL, and the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group (Mooradian A). The Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of different treatment strategies in type 2 diabetes mellitus with Stable ischemic heart disease: Impact of treatment strategy on cardiac mortality and myocardial infarction. *Circulation* 120:2529-2540, 2009.
385. Hlatky MA, Boothroyd DB, Melsop KA, Kennedy L, Rihal C, Rogers WJ, Venkitachalam L, Brooks MM, for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Study Group (Mooradian A site PI). Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the bypass angioplasty revascularization investigation 2 diabetes trial. *Circulation* 120:2550-2558, 2009.
386. Mooradian AD Meenrajan S. The business of academic medicine is a business like no other: A perspective. *The Health Care Manager* 28:344-350, 2009.
387. Pop-Busui R, Lombardero M, Lavis V, Forker A, Green J, Korytkowski M, Sobel BE, Jones TLZ, and the BARI 2D Study Group (Mooradian AD site PI) . Relation of severe coronary artery narrowing to insulin or thiazolidinedione use in patients with type 2 diabetes mellitus (from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study). *American Journal of Cardiology* 104: 52-58, 2009.
388. Chehade JM, Lim W, Silverberg, AB, Mooradian AD. The incidence of Hashimoto's disease in nodular goiter: The concordance in serologic and cytologic findings. *Int. J. of Clin. Practice* 64: 29-33, 2010.
389. Sheikh-Ali, M, Sultan S, Alamir, A, Haas M, Mooradian AD. Hyperglycemia-induced endoplasmic reticulum stress in endothelial cells. *Nutrition* 26: 1146-1150, 2010.

Scientific Publications (cont'd):

390. Berger PB, Bhatt DL, Fuster V, Steg PG, Fox KA, Shao M, Brennan DM, Hacke W, Montalescot G, Steinhubl SR, Topol EJ; CHARISMA Investigators (Mooradian AD). Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. *Circulation*. 121:2575-2583, 2010.
391. Albu JB, Lu J, Mooradian AD, Krone R, Nesto RW, Porter M, Rana JS, Rogers WJ, Sobel BE, Gottlieb S for the BARI 2D Study Group. Relationships of obesity and fat distribution with atherothrombotic risk factors. Baseline results from the BARI 2D trial. *Obesity* 18:1046-1054, 2010.
392. Chehade JM, Sheikh-Ali M, Alexandraki I, House J, Mooradian AD. The effect of health care provider education on diabetes management of hospitalized patients. *International Journal of Clinical Practice* 64:917-924, 2010.
393. Wall BM, Hardison RM, Molitch ME, Marroquin OC, McGill JB, August PA; BARI 2D Study Group (Mooradian A). High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data. *Am J Med Sci*. 339:401-410, 2010.
394. Thomas SB, Sansing VV, Davis A, Magee M, Massaro E, Srinivas VS, Helmy T, Desvigne-Nickens P, Brooks MM; BARI 2D Study Group (Mooradian A). Racial differences in the association between self-rated health status and objective clinical measures among participants in the BARI 2D trial. *Am J Public Health*. 100 Suppl 1:S269-S276, 2010.
395. Sheikh-Ali M, Sultan S, Alamir A, Haas MJ, Mooradian AD. Effects of antioxidants on glucose-induced oxidative stress and endoplasmic reticulum stress in endothelial cells. *Diabetes Research and Clinical Practice* 87:161-166, 2010.
396. Wilson GR, Alexandraki I, Samraj G, Mooradian AD. Endocrinology. In *Textbook of Family Medicine*. RE Rakel and DP Rakel (eds) 8th edition, Elsevier, Philadelphia, PA, 2010.
397. Haas MJ, Mooradian AD. Regulation of high-density lipoprotein by inflammatory cytokines: Establishing links between immune dysfunction and cardiovascular disease. *Diabetes & Metabolism Research and Reviews* 26: 90-99, 2010
398. Alexandraki A, Mooradian AD. Barriers related to mammography use for breast cancer screening among minority women. *Journal of the National Medical Association* 102:206-218, 2010.

Scientific Publications (cont'd):

399. Escobedo J, Rana JS, Lombardero MS, Albert SG, Davis AM, Kennedy FP, Mooradian AD, Robertson DG, Srinivas VS, Gebhart SSP, for the BARI 2D Study Group. Association between albuminuria and duration of diabetes and myocardial dysfunction and peripheral arterial disease among patients with stable coronary artery disease in the BARI 2D study. *Mayo Clin Proc.* 85:41-46, 2010.
400. McBane RD, Hardison RM, Sobel BE, BARI 2D Study Group (A. Mooradian). Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D Trial). *Am. J of Cardiol.* 105:17-24, 2010.
401. Haas, MJ, Mooradian AD. Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection. *Drugs* 70:805-821, 2010.
402. House, J, Mooradian AD. The evaluation and management of shoulder pain in primary care clinics. *Southern Medical Journal* 103:1129-1135, 2010.
403. Banks WA, Morley JE, Lynch JL, Lynch KM, Mooradian AD. Insulin detemir is not transported across the blood-brain barrier. *Peptides* 31:2284-2288, 2010.
404. Grogan M, Jenkins M, Sansing VV, Macgregor J, Brooks MM, Julien-Williams P, Amendola A, Abbott JD and BARI 2D Study Group (A. Mooradian). Health insurance status and control of diabetes and coronary artery disease risk factors on enrollment into the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. *Diabetes Educ.* 36:774-783, 2010.
405. Brooks MM, Chung S-C, Helmy T, Hillegass WB, Escobedo J, Melsop KA, Massaro EM, McBane RD, Hyde P, Hlatky MA and the BARI 2D Study Group (A. Mooradian). Health status after treatment for coronary artery disease and type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *Circulation* 122:1690-1699, 2010.
406. Hlatky MA, Chung SC, Escobedo J, Hillegass WB, Melsop K, Rogers W, Brooks MM; BARI 2D Study Group (A. Mooradian). The effect of obesity on quality of life in patients with diabetes and coronary artery disease. *Am Heart J.* 159:292-300, 2010.
407. Rana JS, Hardison RM, Pop-Busui R, Brooks MM, Jones TL, Nesto RW, Bourassa MG; BARI 2D Investigators (A. Mooradian). Resting heart rate and metabolic syndrome in patients with diabetes and coronary artery disease in bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. *Prev Cardiol.* 13:112-116, 2010.

Scientific Publications (cont'd):

408. Weber M, Bhatt DL, Brennan DM, Hankey GJ, Steinhubl SR, Johnston SC, Montalescot G, Mak KH, Fox KA, Easton DJ, Topol EJ, Hamm CW; CHARISMA Investigators (Mooradian AD). High-sensitivity C-reactive protein and clopidogrel treatment in patients at high risk of cardiovascular events: a substudy from the CHARISMA trial. *Heart*. 97:626-631, 2011.
409. Sheikh-Ali, M, Chehade JN, Mooradian AD. The antioxidant paradox in diabetes mellitus. *Am. J. Therapeutics* 18:266-278, 2011.
410. Lee K, Palacio C, Alexandraki I, Stewart E, Mooradian AD. Increasing access to health care providers through medical home model may abolish racial disparity in diabetes care: Evidence from a cross sectional study. *Journal of the National Medical Association* 103:250-256, 2011.
411. Singh PP, Abbott JD, Lombardero MS, Sutton-Tyrrell K, Woodhead G, Venkitachalam L, Tsapatsaris NP, Piemonte TC, Lago RM, Rutter MK, Nesto RW; Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group (A. Mooradian). The prevalence and predictors of an abnormal ankle-brachial index in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Diabetes Care* 34:464-467, 2011.
412. Tamis-Holland JE, Lu J, Bittner V, Magee MF, Lopes N, Adler D, Kip KE, Schwartz L, Groenewoud Y, Jacobs AK, for the BARI 2D Study Group (A. Mooradian). Sex, clinical symptoms, and angiographic findings in patients with diabetes mellitus and coronary artery disease (From the Bypass Angioplasty Revascularization Investigation [BARI] 2D). *American Journal of Cardiology* 107:980-985, 2011.
413. Mooradian AD. Subclinical hypothyroidism in the elderly: To treat or not to treat?" *Am. J. Therap.* 18:477-486, 2011.
414. Lim W, Haas MJ, Mooradian AD. The thyroid hormone responsive protein (THRP) has a critical role in the embryogenesis of *Xenopus laevis*. *Neuroscience Letters*. 488:272-274, 2011.
415. Mooradian AD. Special considerations in insulin therapy of older adults. *Drugs & Ageing* 28:429-438, 2011.
416. Wehmeier, KR, Al Amir, A-R, Sultan S, Haas MJ, Wong, NC, Mooradian AD. 24,25-Dihydroxycholecalciferol but not 25-hydroxycholecalciferol suppresses apolipoprotein A-I gene expression *Life Sciences* 88:110-116, 2011.
417. Palacio C, Alexandraki I, Bertholf R, Mooradian AD. Transient dyslipidemia mimicking Tangier disease in a diabetic patient with urosepsis. *Annals of Clinical & Laboratory Science* 41:150-153 2011.

Scientific Publications (cont'd):

418. Haas MJ, Mooradian AD. Inflammation, high-density lipoproteins and cardiovascular dysfunction. *Current Opinion in Infectious Diseases* 24:265-272, 2011.
419. Mooradian AD, Haas MJ. Glucose-induced endoplasmic reticulum (ER) stress is independent of oxidative stress: A mechanistic explanation for the failure of antioxidant therapy in diabetes. *Free Radical Biology & Medicine* 50:1140-1143, 2011.
420. Haas MJ, Al Amir, A-R, Sultan S, Chehade JM, Wong, NC, Mooradian AD. Nicotinic acid induces apo A-I gene expression in HepG2 and Caco-2 cell lines. *Metabolism* 60:1790-1796, 2011.
421. Chung SC, Hlatky MA, Faxon D, Ramanathan K, Adler D, Mooradian A, Rihal C, Stone RA, Bromberger JT, Kelsey SF, Brooks MM; BARI 2D Study Group. The effect of age on clinical outcomes and health status BARI 2D (Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes) *Journal of the American College of Cardiology* 58:810-819,2011.
422. Dagenais GR, Lu J, Faxon DP, Kent K, Lago RM, Lezama C, Hueb W, Weiss W, Slater J, Frye RL, for the BARI 2D Trial Research Group (A. Mooradian). Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. *Circulation* 123:1492-1500, 2011.
423. Chung S-C, Brooks MM, Hlatky MA, Stone RA, Rana, JS, Escobedo J, Rogers WJ, Bromberger JT, Kelsey SF, Brooks MM, and the BARI 2D Study Group (A. Mooradian). Body mass index and health status in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). *American Heart Journal*. 161:755-763, 2011.
424. Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD, Schneider, DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL, and for the BARI 2D Investigators (A. Mooradian). Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes. *Circulation* 124: 695-703, 2011.
425. Beohar N, Davidson CJ, Massaro E, Srinivas VS, Sansing VV, Zonszein J, Davis AM, Helmy T, Lopes N, Thomas SB, Brooks MM, and the BARI 2D Study Group (A. Mooradian). The impact of race/ethnicity on baseline characteristics and the burden of coronary atherosclerosis in the Bypass Angioplasty Revascularization Investigation of Type 2 Diabetes (BARI 2D). *American Heart Journal* 161:755-763, 2011.
426. Cresci S, Wu J, Province MA, Spertus JA, Steffes M, McGill JB, Alderman EL, Brooks MM, Kelsey SF, Frye RL, Bach RG (and the BARI 2D Study Group A. Mooradian). Peroxisome proliferator-activated receptor pathway gene polymorphism associated with extent of coronary artery disease in patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial / Clinical Perspective. *Circulation*124:1426-1434, 2011.

Scientific Publications (cont'd):

427. Jaimungal S, Wehmeier, KW, Mooradian AD, Haas MJ. The emerging evidence for vitamin D-mediated regulation of apolipoprotein A-I synthesis. *Nutrition Research* 31:805-812, 2011.
428. Alexandraki I, Mooradian AD. Academic advancement of clinician educators: why is it so difficult? *International Journal of Clinical Practice* 65:1118-1125, 2011.
429. Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, Steg PG, Montalescot G, Bhakta N, Hacke W, Flather MD, Mak KH, Cacoub P, Creager MA, Berger PB, Steinhubl SR, Murugesan G, Mehta SR, Kottke-Marchant K, Lincoff AM, Topol EJ; CHARISMA Investigators (Mooradian AD). The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. *Eur Heart J.* 33:2143- 2150, 2012.
430. Mooradian AD, Chehade JM. Diabetes mellitus in older adults. *Am. J. Therap.* 19:145-59, 2012.
431. Haas MJ, Mazza A, Wong NCW, Mooradian AD. Inhibition of apolipoprotein A-I gene expression by obesity-associated endocannabinoids. *Obesity* 20: 721-729, 2012.
432. Haas MJ, Mooradian AD. What evidence is there for the role of vitamin D and apo A1 in atheroprotection? *Clinical Lipidology* 7:255-257, 2012.
433. Haas MJ, Raheja P, Jaimungala S, Sheikh-Ali M, Mooradian AD. Estrogen-dependent inhibition of dextrose-induced endoplasmic reticulum stress and superoxide generation in endothelial cells. *Free Radical Biology & Medicine* 52:2161-2167, 2012.
434. Krishnaswami A, Hardison R, Nesto RW, Sobel B; BARI 2D Investigators (Mooradian A). Presentation in patients with angiographically documented coronary artery disease and type II diabetes mellitus (from the BARI 2D Clinical Trial). *Am J Cardiol.* 109:36-41, 2012.
435. Abbott JD, Lombardero MS, Barsness GW, Pena-Sing I, Buitrón LV, Singh P, Woodhead G, Tardif JC, Kelsey SF (BARI 2D Investigators; A. Mooradian). Ankle-brachial index and cardiovascular outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *Am Heart J.* 164:585-590, 2012.
436. Brooks MM, Chaitman BR, Nesto RW, Hardison RM, Feit F, Gersh BJ, Krone RJ, Sako EY, Rogers WJ, Garber AJ, King SB 3rd, Davidson CJ, Ikeno F, Frye RL; for the BARI 2D Study Group (A. Mooradian). Clinical and Angiographic Risk Stratification and Differential Impact on Treatment Outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. *Circulation.* 126:2115-2124, 2012.

Scientific Publications (cont'd):

437. Shaw LJ, Cerqueira MD, Brooks MM, Althouse AD, Sansing VV, Beller GA, Pop-Busui R, Taillefer R, Chaitman BR, Gibbons RJ, Heo J, Iskandrian AE (BARI 2D Investigators; A. Mooradian). Impact of left ventricular function and the extent of ischemia and scar by stress myocardial perfusion imaging on prognosis and therapeutic risk reduction in diabetic patients with coronary artery disease: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *J Nucl Cardiol*. 19(4):658-669, 2012.
438. Schwartz L, Bertolet M, Feit F, Fuentes F, Sako EY, Toosi MS, Davidson CJ, Ikeno F, King SB 3rd. (BARI 2D Investigators; A. Mooradian). Impact of completeness of revascularization on long-term cardiovascular outcomes in patients with type 2 diabetes mellitus: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). *Circ Cardiovasc Interv*. 5:166-173, 2012.
439. Alexandraki I, Palacio C, House J, Mooradian AD. Hospital bed utilization by teaching and nonteaching medical services. *Health Care Manag (Frederick)*. 31:295-301, 2012.
440. Naem E, Alcalde R, Gladysz M, Mesliniene S, Jaimungal S, Sheikh-Ali M, Haas MJ, Wong NC, Mooradian AD. Inhibition of apolipoprotein A-I gene by the aryl hydrocarbon receptor: a potential mechanism for smoking-associated hypoalphalipoproteinemia. *Life Sci*. 91(1-2):64-69, 2012.
441. Alexandraki I, Mooradian AD. Redesigning medical education to improve health care delivery and outcomes. *The Health Care Manager* 32(1):37-42, 2013
442. Chehade JM, Gladysz M, Mooradian AD. Dyslipidemia in type 2 diabetes: Prevalence, pathophysiology and management. *Drugs* 73:327-39, 2013.
443. Chehade JM, Alcalde R, Naem E, Mooradian AD, Wong NCW, Haas MJ. Induction of apolipoprotein A-I gene expression by glucagon-like peptide-1 and exendin-4 in hepatocytes but not intestinal cells. *Metabolism* 62:265-274, 2013.
444. Naem E, Haas MJ, Wong NCW, Mooradian AD. Endoplasmic reticulum stress in HepG2 cells inhibits apolipoprotein A-I secretion. *Life Sciences* 92:72-80, 2013.
445. Dagenais GR, Lu J, Faxon DP, Bogaty P, Adler D, Fuentes F, Escobedo J, Krishnaswami A, Slater J, Frye RL; BARI 2D Study Group (A. Mooradian). Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: Results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial. *J Am Coll Cardiol* 61:702-711, 2013.

Scientific Publications (cont'd):

446. Tamis-Holland JE, Lu J, Korytkowski M, Magee M, Rogers WJ, Lopes N, Mighton L, Jacobs AK; BARI 2D Study Group (A. Mooradian). Sex differences in presentation and outcome among patients with type 2 diabetes and coronary artery disease treated with contemporary medical therapy with or without prompt revascularization: A report from the BARI 2D trial (Bypass Angioplasty Revascularization Investigation 2 Diabetes). *J Am Coll Cardiol* 61:1767-1776, 2013.
447. Althouse AD, Abbott JD, Sutton-Tyrrell K, Forker AD, Lombardero MS, Buitrón LV, Pena-Sing I, Tardif JC, Mori Brooks M; for the BARI 2D Study Group (A. Mooradian). Favorable Effects of Insulin Sensitizers Pertinent to Peripheral Arterial Disease in Type 2 Diabetes: Results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Diabetes Care* 36:3269-3275, 2013.
448. Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, Jones TL; for the BARI 2D Study Group (A. Mooradian). Impact of Glycemic Control Strategies on the Progression of Diabetic Peripheral Neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. *Diabetes Care* 36:3208-3215, 2013
449. Bach RG, Brooks MM, Lombardero M, Genuth S, Donner TW, Garber AJ, Kennedy L, Monrad ES, Pop-Busui R, Kelsey SF, Frye RL, for the BARI 2D Investigators (A. Mooradian). Rosiglitazone and Outcomes for Patients with Diabetes and Coronary Artery Disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. *Circulation* 128:785-94, 2013.
450. Beohar N, Sansing VV, Davis AM, Srinivas VS, Helmy T, Althouse AD, Thomas SB, Brooks MM; BARI 2D Study Group (A. Mooradian). Race/ethnic disparities in risk factor control and survival in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) trial. *Am J Cardiol*.112:1298-1305, 2013.
451. Shah B, Srinivas VS, Lu J, Brooks MM, Bates ER, Nedeljkovic ZS, Escobedo J, Das GS, Lopez JJ, Feit F (BARI 2D Group; A. Mooradian). Change in enrollment patterns, patient selection, and clinical outcomes with the availability of drug-eluting stents in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *Am Heart J*. 166:519-526, 2013.
452. Mooradian AD. Is high density lipoprotein (HDL) cardioprotective or simply a marker of cardiovascular disease?" *Am. J. Therapeutics* 21:438-439, 2014.
453. Ismail-Beigi F, Lombardero MS, Escobedo J, Genuth S, Green J, Massaro E, Mooradian AD, Ovalle F, Whitehouse F, Zonszein J the BARI 2D Study Group. Determinants of Successful glycemic control among participants in the BARI 2D Trial: A post-hoc analysis. *Journal of Diabetes and its Complications* 28:101-109, 2014.

Scientific Publications (cont'd):

454. Parseghian S, Onstead-Haas L Wong NCW, Mooradian AD, Haas MJ. Inhibition of apolipoprotein A-I gene expression by tumor necrosis factor alpha in HepG2 cells: Requirement for c-jun. *Journal of Cellular Biochemistry* 115:253-260, 2014.
455. Haas MJ, Onstead-Haas L, Naem E, Arnold A, Rohrbaugh N, Flowers M, Mooradian AD. The effect of black seed (*Nigella sativa*) extract on FOXO3 expression in HepG2 cells. *Phytotherapy Research* 28:873-879, 2014.
456. Mooradian AD, Haas MJ. The effect of nutritional supplements on serum high-density lipoprotein cholesterol and apolipoprotein A-I. *American Journal of Cardiovascular Drugs* 14: 253-274, 2014.
457. August P, Hardison RM, Hage FG, Marroquin OC, McGill JB, Rosenberg Y, Steffes M, Wall BM, Molitch M; BARI 2D Study Group (A. Mooradian). Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study. *Clin J Am Soc Nephrol.* 9:64-71, 2014.
458. Althouse AD, Abbott JD, Forker AD, Bertolet M, Barinas-Mitchell E, Thurston RC, Mulukutla S, Abovans V, Brooks MM; for the BARI 2D Study Group (A. Mooradian). Risk factors for incident peripheral arterial disease in type 2 diabetes: results from the Bypass Angioplasty Revascularization Investigation 2 Diabetes Trial. *Diabetes Care* 37:1346-1352, 2014.
459. Haas MJ, Onstead-Haas LM, Naem E, Wong NC, Mooradian AD. Induction of apolipoprotein A-I gene expression by black seed (*Nigella sativa*) extracts. *Pharmaceutical Biology* 52:1119-1127, 2014.
460. Haas MJ, Shah GN, Onstead-Haas L, Mooradian AD. Identification of ATP8B1 as a blood-brain barrier-enriched protein. *Cell. Mol. Neurobiol.* 34:473-478, 2014.
461. Krone RJ, Althouse AD, Tamis-Holland J, Venkitachalam L, Campos A, Forker A, Jacobs AK, Ocampos S, Steiner G, Fuentes F, Sing IRP, Brooks MM, for the BARI 2D Study Group (A. Mooradian). Appropriate Revascularization in Stable Angina, Lessons from the BARI 2D Trial. *Canadian Journal of Cardiology* 30:1595-1601, 2014.
462. Haas MJ, Onstead-Haas LM, Szafran-Swietlik A, Kojanian H, Davis T, Armstrong P, Wong NC, Mooradian AD. Induction of hepatic apolipoprotein A-I gene expression by the isoflavones quercetin and isoquercitrin. *Life Sci.* 110:8-14, 2014.
463. Mooradian AD. Drug therapy of diabetic dyslipidemia: Do the statins suffice? *Am. J. Therap.* 22:87-88, 2015.
464. Mooradian AD, Haas MJ: Targeting high density lipoproteins: increasing de novo production vs. decreasing clearance. *Drugs* 75:713-722, 2015.

Scientific Publications (cont'd):

465. Alexandraki I, Palacio C, Mooradian AD. The relative merits of low carbohydrate diets in managing obesity: a meta-analysis of low carbohydrate versus low fat diets. *Southern medical Journal* 108:401-416, 2015.
466. Zonszein J, Lombardero M, Ismail-Beigi F, Palumbo P, Foucher S, Groenewoud Y, Cushing G, Wajchenberg B, Genuth S; Bari 2D Study Group. (A. Mooradian). Triglyceride high-density lipoprotein ratios predict glycemia-lowering in response to insulin sensitizing drugs in type 2 diabetes: A post hoc analysis of the BARI 2D. *J Diabetes Res.* 2015; 2015:129891. doi:10.1155/2015/129891.
467. Magee MF, Tamis-Holland JE, Lu J, Bittner VA, Brooks MM, Lopes N, Jacobs AK, Study Group B2. (A. Mooradian). Sex, prescribing practices and guideline recommended, blood pressure, and LDL cholesterol targets at baseline in the BARI 2D Trial. *Int J Endocrinol.* 2015; 2015:610239. doi: 10.1155/2015/610239.
468. Bittner V, Bertolet M, Barraza Felix R, Farkouh ME, Goldberg S, Ramanathan KB, Redmon JB, Sperling L, Rutter MK; BARI 2D Study Group. (A. Mooradian). Comprehensive cardiovascular risk factor control improves survival: the BARI 2D trial. *J Am Coll Cardiol.* 66:765-773, 2015.
469. Makhoul Ahwach S, Thomas M, Onstead-Haas L, Mooradian AD, Haas MJ. The glutathione mimic ebselen inhibits oxidative stress but not endoplasmic reticulum stress in endothelial cells. *Life Sciences* 134:9-15, 2015.
470. Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL for the BARI 2D Study Group (A. Mooradian). Troponin and cardiac events in stable ischemic heart disease and diabetes. *N Engl J Med* 373:610-620, 2015.
471. Mooradian A, Chehade JM, Mooradian AD. The advantages and pitfalls of anti-hyperglycemic combination pills as first-line therapy in the management of type 2 diabetes. *Am J Therap.* 23(6):e1857-e1866, 2016.
472. Haas MJ, Kurban W, Shah H, Onstead-Haas LM, Mooradian AD. Beta blockers suppress dextrose-induced endoplasmic reticulum stress, oxidative stress and apoptosis in human coronary artery endothelial cells. *Am J Therap.* 23(6):e1524-e1531, 2016.
473. Wolk, R, Bertolet M, Brooks MM, Pratley RE, Sobel BE, Frye RL, Singh P, Calvin AD, Rutter MK, Mooradian AD, Somers VK, for the BARI 2D study group. Differential effects of insulin sensitization and insulin provision treatment strategies on concentrations of circulating adipokines in patients with diabetes and coronary artery disease in the BARI 2D Trial. *European Journal of Preventive Cardiology* 23:50-8, 2016.

Scientific Publications (cont'd):

474. Kojanian H, Szafran-Swietlik A, Onstead-Haas L, Haas MJ, Mooradian AD. Statins prevent dextrose-induced endoplasmic reticulum stress and oxidative stress in endothelial and HepG2 cells. *Am J Therap.* 23(6):e1456-e1463, 2016.
475. Palacio C, Mooradian AD. Clinical trials and antioxidant outcomes. In: *Oxidative Stress and Antioxidant Protection: the Science of Free Radical Biology and Disease.* Donald Armstrong and Robert D. Stratton (eds), Wiley, 2016; pp493-506.
476. Singh A, Schaff HV, Mori Brooks M, Hlatky MA, Wisniewski SR, Frye RL, Sako EY; BARI 2D Study Group. (A. Mooradian). On-pump versus off-pump coronary artery bypass graft surgery among patients with type 2 diabetes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *Eur J Cardiothorac Surg.* 49:406-416, 2016.
477. Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL; BARI 2D Study Group. (A. Mooradian). Sex differences in cardiac troponin and the risk of death or major cardiovascular events. *J Am Coll Cardiol.* 68:978-980, 2016.
478. Mooradian AD, Onstead-Haas L, Haas MJ Asymmetrical cross-talk between the endoplasmic reticulum stress and oxidative stress caused by dextrose. *Life Sciences* 144:37-48, 2016.
479. Wehmeier KR, Kurban W, Chandrasekharan C, Onstead-Haas L, Mooradian AD, Haas MJ. Inhibition of ABCA1 protein expression and cholesterol efflux by TNF α in MLO-Y4 osteocytes. *Calcif Tissue Int.* 98(6):586-595, 2016.
480. Wolk R, Bertolet M, Singh P, Brooks MM, Pratley RE, Frye RL, Mooradian AD, Rutter MK, Calvin AD, Chaitman BR, Somers VK, for the BARI 2D study group. Prognostic value of adipokines in predicting cardiovascular outcome - Explaining the obesity paradox. *Mayo Clinic Proceedings* 91:858-866, 2016.
481. Wehmeier K, Onstead-Haas L, Wong NCW, Mooradian AD, Haas MJ. Pro-inflammatory signaling by 24, 25-dihydroxyvitamin D3 in HepG2 cells. *Journal of Molecular Endocrinology.* 57:87-96, 2016.
482. Haas MJ, Onstead-Haas L, Lee T, Torfah M, Mooradian AD. Angiotensin II receptor one (AT1) mediates dextrose induced endoplasmic reticulum stress and superoxide production in human coronary artery endothelial cells. *Int. J. Cardiology* 220: 842-850, 2016.
483. Mooradian AD. Targeting select cellular stress pathways to prevent hyperglycemia-related complications: Shifting the paradigm. *Drugs* 76:1081-1091, 2016.

Scientific Publications (cont'd):

484. Haas MJ, Jafri M, Wehmeier K, Onstead-Haas L, Mooradian AD. Inhibition of endoplasmic reticulum stress and oxidative stress by vitamin D in endothelial cells. *Free Radical Biology & Medicine* 99:1-10, 2016.
485. Mooradian AD. Therapeutic targeting of cellular stress to prevent cardiovascular disease. A review of the evidence. *American Journal of Cardiovascular Drugs* 17: 83-95, 2017.
486. Ikeno F, Brooks MM, Nakagawa K, Kim MK, Kaneda H, Mitsutake Y, Vlachos HA, Schwartz L, Frye RL, Kelsey SF, Waseda K, Hlatky MA; BARI-2D Study Group. (A. Mooradian). SYNTAX score and long-term outcomes: The BARI-2D Trial. *J Am Coll Cardiol.* 69:395-403, 2017.
487. Ghasemzadeh N, Brooks MM, Vlachos H, Hardison R, Sikora S, Sperling L, Quyyumi AA, Epstein SE, (A. Mooradian, site PI). An aggregate biomarker risk score predicts high risk of near-term myocardial infarction and death: Findings from **BARI 2D** (Bypass Angioplasty Revascularization Investigation 2 Diabetes). *J Am Heart Assoc.* 2017 Jul 3; 6 (7). pii: e003587. doi: 10.1161/JAHA.116.003587.
488. Damluji AA, Cohen ER, Moscucci M, Myerburg RJ, Cohen MG, Brooks MM, Rich MW, Forman DE, (A. Mooradian, site PI). Insulin provision therapy and mortality in older adults with diabetes mellitus and stable ischemic heart disease: Insights from **BARI-2D** trial. *Int J Cardiol.* 241: 35-40, 2017.
489. Mooradian AD, Smith M, Tokuda M. The role of artificial and natural sweeteners in reducing the consumption of table sugar: A Narrative review. *Clinical Nutrition ESPEN* 18:1-8, 2017.
490. Haas MJ, Onstead-Haas L, Kurban W, Shah H, Plazarte M, Chamseddin A, Mooradian AD. High-throughput analysis identifying drugs that regulate apolipoprotein A-I synthesis. *Assay and Drug Development Technologies* 15:362-371, 2017.
491. Khan AA, Chung MJ, Novak E, Brown DL, (Mooradian A site PI). Increased hazard of myocardial infarction with insulin-provision therapy in actively smoking patients with diabetes mellitus and stable ischemic heart disease: The BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) Trial. *J Am Heart Assoc.* 2017 Sep 13;6(9). pii: e005946. doi: 10.1161/JAHA.117.005946

Scientific Publications (cont'd):

492. Pallisgaard JL, Brooks MM, Chaitman B, Boothroyd DB, Perez M, Hlatky MA; BARI 2D Study Group. (Mooradian A site PI). Thiazolidinediones and risk of atrial fibrillation among patients with diabetes and coronary disease. *Am J Med.* 131: 805–812, 2018
493. Haas MJ, Plazarte M, Chamseddin A, Onstead-Haas L, Wong NCW, Plazarte G, Mooradian AD. Inhibition of hepatic apolipoprotein A-I gene expression by histamine. *European Journal of Pharmacology*, 823: 49–57, 2018.
494. Rezende PC, Everett BM, Brooks MM, Vlachos H, Orchard TJ, Frye RL, Bhatt DL, Hlatky MA. (Mooradian A site PI). Hypoglycemia and elevated troponin in patients with diabetes and coronary artery disease. *J Am Coll Cardiol.* 72:1778-1786, 2018.
495. Mori M, Shioda K, Bin Mahmood SU, Mangi AA, Yun JJ, Geirsson A. (Mooradian A site PI). Dual antiplatelet therapy versus aspirin monotherapy in diabetics with stable ischemic heart disease undergoing coronary artery bypass grafting. *Ann Cardiothorac Surg.* 7:628-635, 2018.
496. Haas MJ, Jurado-Flores M, Hammoud R, Plazarte G, Onstead-Haas L, Wong NCW, Mooradian AD. Regulation of apolipoprotein A-I gene expression by the histamine H1 receptor: Requirement for NF-kappaB. *Life Sciences* 208:102-110, 2018.
497. Mooradian AD. Evidence based management of diabetes in older adults. *Drugs & Aging* 35:1065-1078, 2018.
498. Mooradian AD. Can sugar substitutes reduce risk of obesity? *Public Health Post*, September 28, 2018. <https://www.publichealthpost.org/research/can-sugar-substitutes-reduce-risk-of-obesity/>
499. Siddique A, Murphy TP, Naeem SS, Siddiqui EU, Pencina KM, McEnteggart GE, Sellke FW, Dworkin LD.(Mooradian A site PI). Relationship of mildly increased albuminuria and coronary artery revascularization outcomes in patients with diabetes. *Catheter Cardiovasc Interv.* 93: E217-E224, 2019.
500. Haas MJ, Jurado-Flores M, Hammoud R, Chen V, Gonzales K, Onstead-Haas L, Mooradian AD. The effects of known cardioprotective drugs on pro-inflammatory cytokine secretion from human coronary artery endothelial cells. *American Journal of Therapeutics* 26: e321–e332, 2019.
501. Mooradian AD. In search for an alternative to sugar to reduce obesity. *International Journal for Vitamin and Nutrition Research.* 89:113-117, 2019.

Scientific Publications (cont'd)

502. Mooradian AD. Evidence based cardiovascular risk management in diabetes. *American Journal of Cardiovascular Drugs* 19:439-448, 2019.
503. Mooradian, AD. Diabetes and atherogenic dyslipidemia. In: *The Diabetes Textbook. Clinical Principles, Patient Management and Public Health Issues*. SJ. Rodriguez-Saldana (ed). Springer Nature, Switzerland AG 2019; 587-596.
504. Mooradian AD. Age –related resistance to thyroid hormone action. *Drugs and Aging* 36:1007-1014, 2019.
505. Genuth SM, Vlachos H, Brooks MM, Bantle JP, Chaitman BR, Green J, Kelsey SF, King SB 3rd, McBane R, Sako EY, Schneider DJ, Steffes M, Frye RL; BARI 2D Study Group. (Mooradian A site PI). BARI 2D: A reanalysis focusing on cardiovascular events. *Mayo Clin Proc.* 94:2249-2262, 2019.
506. Mooradian AD, Haas MJ, Onstead-Haas L, Tani Y, Iida T, Tokuda M. Naturally occurring rare sugars are free radical scavengers and can ameliorate endoplasmic reticulum stress. *International Journal for Vitamin and Nutrition Research Int J Vitam Nutr Res.* 90(3-4):210-220, 2020.
507. Mooradian AD, Stone R, Palacio C, Stewart E. Collaborative care plans reduce subspecialty consults: The experience from a safety net hospital. *The American Journal of Managed Care* 26:177-180, 2020.
508. Haas MJ, Jurado-Flores M, Hammoud R, Feng V, Gonzales K, Onstead-Haas L, Mooradian AD. Inhibition of pro-inflammatory cytokine secretion by select antioxidants in human coronary artery endothelial cells. *International Journal for Vitamin and Nutrition Research.* 90:103-112, 2020.
509. Feghaly JM, Mooradian AD. The rise and fall “ing” of the HDL hypothesis. *Drugs* 80:353-362, 2020.
510. Haas MJ, Victoria Feng V, Krista Gonzales K, Luisa Onstead-Haas L Mooradian AD. High-throughput analysis identifying drugs that reduce oxidative and ER stress in human coronary artery endothelial cells. *European Journal of Pharmacology* 879:173119, 2020. doi: 10.1016/j.ejphar.2020. 173119. PMID: 32325145
511. Mooradian AD. The merits and the pitfalls of low carbohydrate diet: A concise review. *The Journal of Nutrition, Health & Aging* 24:805-808. 2020.
512. Alexandraki I, Rosasco R, Mooradian A. Evaluation of faculty development programs for clinician educators: A scoping review. *Academic Medicine* 96: 599-606, 2021.

Scientific Publications (cont'd)

513. Ghezzi P, Mooradian AD. Demystifying oxidative stress. *Handb Exp Pharmacol*. 2021; 264:3-26. doi: 10.1007/164_2020_379. PMID: 32767143
514. Gonzales K, Feng V, Bikkina P, Landicho AM, Onstead-Haas L, Haas MJ, Mooradian AD. The effect of nicotine and dextrose on endoplasmic reticulum stress and apoptosis in human coronary artery endothelial cells. *Toxicology Research* 10: 284-291, 2021.
515. Franchi F, Yaranov DM, Rollini F, Rivas A, Rivas J, Been L, Tani Y, Tokuda M, Iida T, Hayashi N, Angiolillo DJ, Mooradian AD. Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective: Randomized, crossover study. *BMJ Open Diabetes Research & Care* 2021;Feb;9(1):e001939. doi: 10.1136/bmjdr-2020-001939
516. Mooradian AD, Haas MJ. Reduced cellular glucose transport confers natural protection against dextrose-induced superoxide generation and endoplasmic reticulum stress in domestic hen. *Physiol Rep*. 2021;9:e14816. <https://doi.org/10.14814/phy2.14816>.
517. Kapadia P, Bikkina P, Landicho AM, Parekh S, Haas MJ, Mooradian AD. Effect of antihyperglycemic drugs on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells. *Eu. J. Pharmacol*. 907:174249, 2021.
518. Gandhi G, Mooradian AD. Clinical considerations for insulin therapy in older adults with type 1 diabetes. *Drugs & Aging*. 39:23–37, 2022.
519. Gandhi G, Mooradian AD. Management of hyperglycemia in older adults with type 2 diabetes. *Drugs & Aging*. 39:39–58, 2022.
520. Haas MJ, Warda F, Bikkina P, Landicho MA, Onstead-Haas L, Kalidas P, Parekh S, Mooradian AD. Differential effects of cyclooxygenase-2 (COX-2) inhibitors on endoplasmic reticulum (ER) stress in human coronary artery endothelial cells. *Vascular Pharmacology*. 2022; 142:106948.
521. Haas MJ, Parekh S, Kalidas P, Richter A, Warda F, Wong NCW, Tokuda M, Mooradian AD. Insulin mimetic effect of D-allulose on apolipoprotein A-I gene. *J. Food Biochem*. 2022; 46(2):e14064.
522. Jurado Flores M, Warda F, Mooradian A. Pathophysiology and clinical features of neuropsychiatric manifestations of thyroid disease. *J. Endocrine Society*. 2022; 6(2):bvab194.

Scientific Publications (cont'd)

523. Haas MJ, Naem E, Almdallaleh S, Mooradian AD. The effect of black seed (*Nigella sativa*) extract on lipid metabolism in HepG2 cells. *BBA - Molecular and Cell Biology of Lipids*. 1867:159155; 2022 doi: 10.1016/j.bbalip.2022.159155.
524. Haas MJ, Mooradian AD. Potential therapeutic agents that target ATP Binding Cassette A1 (ABCA1) gene expression. *Drugs*. 2022 (in press).

Google Scholar statistics as of July 1, 2022:

Citations = 39,605; H-Index = 85; i-10 Index = 335